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ABSTRACT
Alzheimer’s Disease is a multifarious disease that progressively affects more
people as both the proportion of older adults in the population and life expectancy increase
in both the United States and worldwide. This devastating disease is a result of rampant
neuronal loss in the memory centers of the brain that robs the independence of those who
are diagnosed and places a heavy burden on those who care for them. Traditionally
speaking, research has focused on the hallmark pathology of amyloid plaques, targeting
them to try and prevent disease onset. However, countless failures in clinical trials aimed
at this said pathology has led researchers to broaden the horizon of what targets might be
successful in mitigating disease. Additionally, the lack of a common cause in the majority
of all cases, which are sporadic, demands a more dynamic approach to treating disease
pathogenesis.
Thus, identifying alternative mechanisms and ways to prevent them during disease
development is vital to help design new therapeutic interventions beyond amyloid alone.
Presented here are a collection of mechanisms uncovered that likely play into the
development of Alzheimer’s Disease and pose potential new routes for therapies to
improve patient outcomes. Here we propose two pharmacological interventions including
that of inhibiting polyamine synthesis to reduce amyloid aggregation and toxicity as well
as preventing the production of the APP intracellular domain due to its neurotoxic role at
ii

the mitochondria. Additionally, we offer a nutritional intervention through the
antioxidative and amyloid preventive effects of a cysteine-rich Whey protein,
Immunocal®. Lastly, we introduce the Kynemics program at the Alumia Institute, a
lifestyle intervention which utilizes a multi-modal immersive approach to improve patient
measures and reduce the burden on their caregivers. Overall, future interventions designed
to address Alzheimer’s Disease should reflect the fact that it is a complicated disease; thus,
generating the treatments that will be most successful will likely require the targeting of
multiple pathways to prevent or slow disease pathogenesis and in turn improve patient
well-being and overall societal burden.
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CHAPTER ONE: INTRODUCTION
1.1 Alzheimer’s Disease: an overview
Alzheimer’s disease and age-related dementias (ADRD) have swiftly increased in
prevalence in recent history as the older population in the United States and globally
steadily increases. Alzheimer’s disease (AD), the most common form of dementia, is
characterized pathologically by extracellular amyloid plaques comprised of aggregated
insoluble beta amyloid (Aβ) peptides and intracellular neurofibrillary tangles (NFT)
comprised of hyperphosphorylated tau. These pathologies induce rampant apoptosis in
specific neuronal populations associated with memory and learning. The devastating
decrease in these neurons results in issues in cognition, memory, and learning, which
impairs patient independence and ultimately results in death. Understanding the complex
mechanisms by which AD develops and affects these patients is necessary to prevent
disease pathogenesis and increase the quality and length of life in those with or at risk of
developing AD.
1.1.1 Prevalence of AD in the United States
In the United States, AD is the most common form of dementia and is estimated to be the
third highest cause of death amongst older adults (James et al., 2014). As the Baby Boomer
generation ages, the proportion of older adults in the total population is growing
progressively. Currently, there are about 6.2 million cases, estimated to reach a prevalence
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of 12.7 million by 2050, resulting in an enormous economic burden on the healthcare sector
which is projected to total $355 billion in 2021 alone. This does not take into account the
weight placed on unpaid caretakers consisting of family members and friends, who were
approximated to have spent over $250 billion in unpaid time caring for loved ones with
AD in 2020 (Alzheimer's Association, 2021). Beyond the economic burden, there is
additional physical, social, and mental health stress placed on those who are responsible
for the wellbeing of AD patients in their day to day life. As it stands, there are no effective
methods of preventing disease onset and progression, so there is a great challenge present
in mitigating AD to decrease both the prevalence of disease and the societal and economic
burdens in not only the United States, but worldwide.
1.1.2 Pathology of AD
Alzheimer’s Disease was first described by Dr. Alois Alzheimer in 1906 when he
described the pathologies discovered in Auguste D., a patient who presented rapidly
progressive symptomatologies of issues with memory, sleep disturbances, and confusion.
Upon analyzing her brain postmortem both histologically and morphologically, Alzheimer
discovered the characteristic plaques and tangles associated with AD (Hippius &
Neundorfer, 2003). However, it has been predicted that AD begins to develop more than
20 years before symptoms of dementia like those that were experienced by Auguste and
subsequent diagnosis generally occur (Bateman et al., 2012; Jack et al., 2009; Villemagne
et al., 2013). These presymptomatic changes noted include the generation and deposition
of the two hallmark pathologies of AD described, Aβ plaques and NFT (Figure 1.1). The
first are comprised of insoluble Aβ peptides, which aggregate to form plaques
extracellularly in the brain. These plaques are thought to cause many downstream effects
2

which lead to neuronal distress and apoptosis including oxidative stress, mitochondrial
disruption, impairments in synaptic function and phosphorylation of NFT. The second
pathology, NFT, are composed of hyperphosphorylated tau protein which result in
deposition of abnormal tau protein inside the neurons (Metaxas & Kempf, 2016). Though
the actual mechanisms are not entirely clear, NFT have been associated with the loss of
function of cytoskeletal microtubule networks and tubulin-associated proteins in the cells.
This then results in disruption of the synapse and impairment of transport within the cells.
The combination of these hallmark pathologies and their effects downstream eventually
lead to neuronal network changes due to progressive and widespread apoptosis in the brain.

3

Figure 1.1 Pathologies of AD. The classic pathologies of AD include intracellular
hyperphosphorylated tau protein and extracellular plaques of aggregated Aβ42 peptide.
Aβ42 monomers aggregate, notably in the synapse between the axon terminals of one
neuron to the dendrites of another, which disrupts synaptic transmission and
neurotransmitter cycling. Inflammatory astrocytes and microglia are activated in response
to this disturbance which coincides with increased oxidative species, organelle
dysfunction, kinase activity and hyperphosphorylation of tau.
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1.1.3 Neuronal network changes in AD
As mentioned, the pathologies of AD cause a wide range of disruption to normal
neuronal functioning. Though there are many populations of neurons affected, these
changes first affect the hippocampal pyramidal, basal forebrain cholinergic, and cortical
pyramidal cells of the neocortex, before spreading to the cerebral cortex. The progression
of AD is often characterized by six phases dependent on the deposition of NFT, as
described by Braak and Braak (Braak & Braak, 1995). This development is as follows:
transentorhinal stages I-II, limbic stages III-IV, and neocortical stages V-VI. This means
that in AD, NFTs begin to develop in the entorhinal cortex (EC), followed by the Cornus
Ammonius (CA) regions starting with the CA1 region of the hippocampus and lastly in the
temporal and neocortical regions. Therefore, since it is the primary glutamatergic input for
the hippocampus, the changes in the EC circuitry directly affect the functioning of the
hippocampus. The loss of such groups of neurons leads to impairment of cholinergic
pathways through decreased synapses and neurotransmitters. Since the hippocampus
functions as the learning and memory center in the brain and as the network there is
impacted, patients' short-term memory function worsens. As the disease progresses, the
reduction in neurons and signaling in the cerebral cortex, results in decreases in the patients'
ability to make decisions and regulate emotions. With the increase in neuronal apoptosis,
there is widespread atrophy of the brain due to severe cortical and hippocampal shrinkage
and enlarged ventricles. Eventually, patients are no longer able to perform day to day tasks
and memory becomes largely nonexistent.
1.1.4 Current limitations in therapeutics
5

Currently, there are limited therapeutics available to prevent or delay the onset of
AD. Up until recently, with the conditional approval of Biogen’s aducanumab, the only
drugs approved by the US Food and Drug Administration (FDA) solely focus on treating
symptoms rather than the underlying pathogenesis and neuronal cell death (Herper,
Feuerstein, & Garde, 2020). These drugs historically have been limited to N-methyl-Daspartic acid (NMDA) antagonists and acetylcholinesterase inhibitors which help to reduce
glutamate excitotoxicity and increase the duration of acetylcholine in the synapse to
improve short term signaling, respectively, but they do not mitigate the underlying
mechanisms of disease. In years past, many drugs have sought to attack the amyloidogenic
processing of Aβ since that is widely agreed upon to be upstream of many of the apoptosis
mechanisms occurring in AD (Hardy & Higgins, 1992). For example, there have been a
number of trials which utilized β-secretase (BACE) inhibitors to attempt to decrease
amyloidogenic processing of amyloid precursor protein (APP) to prevent the generation of
insoluble Aβ, which have shown promising preclinical results, but have largely failed in
patients with AD (Evin, 2016; Vassar, Kovacs, Yan, & Wong, 2009). Pharmaceutical
companies like Eli Lilly have also attempted to combat Aβ through use of the γ-secretases
inhibitor, semagacestat, but this approach also failed when scaled to Phase III clinical trials,
as patients presented worsening outcomes both cognitively and in abilities to perform
activities of daily living (D'Onofrio et al., 2012). Beyond the scale of secretase inhibitors,
more recently there has been development of drugs utilizing human antibodies against Aβ
for the treatment of early onset AD, or familial AD (FAD). One such drug is the
aforementioned aducanumab, however this drug has only received conditional approval
contingent on additional data collection set to be completed by 2030, regardless of the
6

warnings issued by an FDA advisory panel for approval. These widespread failures in
being able to target the underlying etiologies of disease, as well as the lack of treatments
to address the majority of the cases being sporadic AD, pose an issue and opportunity to
explore other pathways and therapeutic options that may be more successful in disease
prevention.
1.1.5 The amyloid cascade hypothesis
Traditionally speaking, most therapeutic attempts and failures at preventing AD
have revolved around the amyloid cascade hypothesis. First proposed by Hardy and
Higgins in 1992, this hypothesis theorizes that as neurons age, as well as exposure to
genetic and environmental risk factors, their ability to clear Aβ42 begins to decline (Hardy
& Higgins, 1992). In FAD, this is notably through the presence of mutations in the
processing of APP, while in sporadic AD, this is attributed to a number of environmental
risk factors and general aging of neurons. Processing of the amyloid precursor protein
(APP) by a series of secretases results in the generation of a number of peptides including
Aβ40/42. Through amyloidogenic processing via BACE and subsequently γ-secretase, the
Aβ42 fragment is generated. The plaques which are a result of the aggregation of these
peptides, are the central cause of the development of AD in the amyloid cascade hypothesis
(Figure 1.2).There is an increase in aggregation of insoluble oligomers of the peptide, either
by the increased amyloidogenic processing in FAD or an inability to clear the insoluble
form in sporadic AD. This leads to aggregation and plaque deposition, notably in the
synapse. Depositions of these plaques increase, leading to a number of disruptions in the
synapse including activation of inflammatory astrocyte and microglial cells. In their
healthy state, these glial cells maintain the integrity of ionic and neurotransmitter
7

homeostasis as well as synapse integrity and plasticity, by releasing cytokines, chemokines,
and reactive oxygen species (ROS) to combat infection (Ransohoff, 2016). However, their
sustained activation results in neuroinflammation accompanied by increased oxidative
stress, abnormal kinase activity specifically in hyperphosphorylation of tau, and
neurotransmitter deficits ending in rampant loss of synapses and cell death (Selkoe &
Hardy, 2016).
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Figure 1.2 Amyloid cascade hypothesis. The amyloid cascade hypothesis deems the
causative agent of AD as production of Aβ42, whether through genetic mutation in familial
AD or through the cell’s decreasing ability to clear Aβ42 in sporadic AD. With an increase
in Aβ42 there is a cascade of events that leads to widespread synaptic and neuronal loss in
the populations of neurons affected in AD including entorhinal cortex, hippocampus, and
cerebral cortex. Adapted from (Selkoe & Hardy, 2016).
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1.1.6 Familial and sporadic Alzheimer’s Disease
Previously mentioned, the amyloid cascade hypothesis has widely been used as the
cornerstone of AD research, largely due to its relevance in regarding high levels of Aβ42 as
the key risk factor. There have been a number of genetic predispositions discovered that
increase Aβ42 associated with FAD, also known as early onset due to the occurrence of
disease happening largely before age 50. Genetic mutations have been found both in the
catalytic subunits of γ-secretase, presenilin-1 (PS1) and presenilin-2 (PS2), as well as in
the BACE cleavage site of APP. These mutations drive the amyloidogenic processing of
APP towards production of Aβ42 (N. S. Ryan & Rossor, 2010). However, FAD accounts
for less than 5% of disease, with the remainder of cases being sporadic or late onset AD
(LOAD) where patients do not harbor these mutations and are diagnosed around age 65 or
older (Bali, Gheinani, Zurbriggen, & Rajendran, 2012).
LOAD is uncharacterized in terms of the genetic and environmental causes, though
there are data to support that certain variants of the apolipoprotein E (apoE), specifically
the epsilon allele variant e4, increases risk of developing LOAD (Bertram, Lill, & Tanzi,
2010). Beyond that there are numerous polymorphisms of genes responsible for regulating
a range of responses including inflammation, protease activity, oxidative stress, just to
name a few, that have been associated with LOAD; however, the population remains
heterogeneous and disjointed in being able to pinpoint the cause of disease onset. That,
along with the failure of therapeutics targeting amyloid in patients, has required researchers
to further dissect the potential role that other factors including fragments of APP might
play in AD pathogenesis.
10

1.1.7 The multifarious nature of AD and related hypotheses
The fact of the matter is that AD is a multifarious, heterogeneous disease. Proper
therapies to treat or prevent likely lie within a puzzle of hypotheses that focus on
different dysfunctional changes occurring during disease onset (Figure 1.3) . While Aβ is
clearly an important piece of that puzzle in its association with hallmark pathologies and
correlation with cellular dysfunction, the lack of effective therapies with targeting only
amyloid highlights the likelihood that there are other causative factors and associated
targets. Many other routes to address AD exist and are important to consider including
the tau hypothesis, which predicts that tau pathology is the initiating event in AD
pathogenesis. This hypotheses finds support in the correlation between tau deposition and
cognitive impairment, as well as the presence of irregular tau well before the appearance
of any amyloid species in patient brains, particularly in populations like the basal
cholinergic neurons which project into the populations vulnerable in AD (Arnsten Datta,
Del Tredici, & Braak, 2021). Also, given the primary input to the memory centers of the
brain are basal cholinergic neurons, the first hypothesis to explain AD development was
the cholinergic hypothesis, which stated that the disruption and cell death in this cell
these neurons precedes AD pathogenesis in the hippocampal and subsequent regions.
This sparked several cholinesterase inhibitors to prolong acetylcholine in the synapse as a
treatment, which has only resulted in symptomatic relief, but not prevention of disease
(Terry & Buccafusco, 2003). Additionally, there is the mitochondrial cascade hypothesis
which predicts that the aging mitochondria becomes less efficient and leads to increased
production of reactive oxygen species (ROS) results in subsequent increased production
of Aβ, phosphorylation of tau, and disease development (Swerdlow & Khan, 2004).
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There is also the inflammatory response hypothesis which blames chronic cytokine
releases by activated astrocytes and microglia as the cause of AD, however antiinflammatory therapies alone have been unsuccessful in mitigating disease development
(Kinney et al., 2018). Additionally, there are predictions that the gut microbiome might
cause AD in that there are neurotransmitter and cytokine released by the microbiome
which is directly associated to the brain via the vagus nerve (Jiang, Li, Huang, Liu, &
Zhao, 2017). More recently, the Type 3 Diabetes (T3D) classification of AD states that is
a condition classified by metabolic issues and insulin resistance in the brain which has
been found to be associated with Aβ clearance, tau, and other downstream effects like
inflammation due to these pathologies (Nguyen, Ta, Nguyen, Nguyen, & Giau, 2020).
There are also known risk factors including single nucleotide polymorphisms (SNPs),
hormonal balances, and neurotrophin (NT) levels like nerve growth factor (NGF) and
brain decried neurotrophic factor (BDNF) (Allen, Watson, & Dawbarn, 2011; Nazarin,
Yashin, & Kulminksi, 2019; Savolainen-Peltonen et al., 2019). Overall, there is also the
important role that healthy aging plays in protection from initiating events in AD for
example in populations declared “Blue Zones” which tend to have better diets, higher
activity, and cognitive and social stimulation (Buettner & Skemp, 2016). These zones
host people who live longer as well as have lower rates chronic disease including AD and
dementia likely due to their connection to their lifestyle habits decreasing the previously
mentioned pieces of the AD “puzzle”.
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Figure 1.3 The various hypotheses of AD development. A number of hypotheses have
been proposed to explain the initiating events of AD pathologies including, but not limited
to, the tau hypothesis, amyloid cascade hypothesis, oxidative stress and mitochondrial
dysfunction (ROS/MOS), inflammatory responses, insulin resistance and T3D, the gut
microbiome hypothesis, associated risk factors, and general healthy aging.
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1.2 The relationship between Aβ42 and polyamines in AD onset
One of the hypotheses that has historically dominated the field of both AD research
and drug development is the amyloid cascade hypothesis. This hypothesis places the central
and causatory event of AD development in the generation of Aβ. It predicts that brain
aging, as well as the presence of both internal and external risk factors, contribute to a
decrease in effective clearance of Aβ42. Previously, there has been extensive research into
how these responses promote the generation of oxidative species through mitochondrial
dysfunction, stress at the synapse, altered kinase activity and promotion of apoptotic
pathways. Additionally, Aβ has been investigated in regard to its involvement in the
polyamine biosynthetic pathway. Polyamines (PA) are a ubiquitous class of molecules
largely involved in cell growth and proliferation. There is increasing evidence that Aβ and
PA might influence the production of each other which could lead to increased oxidative
stress and Aβ aggregation.
1.2.1 Amyloid and cellular dysfunction
Amyloid peptides, specifically Aβ42, has been a primary focus of AD research and
therapeutic development given the amyloid cascade hypothesis and its main role in
pathology. As a result, there has been extensive discoveries made about the cellular
dysfunction associated with high Aβ and its subsequent aggregates (Hampel et al., 2021).
There are a number of pathways that are dysregulated with the increase of Aβ species in
the brain. One such pathway is the inflammatory response elicited by microglia, which are
stimulated to release pro-inflammatory cytokines like tumor necrosis factor-α (TNF-α),
which is chronically high in AD patients (Decourt, Lahiri, & Sabbagh, 2017; M. M. Wang,
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Miao, Cao, Tan, & Tan, 2018). Downstream, this impairs pathways that promote cell
survival such as transforming growth factor- β 1 (TGF-β1), which is decreased in the
disease state (Glass, Saijo, Winner, Marchetto, & Gage, 2010). Additionally, low levels of
TREM2, a protein which influences the ability of microglia to clear Aβ, further influences
the increase in Aβ, resulting in chronic inflammation (Guerreiro et al., 2013). At a cellular
level, research has found that by accumulating in the mitochondrial matrix and binding to
the organelle’s enzymes, Aβ disrupts mitochondrial function, causes oxidative stress, and
initiates a cascade of apoptotic pathways that ultimately leads to cell death (Rajasekhar,
Chakrabarti, & Govindaraju, 2015). Specifically, studies have found that there is a decrease
in PreP, a matrix peptidasome responsible for degradation of Aβ, in AD specifically within
the mitochondria (Falkevall et al., 2006; Manczak et al., 2006). This increase in
mitochondrial Aβ promotes energy failure by disruption of respiration, membrane
potential, and increases the generation of ROS (Mossmann et al., 2014), ultimately causing
initiation of a number of pro-apoptotic cascades (J. X. Chen & Yan, 2007).
1.2.2 Polyamines and AD
There has been increasing interest in the interaction between Aβ42 and a class of
omnipresent molecules, PA. Particularly, a breadth of research has shown that there is a
shift in the subcellular location of PA in the disease state (Bernstein & Muller, 1995;
Nilsson et al., 2006; Seidl et al., 1996) suggesting alterations in PA levels in concordance
with development of AD pathology. Further, Aβ42 aggregation appears to upregulate PA
levels through the proposed mechanism of increasing expression of the rate-limiting
enzyme of the polyamine biosynthesis pathway, ornithine decarboxylase (ODC) (Figure
1.4) (Bae, Lane, Jansson, & Richardson, 2018). This has been hypothesized to occur as a
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response to the increase in free radicals and oxidative stress induced by Aβ (Choi, Kim,
Kim, Lho, & Chung, 2001). Additionally, single nucleotide polymorphisms in ornithine
transcarbamylase (OTC) have been discovered that affect ornithine and arginine
availability and in turn, increase risk of developing AD (Hansmannel et al., 2009).
However, the current studies surrounding the role of PA in AD onset have been
contradictory since accumulations of the molecules instigate pathways which are either
protective or harmful to the cell (Skatchkov, Woodbury-Farina, & Eaton, 2014). Therefore,
further research is required to elucidate the precise relationship between PA and the
development of AD, specifically in regard to amyloid aggregation.
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Figure 1.4 The interaction between PA and Aβ. Putrescine is synthesized from ornithine
through a rate-limiting decarboxylation reaction catalyzed by ornithine decarboxylase
(ODC). Spermidine and Spermine are derived from putrescine by the addition of either one
or two aminopropyl groups, respectively. The overproduction of Aβ42 is hypothesized to
upregulate polyamine synthesis by increasing expression of the rate limiting ODC enzyme.
In turn, greater intracellular concentrations of polyamines are believed to increase Aβ42
aggregation with associated neuronal apoptosis and mitochondrial dysfunction.
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1.2.3 Polyamines and their biosynthetic pathway
Polyamines are a ubiquitous class of small positively charged molecules that have
been widely studied due to their influence on cell growth, specifically in cancers
(Chattopadhyay, Tabor, & Tabor, 2009; Minois, Carmona-Gutierrez, & Madeo, 2011;
Soulet & Rivest, 2003). PA follow a biosynthetic pathway which begins with the amino
acid arginine (Figure 1.5). Arginine is processed into ornithine by arginase, and
subsequently by ODC to generate putrescine. An aminopropyl group is added by spermine
synthase to yield spermine, then an additional aminopropyl group is added by spermidine
synthase to yield spermidine. This production of PA is regulated through the activity of
ODC, the rate-limiting enzyme of this pathway. These molecules have been shown to be
essential for normal cell growth and development in eukaryotes (Thomas & Thomas,
2001).
An increase in PA levels, otherwise known as the “polyamine response”, results in
enhanced PA biosynthesis with a similar increase in exogenous PA uptake (Gilad & Gilad,
1999; Gilad, Gilad, & Wyatt, 1993; Saito, Packianathan, & Longo, 1997). Normally, there
is a precise regulation of PA intracellular levels which ensures that intracellular
concentrations of PA are maintained within strictly controlled limits. PA can be oxidized
resulting in production of toxic compounds that can be captured and buffered by glial cells,
thus providing protection (Sparapani, Dall'Olio, Gandolfi, Ciani, & Contestabile, 1997).
Because PA are essential for cancer cell growth, there has been a recent interest in targeting
PA biosynthesis as a strategy for chemoprevention, especially in combating skin and colon
cancers (Nowotarski et al., 2013). As a result, there are already FDA approved drugs like
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d, l-α-difluoromethylornithine (DFMO), a potent irreversible inhibitor of ODC, which can
modulate the PA pathway.
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Figure 1.5 Biosynthetic pathway of PA. Putrescine is synthesized from ornithine through
a rate-limiting decarboxylation reaction catalyzed by ODC. Spermidine is derived from
putrescine by the addition of an aminopropyl groups by Spermidine synthase (SpdS).
Spermine synthase (SpmS) then catalyzes a reaction adding an aminopropyl group to
Spermidine to yield Spermine. These PA are associated with cell proliferation, autophagy,
and transcriptional regulation. DFMO can be used to irreversibly inhibit the activity of
ODC, halting PA synthesis.
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1.2.4 Modulating PA to reduce Aβ aggregation and toxicity
Given the potential relationship between PA concentration and Aβ aggregation,
utilizing FDA-approved DFMO to halt the production of PA has potential to modulate this
interaction and may prevent the downstream effects of Aβ toxicity. Considering the
aforementioned changes in subcellular location of ODC as well as ODC and PA levels shift
in the disease state (Bernstein & Muller, 1995; Nilsson et al., 2006; Seidl et al., 1996),
inhibiting ODC and subsequent PA production might impact AD pathology. This could be
possible if by inhibiting PA, there is a reduction in the downstream effects of aggregates
including those on mitochondrial dysfunction, oxidative stress, and overall apoptosis.
Elucidating this relationship is valuable twofold in that it first adds to the understanding
the of interaction between PA production and Aβ pathology as there is still a large gap in
knowledge. Second, this could identify an already FDA approved therapeutic as a potential
tool for combating disease development in addition to traditional amyloid targeting, given
the historical failure in targeting the latter alone.
1.3 The potentially neurotoxic role of the APP intracellular domain
As discussed, though Aβ has been extensively studied, other cleavage products of
APP processing are emerging as key players in disease progression. For example, Simón
et al. found cognitive defects independent of Aβ in transgenic mice that overexpressed
APP (Simón et al., 2009). There are multiple pathways by which APP can be processed to
produce Aβ and other peptide fragments. Mentioned earlier, Aβ42 is produced via the
amyloidogenic pathway. However, APP can also be processed via a nonamyloidogenic
route. Regardless of which pathway APP is processed, there is a protein produced called
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the APP intracellular domain (AICD), which is notable as there has been evidence that
AICD might play a role in the pathogenesis of AD.
1.3.1 Amyloid processing to the AICD
Processing of APP begins with cleavage by either α-secretase or BACE to generate
soluble amyloid-beta precursor protein- α (sAPPα) and soluble amyloid-beta precursor
protein- β (sAPPβ), respectively. Nonamyloidogenic processing follows initial cleavage
by α-secretase, while amyloidogenic follows BACE cleavage. From here, there is a C
terminal fragment (CTF) produced in addition which is further processed by γ-secretase.
Via amyloidogenic processing, CTF89/99 is cleaved into either Aβ40 or Aβ42 as well as
AICD. Nonamyloidogenic processing of CTF83 yields both the protein fragment P3 as
well as AICD. This is of particular interest since regardless of whether Aβ is produced,
AICD is generated via either route (Figure 1.6). As a result, there has been increasing
interest in determining the potential role of AICD in the development of AD.
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Figure 1.6 Pathways of APP proteolytic processing. APP processing has two different
pathways once it has been inserted into a lipid membrane. The non-amyloidogenic pathway
utilizes α-secretase to produce sAPPα and CTF83. γ-secretase then cleaves the CTF83 into
a soluble P3 fragment and AICD. The amyloidogenic pathway utilizes processing by βsecretase, which produces sAPPβ and CTF99/89, depending on tissue type. γ-secretase then
cleaves CTF99/89 into Aβ40 or Aβ42, which become extracellular, and the AICD. Adapted
from (Muller, Meyer, Egensperger, & Marcus, 2008).
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1.3.2 Previous research on the AICD
Historically, research surrounding the AICD has largely focused on its role as a
transcription factor since its initial discovery more than 20 years ago when it was
described as pro-apoptotic (Passer et al., 2000). A number of studies have dissected the
role it may play in regulation and induction of apoptosis. For example, in primary
cultures isolated from AICD transgenic mice, the neurons are hypersensitive to toxic
stimuli (Giliberto et al., 2008). In embryonic carcinoma cells, overexpression of AICD
results in the cells’ inability to differentiate and eventual induction of apoptosis
(Nakayama, Ohkawara, Hiratochi, Koh, & Nagase, 2008). Further, overexpression
appears to enhance the apoptotic cascades initiated due to endoplasmic reticulum (ER)
stress or tumor suppressor p53 activity in other cells (Kogel et al., 2012; Ozaki et al.,
2006). In regard to its role as a transcription factor, AICD has been shown to modulate
transcription upon localizing with adaptor protein Fe65 and translocating to the nucleus
to generate a multimeric complex with histone acetyltransferase Tip60 (Figure 1.7)
(Kimberly, Zheng, Guenette, & Selkoe, 2001; Slomnicki & Lesniak, 2008; von Rotz et
al., 2004). There, the complex regulates transcription by upregulating anti-metastasis and
tumor suppressor genes and indirectly upregulates glycogen synthase kinase 3-β
(GSK3β), APP, and BACE1, while it downregulates epidermal growth factor receptor
(EGFR) (Multhaup, Huber, Buee, & Galas, 2015). This co-expression with Fe65 appears
to disrupt mitochondrial bioenergetics and actin assembly in neuroblastoma cells (Ward
et al., 2010). Further, this association appears to be necessary for the expression of ADlike pathology in AICD transgenic mice (Ghosal et al., 2009). Taken together, there has
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been mounting interest in the notion that AICD could be a neurotoxic factor in the
pathogenesis of AD, particularly in cases with lower Aβ production (Borquez &
Gonzalez-Billault, 2012).
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Figure 1.7 AICD as a nuclear transcription factor. Membrane bound APP is
catalytically processed by γ-secretase via both the amyloidogenic and nonamyloidogenic
pathways to release AICD into the intracellular space. In the cytoplasm, AICD is bound
to Fe65 through a PTB2 domain and then translocates to the nucleus. Through the PTB1
domain on Fe65, the complex then associates with other regulatory factors such as Tip60
to modulate transcription of target genes. Adapted from (McLoughlin & Miller, 2008).
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1.3.3 Previous research on AD and the AICD
Though Aβ is well characterized in terms of inducing neuronal death, there is
increasing evidence that AICD could also be neurotoxic (reviewed in (Bukhari et al.,
2017)). AICD has been studied in various models including transgenic mice, cell culture
systems, and in human brains, yielding a consensus that the protein increases apoptosis
(Giliberto et al., 2008; Nakayama et al., 2008; Passer et al., 2000). Simon et al performed
an interesting study that suggests that AICD may have a large Aβ-independent role in AD
development (Simon et al., 2009). In this study, they used transgenic mice harboring the
human wild type APP protein (hAPPwt) or the Swedish/Indiana mutant APP protein
(hAPPswe-ind), which are double mutants with the Swedish (K670N/M671L) and Indiana
(V717F) mutations, increasing amyloidogenic processing through mutations at the βsecretase and γ-secretase cleavage sites of APP respectively, resulting in increased
production of Aβ (Weggen & Beher, 2012). Though both mice overexpressed APP, only
the hAPPswe-ind mutant had high levels of Aβ in the hippocampus due to the promotion of
amyloidogenic processing. What was surprising in this study however was that both mice
developed cognitive deficits despite the lack of Aβ in the hippocampus of the hAPPwt
mouse. Instead, they found high levels of AICD and C terminal fragments, products of both
APP processing pathways. AICD has been attributed to this Aβ-independent cognitive
impairment, perhaps through its indirect modulation of GSK3β transcription, which is
elevated in AD brains (Bhat, Budd Haeberlein, & Avila, 2004; K. A. Ryan & Pimplikar,
2005) and promotes the phosphorylation of tau, leading to NFT (Augustinack, Schneider,
Mandelkow, & Hyman, 2002). Indeed, in a study using overexpressing AICD transgenic
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mice (Ghosal et al., 2009), researchers discovered that there were high levels of AICD as
well as GSK3β, resulting in Aβ-independent cognitive deficits and AD pathology like in
the hAPPwt mice.
1.3.4 Generation of AICD at the mitochondria
Since AICD can be generated in the mitochondrial matrix through mitochondrial γsecretase (Pavlov et al., 2011), understanding how AICD might affect mitochondrial
function could elucidate additional mitochondrial dysfunction occurring in AD. It has been
found that APP can enter the mitochondria through the translocase of the outer
mitochondrial membrane (TOM) (Hansson Petersen et al., 2008) due to a mitochondrial
targeting signal on the N-terminus (Anandatheerthavarada, Biswas, Robin, & Avadhani,
2003) and has an acidic domain sequence present at residue 220 and 290, which acts as a
stop signal. This results in the formation of a stable complex in the mitochondrial
membrane with TOM and the translocase of the inner mitochondrial membrane (TIM)
(Devi, Prabhu, Galati, Avadhani, & Anandatheerthavarada, 2006). With APP trapped in
the mitochondrial membranes, there is a transmembrane region on the C terminus which
inserts itself through the outer membrane (Figure 1.8). Once there, a resident mitochondrial
γ-secretase present in the outer membrane can process APP to yield AICD locally at the

mitochondria (Pavlov et al., 2011). Since AICD can be produced locally within the
mitochondria, and given the extensive dysfunction experienced by this organelle in AD,
understanding the role that AICD might have could be valuable in addressing therapeutics
in addition to those that modulate Aβ.
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Figure 1.8 APP processing at the mitochondria. APP is targeted to the mitochondria due
to a sequence in the N terminus, resulting in the import through TOM/TIM channels. An
acidic domain in APP acts as a stop sequence to form a stable complex. The C-terminus of
APP then doubles back into the outer mitochondrial membrane, where a resident γsecretase produces AICD within the organelle. Adapted from (Pavlov et al., 2011).
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1.3.5 Mitochondrial cascade hypothesis
As mentioned, mitochondrial dysfunction is a distinctive feature of AD
development; mitochondrial oxidative stress (MOS) during disease pathogenesis is well
described. In fact, the mitochondria has more recently been hypothesized to be the
instigator in disease pathogenesis. Deemed the mitochondrial cascade hypothesis, it was
first presented by Mancuso in 2010 and seeks to explain the majority of AD cases, which
are sporadic (Mancuso, Orsucci, LoGerfo, Calsolaro, & Siciliano, 2010). Rather than
placing the generation of Aβ as the causatory event, this hypothesis predicts that the aging
mitochondria becomes less efficient, resulting in increased levels of MOS, which triggers
increased Aβ production. Regardless of whether this is the reason for disease onset,
mitochondrial dysfunction is a well characterized and accepted aspect of AD (Dumont et
al., 2009). In both human AD brains and transgenic AD mouse models, oxidized
mitochondrial DNA and proteins, as well as lipid peroxidation have been found, even prior
to symptomology and Aβ deposition (Resende et al., 2008; J. Wang, Xiong, Xie,
Markesbery, & Lovell, 2005). Aβ has been implicated to increase ROS upon binding with
Aβ-binding alcohol dehydrogenase (ABAD) (Yan & Stern, 2005) and has also been
associated with decreased Complex III and Complex IV activity (Caspersen et al., 2005).
Aβ is associated with the opening of the mitochondrial permeability transition pore
(mPTP), resulting in a loss in membrane potential, Ca2+ influx into the mitochondria, and
release of pro-apoptotic factors like cytochrome c and apoptosis inducing factor (AIF)
(Rao, Carlson, & Yan, 2014), similar to calcium dysregulation found in AD (Hung, Ho, &
Chang, 2010). Decreased mitochondrial function, which generates ROS, is well
30

characterized in sporadic AD (X. Chen, Stern, & Yan, 2006; Dumont, Lin, & Beal, 2010).
Cytochrome c oxidase (Complex IV) as well as Complex I activity are decreased (Moran
et al., 2012; Murphy, 2009) in Alzheimer’s brains. This ETC dysfunction leads to higher
levels of ROS, a hallmark of AD. Aβ has been shown to inhibit the functioning of the ETC,
specifically in the subunit 1 of Complex IV, known as COX1 (Atamna, 2006; Atamna &
Frey, 2004). Given the substantial role that mitochondrial dysfunction has in the
development of disease, understanding the full breadth of changes occurring beyond Aβ
are vital to preservation of mitochondrial health and disease mitigation. Therefore, closing
the gap in knowledge about how other APP fragments might affect the mitochondria,
notably AICD which can be generated there locally, is necessary.
1.4 Preservation of Reelin to protect against AD onset
Additional targets beyond the scope of products of APP are also important to
assess in prevention of AD. One such target is that of a glycoprotein, Reelin. In
developmental stages, Reelin is instrumental in proper cellular patterning in the cerebral
cortex, while later on it is required for synaptic plasticity and memory and plays key roles
in the hippocampus. Some of the first populations of neurons to die in AD are the Reelinexpressing cells of the EC, which project into the hippocampus, or the memory center of
the brain. Considering many studies have found reductions in Reelin and Reelinexpressing cells in AD, investigating ways to support the health of these cellular
populations are of interest in mitigating disease onset. Particularly, one such way may be
to utilize antioxidants as a way to combat associated oxidative stress in these cells to
maintain Reelin expression and cellular health.
1.4.1 Reelin and neuronal development
31

Reelin is a large glycoprotein secreted by specific cells into extracellular space,
which is vital in the central nervous system for layering of the cerebral cortex and other
regions of the brain during development. Reelin was first discovered due to a mutation in
a mouse model of ataxia, which resulted in mice displaying a unique gate, described as
“reeling” (Lambert de Rouvroit et al., 1999). Later, Reelin was discovered through a series
of chromosome mapping studies and antibody production. Mice harboring autosomal
recessive Reelin mutations, or reeler mice, display issues in mobility due to grossly
underdeveloped cerebellum as well as disorganized cortical neurons. Through studying this
mutant, it was discovered that Reelin is required for neuronal patterning by serving as a
guide for migration of specific cell types during prenatal development (Tissir & Goffinet,
2003). Reelin is required for the proper layering of the cortex and has a key part in
processes that influence synapse formation and neuronal plasticity required for learning
and memory, such as the regulation of dendritic spine architecture and the maintenance of
long-term potentiation (Beffert et al., 2005; Bosch et al., 2016; M. Kim, Jeong, & Chang,
2015; Niu, Yabut, & D'Arcangelo, 2008).
1.4.2 Reelin and subsequent signaling cascades
In developing and post-developmental phases, Reelin functions to induce both
canonical and noncanonical signaling cascades which have diverse roles involving cell
survival, microtubule dynamics, long term potentiation, and synaptic plasticity among
others (Beffert et al., 2005; Weeber et al., 2002). Using knock out mice, researchers have
been able to determine some of the canonical signaling pathways, revealing that Reelin
interacts with either very low-density lipoprotein receptor (VLDR) or ApoE receptor-2
(ApoER2), where it induces the phosphorylation by the tyrosine kinases Src/Fyn of
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Disabled-1 (Dab-1) (Figure 1.9) (Bock & May, 2016). When phosphorylated, the adapter
Dab-1 activates a number of signaling cascades through phosphatidylinositol 3-kinase
(P13K). One such cascade is that of the kinase Akt, which modulates CREB and Bcl-2 to
regulate cell survival, as well as the inhibition of GSK3β, a kinase associated with
hyperphosphorylation of tau in AD (Wasser & Herz, 2017). Additionally, activation of Rac
and Cdc42 regulates actin dynamics. There have also been noncanonical pathways
discovered which yield the activation of Dab-1 through alternative receptors, including low
density lipoprotein (LDL) and NMDA receptors (Lee & D'Arcangelo, 2016). NMDA
receptors are not only essential for memory formation due to their role in long term
potentiation, but also are implicated in the excitotoxicity present in AD and other
neurodegenerative diseases. LDL receptors interact with apolipoproteins, including
ApoE4, the variant linked with an increased risk of AD in LOAD (Yu, Tan, Yu, Xie, &
Tan, 2016).
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Figure 1.9 Canonical signaling of Reelin. Reelin binds to one of two cell surface
receptors, VLDLR or Apoer2, and induces phosphorylation of the adapter protein, Dab-1,
via tyrosine Src family kinase (SFK) activity. Phosphorylated Dab1 acts as a docking site
to initiate multiple downstream signaling cascades including Akt, Rac, Cdc42. Adapted
from (Wasser & Herz, 2017).
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1.4.3 Reelin and the hippocampus
As mentioned previously, there are certain populations of neurons that are most
significantly affected in AD including hippocampal neurons, cortical pyramidal neurons,
and cholinergic neurons in the forebrain. A population closely associated with the
hippocampus which is one of the first affected in the development of AD are those of the
EC, which project, via the perforant pathway, to the dentate gyrus (DG) of the hippocampus
and is heavily involved in memory formation. This projection is accomplished through the
EC layer II neurons which provide the excitatory glutamatergic input into this region of the
brain (Figure 1.10). From here the signal moves from the mossy fibers of the DG to the
pyramidal cells of the CA region. The signal first reaches the CA3 then moves from the
CA3 axons titled the Schaffer collaterals to the CA1 before exiting the hippocampus
through the subiculum and EC layer V neurons. This pathway results in synaptic plasticity
which allows for learning, memory, and recall. Additionally, there are alternative pathways
including the direct pathway of EC layer III neurons which form synapses with CA1, as
well as in the CA3 regions where CA3 axons connect back to CA3 neurons, which has
been postulated to be involved in auto associative memory function. In AD, the Reelinexpressing EC layer II neurons are one of the first populations to die. Reelin has been found
to promote synaptic plasticity and enhance learning and memory via connections from the
EC to the hippocampus (Herz & Chen, 2006). In addition, there is evidence that Reelin is
involved in cytoskeletal regulation of actin and microtubules and is also required for
differentiation and maturation of dendrites and dendritic spines (Tissir & Goffinet, 2003),
which is important in AD since dendritic remodeling often occurs in response to synaptic
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impairment. Since Reelin is involved in the maintenance of healthy neurons and protection
of many pathways affected by AD, the outcomes of its reduction are widespread and likely
magnify the speed of disease progression. As a result, there is cytoskeletal disruption in
both the limbic system and cortex, impaired synaptic plasticity in the hippocampus, and
increases in hyperphosphorylated tau in these regions (Krstic, Pfister, Notter, & Knuesel,
2013).
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Figure 1.10 Hippocampal circuitry. The perforant pathway begins at the entorhinal
cortex (EC) layer II neurons which connect to the dendrites of the dentate gurus (DG) (red).
The mossy fibers of the DG relay signals to the pyramidal cells of Cornus A (CA) 3 (CA3)
region (green) where the signal is relayed to the CA1 (yellow) and out of the hippocampus
to the EC layer V neurons (blue). Additionally, there is the direct circuit from EC layer III
to CA1 (purple) and back to EC layer V (blue) as well as the feedback from CA3 to CA3
internally (yellow). (Adapted from (Lopez-Madrona, Matias, Pereda, Canals, & Mirasso,
2017).
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1.4.4 Reelin and AD
There has been extensive research surrounding the role of Reelin in AD given its
importance in the proper functioning of the EC and therefore hippocampus. Specifically,
the Reelin-expressing neurons of EC layer II are significantly reduced in the brains of
human APP transgenic mice expressing the Swedish and Indiana mutant form of the hAPP
gene (J20 strain). Following the loss of these neurons, Reelin levels in the hippocampus of
J20 mice are also significantly reduced, compared to non-transgenic controls (Chin et al.,
2007). Similarly, there is loss of EC layer II neurons observed in AD patients (Herring et
al., 2012). In a rat model of AD (McGill-R-Thy1-APP strain), EC layer II neurons were
found to selectively express increased levels of soluble intracellular Aβ early in disease,
prior to the deposition of amyloid plaques (Kobro-Flatmoen, Nagelhus, & Witter, 2016).
Reelin has also been reported to have a role in suppression of tau hyperphosphorylation.
When activated, the Akt/PKB pathways inhibits GSK3β. This in turn, inhibits tau
hyperphosphorylation, thus reducing NFTs. Indeed, studies have found that Reelin
modulates this activity of the Akt/PKB pathway (Beffert et al., 2002), serving as another
example of Reelin’s involvement in disease progression. It should also be noted that in
regards to the NMDA receptor pathway, ε4 competitively competes with Reelin for binding
of the ApoE2 receptor and inhibits it, by not only degrading the receptor, but sequestering
NMDA receptors in intracellular compartments (Y. Chen, Durakoglugil, Xian, & Herz,
2010). The reduction of Reelin in the disease state likely causes a drastic decrease in
synaptic plasticity. It has also been proposed that Reelin may be involved in APP
processing through its connection to LDL receptors. Studies performed both in vitro and
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vivo found that Reelin increased the presence of LDL receptors and decreased
amyloidogenic processing of APP (Hoe et al., 2009). Together, these studies suggest that
EC layer 2, Reelin-expressing cells are closely aligned with the early pathogenic changes
in AD and that the loss of such cells are early markers of disease development (Krstic et
al., 2013). Thus, decreased Reelin expression through the loss of EC layer II neurons and
their signaling to the hippocampus are likely associated with the cognitive decline
experienced by patients (Cuchillo-Ibanez, Balmaceda, Mata-Balaguer, Lopez-Font, &
Saez-Valero, 2016; Yu et al., 2016).
1.4.5 Oxidative stress in neurodegeneration
Oxidative stress is an occurrence closely tied to aging and neurodegenerative
disease. The presence of free radicals is part of normal homeostasis, but when unchecked
due to mitochondrial dysfunction, reactive gliosis, or depletion of intracellular antioxidant
pools, the excessive production of ROS can be detrimental to the cell. These species are
produced due to the tendency of oxygen to form free radicals due to unpaired electrons
yielding superoxide radicals, hydrogen peroxide (H2O2), and hydroxyl radicals as a few
examples. These species come from exogenous insults such as UV exposure, drugs which
generate ROS as a nonspecific mode of action, or ionizing agents (Li et al., 2013). They
can also come from endogenous sources such as natural metabolic by-products like in the
ETC as previously discussed. Additionally, ROS can be generated through immune
responses like the antigen presenting cells (APC) or cytokine release in response to cellular
injury. Enzymes can also produce ROS as by-products like nitric oxide synthase (NOS),
cytochrome P450, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, or
xanthine oxidase. It is vital that the cell keeps ROS in check in order to perform many
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processes such as immune activation, differentiation, and protein modification to name a
few. Generally the levels of ROS are maintained at sensitive homeostatic levels through
both the ETC sequestering ROS through electron carriers as well as through the presence
of multiple cellular antioxidant pools such as superoxide dismutase (SOD), catalase (CAT),
and glutathione peroxidase (GPx) (G. H. Kim, Kim, Rhie, & Yoon, 2015). Errors in these
mechanisms are well documented in neurodegenerative diseases since the reduction in
efficiency of these systems results in steadily increasing ROS associated with widespread
neuronal dysfunction.
1.4.6 Endogenous antioxidant glutathione
Glutathione (GSH) is an endogenous antioxidant consisting of glutamate, cysteine,
and glycine which plays an important role in regulating the concentration of ROS in the
cell. The ratio of reduced to oxidized glutathione (GSH:GSSG) is often used a marker of
cellular oxidative stress and toxicity. Under resting conditions, the cellular reduced GSH
concentration is normally around 1-2 mM and reduced GSH makes up approximately 98%
of the total cellular GSH pool, but can decrease significantly under periods of oxidative
stress (Zitka et al., 2012). Shown in Figure 1.11, GSH is synthesized such that first,
glutamate and cysteine are converted to glutamylcysteine by the rate-limiting enzyme γglutamylcysteine ligase (γ-GCL). Subsequently, glutamylcysteine and glycine are then
synthesized into GSH by glutathione synthetase (GS). GSH harbors the ability to then
neutralize free radicals in the cell by conversion of 2 GSH to its oxidative form GSSG by
GSH peroxidase (GP) by donating hydrogen molecules. GSSG can then be returned to 2
GSH through reduction by GSH reductase (GR) to repeat the redox cycle to help maintain
homeostasis (Figure 1.11) (Xiong, Uys, Tew, & Townsend, 2011). Through kinetic studies,
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it’s been found that the rate limiting substrate for GSH production is the availability of
cysteine. Therefore, maintenance of GSH:GSSG ratios, specifically through boosting
cysteine, has been considered a strategy to combat the deleterious effects of oxidative stress
in neurodegeneration.
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Figure 1.11 Glutathione redox reaction. The balance of reduced glutathione GSH and
oxidized GSSG is maintained through a redox reaction utilizing GR and glutathione
peroxidase GP. 2 GSH are oxidized and donate 2 H+ to scavenge ROS through a reaction
catalyzed by GP resulting in GSSG. GSSG is then reduced back to GSH via GR and the
cofactor, NADPH, to continue the redox cycle. Adapted from (Xiong, Uys, Tew, &
Townsend, 2011).
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1.4.7 Modulation of reducing factor GSH with Immunocal®
The novel undenatured whey protein supplement, Immunocal®, is a rich source of
the GSH precursor, cysteine. This supplement is of interest since cysteine supplements are
generally not effective treatments for neurodegenerative diseases as they are catabolized in
the digestive tract and blood before reaching the brain and considered cytotoxic alone
(Bounous & Gold, 1991). Immunocal® rather is rich in serum albumin, α-lactalbumin, and
lactoferrin which have high numbers of cystine residues, a precursor of cysteine which is
resistant to proteolysis and can move freely through the bloodstream. These proteins are
processed in the liver to yield cystine, which is readily transported to neurons via the system
xc- antiporter (Sxc-). Once there, it is hydrolyzed into two cysteine molecules and can be
used by neurons for GSH de novo synthesis (Figure 1.12) (Winter et al., 2017).
Immunocal® was originally developed to enhance immune system function and has been
studied in various disease models including cancers, human immunodeficiency virus
(HIV), amyotrophic lateral sclerosis (ALS), and cystic fibrosis both in vitro and in vivo,
yielding the consensus that it is a potent GSH precursor that boosts cellular antioxidant
levels in the disease state (Baruchel & Viau, 1996; Grey, Mohammed, Smountas, Bahlool,
& Lands, 2003; Neymotin et al., 2011; Tozer et al., 2008).
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Figure 1.12 Cystine-rich Immunocal® processing to GSH. Immunocal® is rich is
cystine which is able to be transferred to neurons via Sxc- transport, where it is processed
into cysteine, which can be readily processed into GSH via a number of catalytic steps. γGCL; gamma-glutamylcysteine ligase, the rate-limiting step in GSH synthesis.
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1.4.8 Preservation of Reelin-expressing cells with Immunocal® supplement
More recently, Immunocal® was investigated in a schizophrenia mouse model
characterized by low Reelin levels, particularly in prefrontal cortex. In this study,
Immunocal® treatment significantly elevated Reelin in the brain (Song et al., 2017).
Considering that a similar loss of Reelin-expressing EC layer II neurons has also been
observed in the brains of patients with AD, Immunocal® could be a feasible treatment to
elevate Reelin expression and signaling in the EC of a mouse model of AD, specifically
J20 mice. As noted above, Reelin-expressing cells of the EC layer II are significantly
reduced in the brains of this strain, making it an ideal model to study the effects of
Immunocal® supplementation. Preservation of Reelin in these animals could mitigate loss
of these populations of neurons to potentially slow or prevent apoptosis and subsequent
cognitive impairment and provide key preclinical data to support the use of Immunocal®
as a therapeutic option for the treatment of AD.
1.5 Cell culture to mouse models to clinical studies: investigating interventions to
mitigate AD pathogenesis
With the largely unfulfilled need for therapeutics to address the underlying
etiologies of AD to prevent symptom onset, identifying alternative strategies before it
affects not only patients, but their caretakers and economic and healthcare systems has
never been more crucial. The studies presented here sought to uncover additional
mechanisms to do just that. First, we uncover a relationship between Aβ42 and PA
biosynthesis and propose the use of FDA approved DFMO as a way to reduce Aβ42
aggregation and downstream effects. Next, we present the novel neurotoxic role of the
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AICD at the mitochondria and the potential synergistic role it may have along with Aβ42
in disease pathogenesis. We also investigate the protective benefits of a cysteine-rich
whey protein Immunocal® in a mouse model of AD to preserve Reelin levels and reduce
ROS in the brain. Lastly, we briefly report the results of a multimodal approach to care at
the Alumia institute in a small population of patients with ADRD. Pinpointing alternative
approaches to the treatment of AD will likely be most successful in mitigating this
dynamic and complex disease.
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.CHAPTER TWO: MODULATING POLYAMINES AS A METHOD OF
REDUCING AMYLOIDOGENIC TOXICITY AND AGGREGATION

2.1 Abstract
Polyamines (PA) are a ubiquitous class of molecules associated with cell growth,
proliferation, and immune response. The PA pathway has been proposed to be involved in
Alzheimer’s disease (AD) pathology, but its role is currently unclear. Here, we elucidated
the relationship between amyloid beta1-42 (Aβ42) and the PA pathway. Previous evidence
suggested there is an increase in PA biosynthesis and changes in subcellular location and
levels of PA pathway components in AD brains, though PA involvement in AD has been
contradictory. We examined the relationship between PA synthesis and amyloid using
mouse hippocampal cells and found that Aβ42 increased polyamines in a dose dependent
fashion through enhanced expression of ornithine decarboxylase (ODC), the rate-limiting
enzyme of polyamine biosynthesis. Further, aggregation and apoptosis were markedly
decreased by treatment with the ODC inhibitor d, l-α-difluoromethylornithine (DFMO) in
these cells, suggesting a reciprocal relationship between PA and aggregation properties.
Finally, we found that PA were significantly increased in human hippocampal tissue from
patients with AD, compared to age-matched controls. Together, these data suggest that
increased PA may be a response to Aβ42 accumulation and further may promote Aβ42
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toxicity by enhancing its aggregation. Therefore, targeting the PA pathway may represent
a novel therapeutic intervention in the treatment of AD by mitigating Aβ42-related
pathophysiological mechanisms.

2.2 Introduction
AD currently afflicts over 6 million Americans; projected to increase steadily in the
coming years. Being that AD is both the sixth leading cause of death and has a negative
impact of billions of dollars on the economy, extensive research has and continues to be
conducted to develop efficacious treatments (Alzheimer’s Association, 2021). The current
lack of success in treatments to combat disease pathogenesis of AD in the general
population highlights the necessity to further understand the complex mechanisms of AD
to develop more successful treatment avenues. AD pathology develops at least a decade
prior to onset of dementia symptoms, there is a therapeutic window for intervention, but
biological mechanisms that could be targeted have not yet been defined. A number of
hypotheses exist to explain the cumulative and widespread death of neurons in both cortical
and subcortical brain regions and the emergence of amyloid plaques and neurofibrillary
tangles (NFT) that characterize AD (Adriaanse, et al., 2014; Baird, Westwood, &
Lovestone, 2015; Braak & Braak, 1995; Braak & Del Tredici, 2011; Cheignon et al., 2018;
Ferreira-Vieira, Guiamaraes, Silva, & Ribeiro, 2016; Guo et al., 2020; Salgado-Puga &
Pena-Ortega, 2015; Salloway et al., 2020; Shi, Sabbagh, & Vellas, 2020).
The amyloid cascade hypothesis posits that aberrant processing of amyloid
precursor protein (APP) causes naturally produced Aβ peptide to aggregate into plaques,
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inducing oxidative damage and mitochondrial dysfunction, leading to cell death (Billings,
Oddo, Green, McGaugh, & LaFerla, 2005; Hanon et al., 2018). While some studies suggest
that the aggregation of intraneuronal toxic tau is downstream to that of Aβ, the protein has
been shown to exhibit neurodegenerative effects independent of Aβ, leading to the
conclusion that tau and Aβ work in concert and may even enhance each other’s deleterious
impacts on different neuronal populations (Oddo et al., 2003; Scheltens et al., 2016).
However, it is undisputed that Aβ serves as a key player for accumulation and progression
of AD pathology in the brain. Previous work has shown that by accumulating in the
mitochondrial matrix, Aβ promotes the generation of reactive oxygen species (ROS),
leading to neuronal apoptosis (Bartley et al., 2012; Cheignon et al., 2018; J. X. Chen &
Yan, 2007).
PA are a ubiquitous class of positively charged aliphatic amines, which appear to
not only affect cell proliferation and differentiation through their ability to interact with
negatively charged molecules (Chattopadhyay et al., 2009; Minois et al., 2011; Soulet &
Rivest, 2003), but also increase in response to ROS induced by Aβ-driven AD (Choi et al.,
2001). Previous animal and human studies including postmortem AD brain analysis has
shown increased levels of key enzymes in the PA pathway (Bernstein & Muller, 1995;
Morrison, Bergeron, & Kish, 1993; Yatin, Yatin, Aulick, Ain, & Butterfield, 1999; Yatin,
Yatin, Varadarajan, Ain, & Butterfield, 2001). Furthermore, metabolomics studies show
alterations in the PA pathway in AD (Inoue et al., 2013; Seidl et al., 1996). An increase in
PA levels, otherwise known as the “polyamine response,” results in enhanced PA
biosynthesis with similar increases in exogenous PA uptake (Gilad & Gilad, 1999; Gilad,
Gilad, & Wyatt, 1993; Saito, Packianathan, & Longo, 1997). The rate-limiting step of the
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synthesis of PA occurs when ornithine is processed by ornithine decarboxylase (ODC) to
yield putrescine, followed by spermidine and spermine through the addition of subsequent
amine groups. The subcellular location of ODC, as well as ODC and PA levels, are changed
in AD brains, suggesting that alterations in PA biosynthesis likely occur as a result of AD
pathology (Bernstein & Muller, 1995; Nilsson et al., 2006; Seidl et al., 1996).
Research on the role of PA in AD pathogenesis has been paradoxical, suggesting
accumulations of PA can be both protective and harmful to the cell via many different
pathways as well as through neuronal and glial interactions (Skatchkov, Woodbury-Farina,
& Eaton, 2014). However, elucidating their roles in disease, specifically AD, could make
them an attractive therapeutic target (Nakanishi & Cleveland, 2021). For instance, in vitro
evidence suggests that PA have the capacity to facilitate protein aggregation, speficially
where amyloidosis plays a critical role (Gomes et al., 2014; Kabir, Jash, Payghan, Ghoshal,
& Kumar, 2020; Luo et al., 2013), though the mechanism of action in vivo is not fully
understood. Therefore, further research is required to understand the relationship between
PA and the development of AD, specifically in regard to Aβ42. This is especially important
from the translational perspective, since there are FDA approved drugs that modulate the
PA pathway. These drugs exist considering traditional PA research has found they are
essential for cancer cell growth, resulting in interest in targeting PA biosynthesis as a
strategy for chemoprevention, especially in combatting skin and colon cancers
(Nowotarski, Woster, & Casero, 2013).
Here we hypothesized a relationship between PA and Aβ accumulation, through
the modulation of the rate-limitung ODC enzyme. Furthermore, we hypothesized that PA
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contribute to Aβ oligomerization leading to neuronal dysfunction in AD. We utilized cell
models of Aβ accumulation and determined that ODC inhibition via DFMO can reduce
Aβ-mediated apoptosis as well as aggregation, thus slow AD pathology in a neuronal cell
system. Additionally, using AD brain tissue, we found that PA levels are increased.
Together, this suggests an interaction between PA levels and Aβ42 aggregation and toxicity
in AD.

2.3 Methods
2.3.1 Reagents
Lipofectamine 2000, Lipofectamine 3000, Opti-MEM, Dulbecco’s Modified Eagle
Medium (DMEM), were purchased from Invitrogen (Carlsbad, CA). Hank’s Balanced Salt
Solution, Staurosporine, 2’,7’-Dichlorofluorescin diacetate (DCF), and Hoechst stain (St.
Louis, MO). L-𝛼-difluoromethylornithine DsRed-Express2 plasmids were purchased from
Clontech (Mountain View, CA). Primary antibodies for Amyloid-Beta Peptide antibody
(MOAB-2) and Ornithine decarboxylase (ODC) antibody and cytosolic/mitochondrial
tissue fractionation kit were purchased from Abcam (San Francisco, CA). Primary antibody
for beta-actin was purchased from Cell Signaling Technologies (Danvars, MA). Cy3conjugated secondary antibodies were purchased from Jackson Immunoresearch
(Westgrove, PA). Normocin (Broad spectrum antimicrobial reagent) from InvivoGen (San
Diego, CA).

DL-α-Difluoromethylornithine (DFMO, CAS No. 96020-91-6), and

Polyamine standards were obtained from Cayman Chemical (Ann Arbor, MI). Antibody
concentrations for applications listed in Supplementary Table 1.
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2.3.2 Experimental Models
HT22 Cell Culture
Immortalized mouse hippocampal cells (HT22) were a gift from Dr. Russell
Swerdlow’s research group (University of Kansas Medical School). They were plated in
35mm diameter 6- well culture plates in Dulbecco’s modified eagle’s medium (DMEM)
containing 4.5g/L glucose supplemented with 10% fetal bovine serum (FBS), and penicillin
(100 Units/mL)/streptomycin (100μg/mL). Cells were incubated overnight at 37°C in 10%
CO2. The next day the HT22 cells were transfected and treated appropriately at 80-90%
confluence.
Tissue Sources
The hippocampal brain tissue used was obtained from a collaboration with Dr. AnnCharlotte Granholm and the MUSC Carroll Campbell Jr. Neuropathology laboratory. This
South Carolina Brain Bank contains frozen and fixed tissues from >250 Alzheimer cases
and Controls, and all cases have undergone neuropathological and clinical staging
including the ABC assessment as described by Jack et al (Jack et al., 2012) and recently
amended by DeTure and Dickson (DeTure & Dickson, 2019). Fifty mg frozen tissue
dissected from 3 neuropathologically-confirmed postmortem Alzheimer’s disease cases
(Braak V-VI and CERAD C), and 3 age-matched controls which showed no AD pathology
(Braak <II and CERAD 0-A) were collected. The tissue was then lysed and isolated into
cytosolic and mitochondrial fractions according to the manufacturer’s protocol (Abcam,
San Francisco, CA).
2.3.3 Plasmid Preparation
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Empty pIRES2 DsRed-Express2 (DsRed2) bicistronic vectors containing Aβ42
sequence were originally transformed using 50 ng of plasmid in JM109 Escherichia coli
and grown on LB agar plates containing 35 μg/mL kanamycin sulfate at 37°C overnight.
Starter cultures were created using a colony containing transformed cells and grown in LB
broth with 35 μg/mL kanamycin sulfate for 6-8 h at 37°C and diluted to 1:250 into
overnight cultures. Plasmids were isolated and purified using a Maxi prep Kit according to
the manufacturer’s instructions (Clontech, Mountain View, CA). Plasmid concentrations
were quantified using three averaged recordings by a NanoDrop 2000 (Thermo Scientific).
Bicistronic vectors that allow for co-expression of DsRed separate from the protein of
interest are used in this experiment in place of protein fusion construction to prevent
interference with the normal functioning and localization of the small proteins being
examined. Because DsRed is expressed in the cell separately from Aβ42, there is no
interference with normal function of Aβ42 or formation of unnatural aggregation following
overexpression.
2.3.4 Transfection
HT22 cells were transfected with 5 μg, unless otherwise specified, of DsRed2
plasmids containing Aβ42 or empty IRES vector sequences using a standard Lipofectamine
2000 protocol as outlined by Bartley et al (Bartley et al., 2012). Both cell types were
incubated in Opti-MEM with the DsRed2 bicistronic plasmid/Lipofectamine 2000 mixture
for 4-6 h at 37°C in 10% CO2 for HT22. Transfection was terminated in both cell cultures
after 4-6 h through replacement of the Opti-MEM with 1 mL culture media. Cells were
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incubated for 24 or 48 h at 37°C in 10% CO2 before proceeding with additional
experimental analysis.
2.3.5 Fluorescence Staining and Imaging
Transfected and treated HT22 cells were washed once with PBS (pH 7.4) and fixed
for 45 minutes in 4% paraformaldehyde at 25°C. Cells were washed twice with PBS then
incubated in a 1:1000 dilution of Hoechst nuclear stain in PBS at 4°C overnight. The
following day, cells were washed twice with PBS and placed in an anti-quench solution
composed 0.1% p-phenylenediamine in PBS for imaging.
For immunohistochemistry experiments, following paraformaldehyde fixation,
HT22 cells were washed twice with PBS then non-specific sites were blocked with 5%
BSA in PBS containing 0.2% TritonX-100 for 1 h at 25°C. Blocking solution was then
aspirated and cells were incubated overnight at 4°C in a primary antibody solution
consisting of 2% BSA in PBS containing 0.2% TritonX-100 and primary antibody diluted
according to manufacturer’s recommendations (Supplementary Table 1). Cells were then
washed five times with PBS over the course of 1 h and then incubated in 1:1000 dilution
of Hoechst nuclear stain and 1:250 dilution of secondary antibody in PBS at 25°C,
protected from light for 1 h. Cells were then washed five times with PBS over the course
of 1h before plating in an anti-quench solution composed of 0.1% p-phenylenediamine in
PBS in for imaging.
Cells were imaged using a Zeiss Axiovert-200M epi-fluorescence microscope with
five representative images taken of each well for assessment of apoptosis. All experimental
conditions were performed in duplicate or triplicate wells in each experiment. Only cells
54

fluorescing red through the expression of the DsRed-Express2 vector were counted and
assessed for apoptosis through the visual evaluation of condensed or fragmented nuclei as
indicated by Hoechst nuclear stain. Three wells with at least 25 transfected cells per wells
were randomly selected and quantified for each experimental condition.
2.3.6 Reactive Oxygen Species Detection
ROS detection was performed on live HT22 cells using DCF fluorescence 24 h post
transfection. Anhydrous DCF was reconstituted in DMSO to yield 2mM stocks that were
used for up to 2 months. Positive control groups were treated with H2O2 (125 μM) for 4560 minutes at 37°C protected from light prior to loading with DCF. Then, all groups were
loaded with 1 mL of 10 μM DCF dye in warmed PBS (pH 7.4) for 30 minutes at 37°C
protected from light. Labeling solution was then aspirated and cells were stained with
Hoechst stain (1μM) in warmed PBS for 15 minutes at 37°C protected from light. The cells
were then mounted in anti-quench solution consisting of 0.1% p-phenylenediamine in PBS
for imaging.
2.3.7 Thioflavin T-Based Aggregation Kinetic Assays
Thioflavin T (ThT)-based aggregation kinetic assays were conducted on an Infinite
M200PRO plate reader (Tecan, Männedorf, Switzerland). Experiments were conducted in
triplicate in a Costar black 96 well plate (Corning Inc., Kennebunk, ME). with a final
volume of 200 μL per well. Every measurement was an average of 50 readings. The
aggregation of Aβ42 was initiated by the addition of peptide from a stock solution (in
DMSO, 0.5− 1 mM) to phosphate buffer to a final concentration of 10 μM. The
concentration of ThT dye used in the experiment was 5 μM. The aggregation of Aβ42 was
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monitored by ThT fluorescence (λex = 445 nm and λem = 485 nm). The blank sample
contained everything except Aβ42. The Kinetic assays in the presence of polyamines were
conducted under the matched conditions except that the polyamines were added from a
stock solution (10-50 mM in Milli Q water) to keep the final concentration of water less
than 1.0% (v/v). The polyamines were added to the wells with ThT dye and buffer and
mixed gently before adding Aβ42. To keep the conditions identical, an equal amount of
Milli Q water was added to the wells with Aβ42. Kinetic profiles were processed using
Origin (version 9.1). The sample data were processed by subtracting the blank and
renormalizing the fluorescence intensities of graphs and keeping the intensity of Aβ42
aggregation as one. The Kinetic curves of the Aβ42 aggregation were fit using the built-in
sigmoidal fit. Each experiment was fit independently to extract the t50 (time required to
reach 50% of the maximum fluorescence intensity).
2.3.8 Cell Lysis
MEK-LIF
HT22 cells were lysed either 24 or 48 h post transfection termination. First, cells
were washed once with ice cold PBS (pH 7.4) before adding of Wahl lysis buffer (200 𝜇L)
supplemented with leupeptin and aprotinin at volumes of 1 𝜇L per mL buffer, then
incubated on ice for 10 minutes. Following incubation, a pipet tip was used to scrape the
surface of each well before collection of lysis buffer. Each sample was centrifuged for 2
minutes at 9,600 g and the resulting lysate was collected.
Western Blotting and Aβ42 ELISA
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HT22 cells were lysed at either 24 or 48 h post transfection termination. First, cells
were trypsinized before being collected and centrifuged for 5 minutes at 1100 g. The pellets
were then washed with ice cold Dulbecco’s phosphate buffered saline solution (DPBS)
before centrifuged again for 5 minutes at 3,500 g. The resulting pellets were resuspended
in 1X RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50
mM Tris, pH 8.0) supplemented with leupeptin and PMSF and incubated on ice for 30
minutes. The samples were then sonicated in a water bath for 1 minute before being
centrifuged at 14,000 g for 15 minutes at 4°C. The subsequent supernatants were collected
for analysis.
2.3.9 Micellar electrokinetic chromatography with laser induced fluorescence
PA were analyzed with a modified protocol using micellar electrokinetic
chromatography with laser induced fluorescence (MEKC-LIFD) from (Betancourt et al.,
2018). Briefly, samples were derivatized with 1.28 mM FITC/Acetone in 200 mM
carbonate buffer (1:1) at pH 10 or derivatizing solution and stored at room temperature
during 24 hours followed by analysis in the MEK-LIFD instrument.
MEKC-LIFD instrument
The MEKC-LIFD instrument was built in-house described elsewhere (Hernandez
et al., 1993). In brief, a Glassman High Power Supply model PS-MJ30P04400X88
(Glassman High Voltage Inc. Whitehouse Station, NJ, USA), a collinear fluorescence
detector described elsewhere (Dada, Huge, & Dovichi, 2012) equipped with a Hamamatsu
Photo Multiplier Tube Model H-9306 (Hamamatsu Co, Middlesex, NJ, USA) and a Cobolt
state, 488 nm, continuous wave laser model 0488-06-01-0060-100 (Cobolt MLD, Solna,
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Sweden). The signals were collected by a National Instruments data acquisition card,
model PCI-6221 (National Instruments Co. Austin, TX, USA) in a computer programmed
with custom-made software both for acquisition and processing.
Sample treatment
Cell lysates: After quantifying protein concentration via BCA protein assay, the
cell lysates were deproteinized by mixing lysates with acetonitrile in a ratio of 1:1, vortex
and centrifuged at 14,000 g at 4 °C for 15 minutes. Supernatants were mixed with
derivatizing solution (1:1). After 24 h in darkness, the samples were ready for MEKC-LIF
analysis. To identify PA, samples were spiked with a solution of 2 μM of PA standards and
derivatized as described above. Then the electropherograms were compared by overlapping
to detect the enhanced peak.
Brain tissue: Tissue was homogenized in 20 mM borate buffer (pH 9.3) in a ratio
of 2 mg of tissue per 100 uL of buffer. The homogenates were mixed with an equal volume
of chloroform and vortexed (20 min) followed by centrifugation at 15,000 g for 20 min,
the supernatants were transferred to Eppendorf tubes and deproteinized with acetonitrile at
1:1 ratio, followed by derivatization as described above. Samples were centrifuged at
14,000 g for 15 minutes and stored in dark at room temperature for 24 hours, after which
they were ran in the MEKC-LIFD for quantification of PA.
Running procedure
The standard solutions and the samples were hydrodynamically injected by
applying a negative pressure of −10 psi for 1 second at the cathodic end of a fused silica
capillary model TPS 025375, polyimide coated, 350 μm external diameter, 25 μm inside
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diameter and 60 cm long (Polymicro Technologies Inc., Phoenix, AZ, USA) while the
anodic end of the capillary was immersed into the tested solution. The running buffer was
40 mM Sodium Borate and 20 mM SDS at pH 9.0 (Paez, Rada, & Hernandez, 2000). After
injection the anodic end of the capillary was immersed in a buffer reservoir equipped with
a Platinum-Iridium electrode while the cathodic end remained in the buffer reservoir of the
cathode. A positive, 27 kV was applied at the anode for the electrophoretic separation and
the data collected for 45 minutes.
Sample data analysis
The signal was collected at 40 points per second using a homemade software in
MATLAB® and data output in the form of voltage versus time was presented as
electropherograms. The data were analyzed by means of a PicoAnalytical software Inc.
(Miami, FL), that is capable of filtering with a moving average digital filter and has both
horizontal and vertical displacement capabilities for automatic electropherograms
alignment. The software deconvoluted the peaks and calculated the best fitting Gaussian
curve for each peak. The same software also calculated the average of unlimited number
of electropherograms.
2.3.10 Western Blotting
Western blots were utilized to analyze HT22 cell lysates (See Cell Lysis for
Western Blotting and Aβ42 ELISA). Protein samples (10-15 µg/lane) were resolved by 816% gradient Novex Tris-glycine gels (Thermo Fisher, Carlsbad, CA) and proteins were
then transferred to PVDF membranes. Non-specific binding sites were blocked using 1%
BSA in PBS (pH 7.4) containing 0.1% Tween-20 (PBS-T) for 1 h at 25°C. The blocking
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buffer was drained, and the membrane was allowed to incubate in primary antibody diluted
in blocking buffer according to manufacturer’s recommendations (Supplementary Table 1)
overnight at 4 °C. The membrane was washed three times for 15 minutes in PBS-T and
was then incubated with the secondary antibody for 1.5 h at 25 °C. The secondary was then
removed, and the membrane was washed again in PBS-T, three times for 15 minutes.
Immunoreactive proteins were detected using enhanced chemiluminescence (ECL)
reagents (GE Healthcare; Pittsburgh, PA) and films were imaged using a ChemiDoc
(BioRad, Hercules, CA). Re-probing of blots was performed by stripping in 0.1 M TrisHCl (pH 8.0), 2% SDS, and 100 mM β-mercaptoethanol for 30 minutes at 52 °C. The blots
were rinsed twice in PBS-T and processed as above with a different primary antibody.
2.3.11 DFMO Treatment
Six hours following plating, HT22 cells were pre-treated with DFMO (5 mM; stock
made in culture media) before transfection. Cells were transfected according to the protocol
listed. Following the removal of the transfection medium, DFMO (5 mM) was
administered. All cells were left in treatment media for 24 or 48 h before proceeding
2.3.12 Aβ42 Monomer ELISA
Monomeric Aβ42 was detected in both HT22 cell lysates utilizing an Aβ42 Mouse
enzyme-linked immunosorbent assay kit (ELISA) (Thermo Fisher, cat #KMB3441,
Carlsbad, CA). Briefly, Aβ42 standard was reconstituted in sodium bicarbonate (55 mM,
pH 9.0) then utilized to generate a standard curve ranging from 3.12 – 200 pg/mL in a 96
well pre-coated clear bottom plate. Next, 100 µL of each sample was plated in duplicate
and allowed to incubate at room temperature for 2 h. Following incubation, wells were
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washed four times with 1X wash buffer before adding 100 µL of detection antibody, which
was incubated at room temperature for 1 h. The wells were then washed four times with
1X wash buffer before adding 100 µL Streptavidin-HRP and incubating at room
temperature for 1 h. Then wells were then washed four times with 1X wash buffer before
adding 100 µL chromogen to each well and incubating protected from light at room
temperature for 30 minutes. Finally, 100 µL stop solution was then added to each well
before reading with a colorimetric microplate reader at 450 nm.
2.3.13 Statistical Analysis
All experimental conditions were performed in duplicate and statistical analysis
was only performed on experiments quantified a minimum of three times. Data represents
the means +/- SEM for the total number (n) of experiments carried out. The statistical
comparisons were made with t-test, and analysis of variance (ANOVA) with
Graphpad Prism 9 software. A p-value of <0.05 was considered statistically significant.

2.4 Results
2.4.1 Aβ42 increased PA biosynthesis in a dose-dependent manner
To determine whether PA were capable of aggregating Aβ42, we first utilized a cellfree Tht fluorescence aggregation assay (Figure 2.1A-B). Figure 2.1A depicts amyloid
formation kinetics in the ThT fluorescence assay over time for 10 μM Aβ42 peptide in the
presence (black) or absence (red) of putrescine (100 μM). In the presence of putrescine,
aggregation is faster. Aβ42 aggregation relative intensity is displayed in black in the
presence of putrescine at 50:1 molar ratio and in red without putrescine. Comparing the
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time to reach 50% fluorescence (t50) for Aβ42 showed a dose-dependent increase in
aggregation speed as a function of putrescine concentration. Therefore, in a cell-free
environment, PA, specifically putrescine, can increase the speed of Aβ42 aggregation.
We then evaluated whether Aβ42 aggregation could cause changes in PA levels in
hippocampal neurons. HT22 cells were transfected either empty IRES vector or increasing
concentrations of Aβ42 for 48 hours. Subsequent analysis of the 48-hour cell lysates using
MEKC-LIF yielded a dose dependent increase in which higher transfection concentrations
of Aβ42 were associated with similarly increased levels of the PA, putrescine, spermidine
and spermine (Figure 2.1C-D). Separate one-way Analysis of Variance (ANOVA) were
conducted for putrescine, spermidine and spermine followed by post hoc analysis to isolate
simple effects. As can be seen in Figure 2.1C there was a significant main effect of
transfection dose on putrescine levels, with 5 μg and 10 μg of Aβ42 producing significantly
higher levels of putrescine compared to 0 μg of Aβ42, 5 μg of IRES, 1 μg of Aβ42, and 2.5
μg of Aβ42 [F(5,12)=17.93, p<0.0001]. Similarly, there was a significant main effect of
transfection dose on spermidine levels, where transfection with every dose of Aβ42 elicited
significantly higher spermidine levels compared to 0 μg of Aβ42 [F(5,12)=82.35,
p<0.0001]. Additionally, transfection with 2.5, 5 and 10 μg of Aβ42 produced significantly
higher levels of spermidine compared to 5 μg of IRES (p<0.05). A significant dose
response of Aβ42 transfection was also shown with spermine [F(5,12)=35.55, p<0.0001],
where 5 and 10 μg of Aβ42 producing significantly higher levels of putrescine compared to
0 μg of Aβ42, 5 μg of IRES, 1 μg of Aβ42, and 2.5 μg of Aβ42. Notably, transfection with 5
and 10 μg of Aβ42 caused a significant increase in the concentration of all three polyamines
as compared to IRES, with putrescine showing the largest dose-dependent relationship
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between Aβ42 and upregulation. These data indicated that while polyamines can influence
Aβ42 aggregation, Aβ42 can also in turn affect polyamine production.
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Figure 2.1 PA levels increased with increasing concentration of Aβ42. A & B) ThT
fluorescence assays. Amyloid formation kinetics of 10 μM Aβ1-42 peptide in the presence
or absence of putrescine (100 μM). Average of triplicate wells with standard deviation
plotted. A) ThT fluorescence assay of Aβ42 over time. Aβ42 aggregation relative intensity
is displayed in black in the presence of putrescine at 50:1 molar ratio. B) Tht fluorescence
assay t50 for Aβ42 is indicated in black versus t50 for various molar ratios of putrescine as
follows; 1:1, 10:1, 50:1 displayed in red. C-D) MEKC-LIF was used to measure
concentrations of putrescine (C), spermidine (D), and spermine (E) in HT22 cell lysate that
was acquired 48 hours after transfection with no plasmid (0 μg), empty pIRES DsRedExpress2 (Ires) bicistronic vector (5 μg) or vector co-expressing DsRed2 with Aβ42 at
increasing concentrations (1, 2.5, 5, or 10 μg). Results shown as mean SEM, n=3. **
indicates p<0.01 compared to IRES control, *** indicates p<0.001 compared to IRES
control as determined using one-way ANOVA with a post hoc Tukey’s test.
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2.4.1 Aβ42 induced ODC expression in HT22 cells
One possible mechanism for increased PA levels in the presence of Aβ42
aggregation is if the Aβ42 aggregation affects the level of rate-limiting PA-producing
enzyme ODC. To test this possibility, lysates of 24-hour IRES and Aβ42 transfected HT22
cells were analyzed using Western blotting with an antibody specific to ODC. As shown
in Figure 2.2, the bands detecting ODC at 52 kDA were noticeably darker in the Aβ42
sample lysates in comparison to the IRES samples. After normalizing to beta-actin, oneway ANOVA revealed a significant increase in the ratio of ODC abundance 24 hours
post transfection with Aβ42 in comparison to those with IRES as well as 48 hours post
transfection [F(2,19)=9.569, p=0.0013]. At 48 hours post transfection, the cells
transfected with Aβ42 displayed similar levels of ODC as the control likely due to a
negative feedback loop limiting ODC expression described by others previously (Yuan et
al., 2001). We therefore concluded that the Aβ42 transfected cells had initially increased
levels of ODC compared to control HT22 cells, which was then resolved with time.
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Figure 2.2 Aβ42 increased relative concentration of ODC. A) Western blot analysis of
HT22 lysates acquired 24 hours post-transfection after transfection with empty pIRES
DsRed-Express2 (Ires) bicistronic vector or vector co-expressing DsRed2 with Aβ42 using
antibodies specific for ODC (top panel) and beta-actin (bottom panel). B) Western blot
analysis of HT22 lysates acquired 48 hours post-transfection after transfection with empty
pIRES DsRed-Express2 (Ires) bicistronic vector or vector co-expressing DsRed2 with Aβ42
using antibodies specific for ODC (top panel) and beta-actin (bottom panel). C)
Densitometry quantification of (A) and (B). Results shown as mean + SEM, n=10 for Ires,
n=6 for 24 hours, n=6 for 48 hours. ** indicates p<0.01 compared to 24h Aβ42 as
determined using one-way ANOVA with a post hoc Tukey’s test.
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2.4.3 DFMO decreased polyamine levels in response to Aβ42
DFMO is an irreversible inhibitor of ODC. As polyamines affected Aβ42
aggregation speed, we hypothesized that inhibiting ODC could affect Aβ42 aggregation and
subsequent effects. First, we investigated whether DFMO could reduce the increase in PA
induced by Aβ42. HT22 cells were pre-treated 6 hours after plating with DFMO (5 mM) in
growth media, where they were incubated overnight before transfection the following day.
When terminating transfection, the cells were treated again with DFMO (5 mM) in growth
media followed by incubation. Using MEKC-LIF, lysates collected 48 hours post
transfection were analyzed for PA levels (Figure 2.3). Separate one-way ANOVAs were
conducted for putrescine, spermidine and spermine followed by post hoc analysis to isolate
simple effects. As can be seen in Figure 2.3, there was a significant main effect of Aβ42
transfection on putrescine levels [F(2,7)=20.16, p=0.0012], spermidine levels
[F(2,7)=47.97, p<0.0001] and spermine levels [F(2,7)=41.56, p<0.0001]. Specifically,
putrescine, spermidine and spermine levels were significantly higher after Aβ42
transfection compared to IRES, and the increase in PA was attenuated by DFMO.
Therefore, the inhibition of ODC by DFMO reduced PA production due in response to
Aβ42.
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Figure 2.3 ODC-inhibitor DFMO decreased Aβ42-induced PA levels. MECK-LIF was
used to measure concentrations of putrescine (A), spermidine (B), and spermine (C) in
HT22 cell lysate that was acquired 48 hours after transfection with either empty pIRES
DsRed-Express2 (Ires) bicistronic vector or vector co-expressing DsRed2 with Aβ42 at in
the presence or absence of difluoromethylornithine (DFMO; 5mM). Results shown as
mean SEM, n=3 for Ires and Aβ42, n=4 for Aβ42 + DFMO. * indicates p<0.05 Aβ42+DFMO
compared to Aβ42 alone, ** indicates p<0.001 Aβ42+DFMO compared to Aβ42 alone as
determined using one-way ANOVA with a post hoc Tukey’s test.
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2.4.4 DFMO reduced Aβ42 aggregation and ROS in HT22 cells
Next, we analyzed the effect of ODC inhibition by DFMO and thus reduced levels
of PA on Aβ42 aggregation in HT22 cells. Imaging of the cells following transfection and
treatment protocol revealed that DFMO decreased the relative amount of Aβ42 aggregation
in Aβ42 transfected cells, as evidenced by noticeably less intense aggregate staining as
displayed by MOAB-2 signal in the Aβ42 + DFMO images in comparison to those without
DFMO (Figure 2.4A). Further, using a monomeric Aβ42 ELISA assay, we measured the
levels of Aβ42 monomers 48 hours post transfection. As can be seen in Figure 4B, an
unpaired t-test revealed a significant increase in monomers in cells treated with DFMO as
compared to Aβ42 and IRES, suggesting a reduction in aggregated peptides in the treated
group [t(6)=2.465, p=0.0488].
Aβ expression and aggregation is known to cause increased ROS levels (Bartley et
al., 2012; Cheignon et al., 2018; J. X. Chen & Yan, 2007). With a decreased level of Aβ42
aggregation with ODC inhibition, it is also possible that ROS levels would be similarly
reduced. We therefore measured the effects of DFMO on Aβ-induced ROS using DCF
staining. ROS was noticeably reduced in cells treated with DFMO, as displayed through
the reduction in DCF signal (Figure 2.4C).
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Figure 2.4 DFMO decreased Aβ42 aggregation and ROS production in vitro. A)
Representative HT22 cells imaged 48 hours after transfection with empty pIRES DsRedExpress2 (Ires) bicistronic vector or vector co-expressing DsRed2 with Aβ42 in the
presence or absence of difluoromethylornithine (DFMO; 5mM). On the left, decolorized
nuclei are shown stained with Hoechst dye. On the right, decolorized Aβ42 aggregates
indicated by MOAB-2 staining are shown. Scale bar = 10 microns. B) ELISA quantification
of Aβ42 monomers in lysates from HT22 cells 48 hours after transfection with bicistronic
vector co-expressing DsRed2 with Aβ42 in the presence or absence of DFMO (5 mM).
Results shown as mean SEM, n=4. * indicates p<0.05 Aβ42+DFMO compared to Aβ42
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alone using an unpaired t-test. C) Representative images of DCF staining assay in HT22
cells 48 hours after transfection as described in (A). Successfully transfected cells are
indicated by DsRed2 fluorescence in the top panel, oxidative species are indicated by DCF
staining in the middle panel. Overlay of the two signals are shown in the bottom panel.
Arrows indicate transfected cells with positive ROS staining. Scale bar = 10 microns.
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2.4.5 DFMO protected HT22 cells from apoptosis induced by Aβ42
Since reduction in the PA synthesis reduced both Aβ aggregation and associated
ROS, we sought to determine if such inhibition would reduce apoptosis in Aβ42-transfected
cells. Upon quantifying the percentage of apoptotic transfected cells 48 hours post
transfection marked by the DsRed signal and evaluating this population for apoptosis via
appearance of nuclear condensation and fragmentation, there was a significant increase in
apoptosis in cells transfected with Aβ42 in comparison to IRES [F(2,9)=43.83, p<0.0001].
Interestingly, treatment with DFMO significantly reduced the number of apoptotic cells
following Aβ42 transfection (Figure 2.5B). Taken together, these data support that
application of DFMO in physiological doses partially protects HT22 cells from Aβ42
aggregation, and in turn, ROS production and cell death.
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Figure 2.5 DFMO decreased apoptosis induced by Aβ42 in vivo. A) Representative
images of HT22 cells imaged 48 hours after transfection with IRES bicistronic vector coexpressing DsRed2 with Aβ42 .in the presence or absence of DFMO (5 mM). Arrows
indicate transfected cells through DsRed2 fluorescence (red), nuclei are stained with
Hoechst dye (blue). Bottom panels are shown in black and white to emphasize nuclear
morphology. Scale bar = 10 microns. E) Quantification of apoptosis observed in HT22
cells 48 hours after transfection with empty IRES bicistronic vector or vector co-expressing
DsRed2 with Aβ42 in the presence or absence of DFMO (5mM). Only DsRed2-positive
cells were counted and marked as apoptosis based on the appearance of condensed or
fragmented nuclei as indicated by Hoechst nuclear stain. Data are expressed as the mean
SEM, n=4, independent experiments performed in triplicate. *** indicates p<.001 Aβ42
compared to IRES control; Aβ42 + DFMO compared to Aβ42 alone as determined using a
one-way ANOVA with a post hoc Tukey’s test.
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2.4.5 PA levels are increased in AD tissues
Thus far, the experiments have been performed in cell lines, but do PA level trends
also occur in human tissue from AD patients as compared with controls? In order to address
this question, we examined PA levels from postmortem hippocampal tissue from AD
patients. Using MEKC-LIF, postmortem hippocampal samples from patients with a
confirmed neuropathological diagnosis of AD as well as age-matched controls were
analyzed for levels of putrescine, spermidine, and spermine (Figure 2.5A-C). Levels of
spermidine [t(4)=4.989, p=0.0075] and spermine [t(4)=3.166, p=0.034] were significantly
elevated in samples from individuals with AD in comparison to age-matched control
samples (n= 3 per group). Thus, these findings in hippocampal tissue from patients with
AD show a similar polyamine profile as the in vitro cell systems in the current study,
providing further rationale for investigating modification of polyamine levels in these
conditions.
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Figure 2.6 PA levels were increased in AD hippocampal tissue samples. MEKC-LIF
was used to measure concentrations of putrescine (A), spermidine (B), and spermine (C)
in lysates of postmortem human hippocampal tissue of sporadic AD and age matched
controls. Results shown as mean SEM, n=3. ** indicates p<0.01 compared to control
group; * indicates p<0.05 compared to the control group as determined using an unpaired
t-test.
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2.5 Discussion
In this study, we sought to determine the relationship of Aβ aggregation and PA
synthesis. Our data suggest that Aβ increases levels of PA in a dose dependent fashion,
possibly via increased expression of ODC. Further, we found that inhibiting ODC with the
irreversible inhibitor DFMO decreases the deleterious effects of Aβ aggregation, oxidative
stress, and in turn apoptosis in hippocampal neurons. Finally, we found that when
measuring levels of PA in human AD hippocampal samples, there was a significant
increase in PA levels in comparison to controls. Together, these data provide novel
evidence of the relationship between PA and Aβ-induced toxicity and cell death, which has
not been explored previously but is a vital step in understanding the complex mechanisms
of dysfunction in the development of AD and may also lead to development of novel
treatment avenues.
AD multifarious pathology includes the toxic accumulation of NFT and senile Aβ
plaques in the brain. The proteolytic cleavage of APP into the Aβ42 peptide is directly
implicated in the pathogenesis of AD due to the propensity of Aβ42 to form aggregate
plaques that disrupt neuronal functioning (Adriaanse et al., 2014; Braak & Braak, 1995;
Braak & Del Tredici, 2011; Cheignon et al., 2018; DeTure & Dickson, 2019). While there
is a large body of converging evidence supporting the existence of a positive relationship
between Aβ42 aggregation and PA levels, mechanisms and consequences for this
connection have not been elucidated to date.
Aβ42 aggregation kinetics were altered in vitro by the addition of putrescine (100
μM, Figure 1), strongly suggesting a direct effect of this PA precursor on the aggregation
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properties of Aβ42. A ThT-based amyloid kinetic assay was performed to assess the effect
of PA on the aggregation profile of Aβ42. There was a dose-dependent effect of putrescine
on Aβ42 aggregation as evidenced by the reduction in t50 for Aβ42. The aggregation kinetics
of Aβ42 was enhanced (lower t50) by increasing molar ratios of putrescine (Figure 2.1B). It
has been shown earlier that PA are capable of promoting Aβ fibrillation via modulation of
aggregation pathways (Luo et al., 2013), and suggested that this could be due to the fact
that the three PA share a similar binding mode to monomeric Aβ42 peptide, leading to the
acceleration of the aggregation process of Aβ42. Interestingly, Luo and collaborators
suggested that this process was different for each PA, suggesting that very specific
targeting molecules may have to be developed to successfully reduce amyloid aggregation
via the PA pathway.
In addition to the effects of Aβ42 on PA observed in vitro, others have found direct
and indirect evidence that elevated Aβ42 levels can associate with increased PA
concentrations from analyses of rat embryonic hippocampal cells, AD brain tissue, and hair
samples from AD patients (Choi et al., 2001; Inoue et al., 2013; Yatin et al., 1999). Our
results, taken together with the findings of previous studies, it can be concluded that PA
are upregulated by Aβ42 in a dose-dependent manner; that is, the amount of Aβ42
aggregation is directly correlated to the intracellular concentration of PA. PA have been
implicated in Aβ42 and other protein aggregation properties and although biogenic PA can
accelerate the rate of fibrillation of Aβ42 significantly (Kabir et al., 2020), the expression
of PA in cell lines transfected with Aβ42 had not been explored prior to this study.
Additionally, reduced putrescine and elevated spermine and spermidine levels in temporal
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cortex of patients with AD has been found (Morrison & Kish, 1995). And, we observed
increased PA levels in hippocampal tissue from patients with AD (Figure 2.6).
Previous work suggests that Aβ42 aggregation upregulates PA levels by increasing
expression of ODC, the rate-limiting enzyme of the PA biosynthesis pathway, responsible
for the conversion of ornithine into putrescine (Lane et al., 2018; Polis, Karasik, & Samson,
2021). In addition, ODC has previously been shown to exhibit increased activity in the
presence of ROS as well as translocate from the nucleus to the cytoplasm in AD brain tissue
(Nilsson et al., 2006; Saito et al., 1997). As expected, there was a significant increase in
the ODC/actin ratio in cells exposed to increasing levels of Aβ42 compared to cells exposed
to IRES at the 24-hour timepoint (Figure 2.2C). The ratio of ODC to beta-actin was greater
in the Aβ42 transfected lysates, allowing us to draw the conclusion that Aβ42 increases PA
levels through increased expression of ODC. The number of ODC immunoreactive neurons
have been found to be enhanced in AD brains relative to control brains (Bernstein &
Müller, 1999) further providing a link between Aβ42 toxicity and ODC expression and
supporting our findings presented herein. While previous studies have shown that ROS
leads to greater ODC activity (Saito et al., 1997), the findings presented in Figure 2.2 are
novel and warrant further investigation into uncovering what exact mechanism by which
Aβ42 expression drives ODC levels.
Having established that Aβ42 aggregation increased PA levels in HT22 cells at least
partially via the involvement of ODC, we subsequently investigated whether inhibition of
PA synthesis by ODC inhibition would affect Aβ42 levels. DFMO has been proven to
irreversibly inhibit ODC in vitro and in vivo (Gomes et al., 2014; Nie et al., 2005). Indeed,
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DFMO treatment of the HT22 cells transfected with Aβ42 resulted in a significant decrease
in PA levels in cells transfected with Aβ42 (Figure 2.3). Further, inhibition of PA synthesis
decreased Aβ42 aggregation, reduced oxidative stress, and protected against apoptosis
(Figure 2.4, 2.5).
The present success of DFMO as an anti-cancer agent in humans may allow for
easier repurposing of the drug for use in AD treatments once its ability to positively impact
cognition and stymie disease progression is confirmed pre-clinically through the use of AD
mouse models or in those at risk of developing AD (LoGiudice, Le, Abuan, Leizorek, &
Roberts, 2018). Overall, by elucidating the relationship between PA and Aβ42 plaque
accumulation, it was discovered that PA enhance Aβ42 -mediated toxicity. Moreover,
DFMO’s ability to protect cells against Aβ42 aggregation – shown here using an artificially
introduced amyloid vector provides a potentially novel therapeutic avenue for AD. Thus,
it would be prudent for future studies to further investigate the relationship between Aβ42
and the PA pathway, as well as the involvement of the PA pathway in other AD-related
pathologies including NFT and neuroinflammation, as we strive to understand and prevent
AD
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CHAPTER THREE: THE NOVEL NEUROTOXIC ROLE OF THE APP
INTRACELLULAR DOMAIN AT THE MITOCHONDRIA

3.1 Abstract
Amyloid beta (Aβ) is a principal cleavage product of amyloid precursor protein (APP) and
is widely recognized as a key pathogenic player in Alzheimer's disease (AD). Yet, there is
increasing evidence of a distinct neurotoxic role for the APP intracellular domain (AICD)
which has been proposed to occur through its nuclear function. Intriguingly, there is a γsecretase resident at the mitochondria which could produce AICD locally within this
organelle. Here, we examined the potential of AICD to induce neuronal apoptosis when
targeted specifically to the mitochondria and compared its mechanism of neurotoxicity to
that of Aβ using transient transfection of HT22 hippocampal cells with bicistronic plasmids
coding for DsRed and either an empty vector (Ires), Aβ, AICD59, or mitochondrial-targeted
AICD (mitoAICD). AICD induced significant neuronal apoptosis only when targeted to
the mitochondria. Apoptosis required functional mitochondria as neither Aβ nor mitoAICD
induced significant cell death in SH-SY5Y cytoplasmic hybrid ρ0 cells that are devoid of
mitochondrial DNA. Both glutathione (GSH) and a Bax inhibitor protected HT22 cells
equally well from either peptide. However, inhibition of the mitochondrial permeability
transition pore (mPTP) with cyclosporin A only protected cells from Aβ, while pan-caspase
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inhibitors uniquely rescued cells from mitoAICD. Our results show that AICD displays a
novel neurotoxic function when targeted to mitochondria. Moreover, mitoAICD induces
apoptosis via a mechanism that is distinct from that of Aβ. These findings suggest that
AICD produced locally at mitochondria via organelle-specific γ-secretase could act in a
synergistic manner with Aβ to cause mitochondrial dysfunction and neuronal death in AD.

3.2 Introduction
AD is a progressive and irreversible form of dementia, which is characterized
pathologically by the presence of amyloid plaques consisting principally of Aβ peptide
aggregates and neurofibrillary tangles (NFT) made up of hyper-phosphorylated Tau
protein. These plaques and tangles are believed to contribute to synaptic dysfunction and
the progressive death of pyramidal neurons in the hippocampus and cerebral cortex
(Mancuso et al., 2010; Scheltens et al., 2016). Two major factors, the ongoing demographic
shift of the U.S. population towards more elderly adults contributing to rising diagnoses
and the consistent failure of clinical trials as resulting lack of effective drugs to treat and
prevent AD, pose a critical need to discover novel therapeutics that target the complex
mechanisms of disease progression.
Later stages of AD are marked by the formation of extracellular senile plaques
comprised of Aβ. Multiple forms of Aβ and in particular, soluble oligomers of this peptide,
have been shown to induce mitochondrial dysfunction partly through an increase in
reactive oxygen species (ROS) (J. X. Chen & Yan, 2007; Mancuso et al., 2010; X. Wang,
Su, Perry, Smith, & Zhu, 2007). The mitochondrial dysfunction in turn causes further
generation of ROS creating a vicious feed forward cycle of organelle damage. Aβ is
81

generated by sequential β-secretase (BACE) and γ-secretase-mediated cleavage of APP
and has been shown to induce apoptosis when overexpressed in various neuronal systems
(Mark, Hensley, Butterfield, & Mattson, 1995; Morishima-Kawashima, 2014). However,
due to the recent failure of multiple clinical trials using therapeutics targeting the amyloid
cascade including BACE inhibitors, γ-secretase inhibitors, and antibodies against Aβ,
specifically in sporadic AD (Mullard, 2018; Oxford, Stewart, & Rohn, 2020), other
mechanisms besides that of amyloid deposition have been hypothesized to play a role in
disease progression. Indeed, additional cleavage products of APP besides Aβ are
increasingly being examined as possible pathogenic molecules in AD. APP is processed to
yield a number of protein fragments including the AICD which is produced in both the
amyloidogenic and non-amyloidogenic pathways via γ-secretase activity. Increasing
evidence has emerged supporting the role of AICD as a neurotoxic molecule in AD using
various models including transgenic mice, cell culture systems, and human brain tissue,
yielding the consensus that AICD is a transcriptional regulator of pro-apoptotic genes
(Bukhari et al., 2017; Ghosal et al., 2009; Giliberto et al., 2008; Nakayama et al., 2008;
Passer et al., 2000; Simon et al., 2009).
In AD, free radical-induced oxidative damage plays a significant role in initiation
of the complex pathogenic mechanisms leading to neuronal cell death (Nunomura et al.,
2001). Specifically, mitochondrial dysfunction and mitochondrial oxidative stress (MOS)
are thought to be key and potentially initiating sources of ROS in AD pathology (Cardoso,
Seica, & Moreira, 2017; Smith, Nunomura, Zhu, Takeda, & Perry, 2000). To induce
apoptosis in vitro, full-length APP targets the mitochondria (Bartley et al., 2012).
Additionally, studies have found that APP can translocate to the mitochondria and may
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become stuck in translocase of the outer mitochondrial membrane (TOM)/ translocase of
the inner mitochondrial membrane (TIM) channels leading to a disruption of mitochondrial
transport (Anandatheerthavarada et al., 2003). This mitochondrially-localized APP may
then be targeted for cleavage by the resident γ -secretase present in the outer mitochondrial
membrane, yielding AICD locally at the mitochondria (Pavlov et al., 2011). The possibility
of endogenous production of AICD at the mitochondria raises the question of whether this
protein might contribute to the mitochondrial dysfunction and neurotoxicity seen in AD.
Here, we demonstrate that although AICD overexpression is not toxic in itself to
hippocampal neurons, when forced to localize to mitochondria through the addition of a
mitochondrial targeting sequence, mitoAICD induces significant apoptosis. In addition, we
find that the neurotoxic mechanism of mitoAICD is distinct from that of Aβ, suggesting
the possibility that these two peptides might act synergistically at the mitochondria to
amplify organelle dysfunction and hippocampal cell death in AD. These findings begin to
elucidate the distinct apoptotic mechanisms of unique APP cleavage products and may
contribute to the development of novel therapeutics to combat the pathogenesis of AD
beyond strictly targeting the amyloidogenic pathway.

3.3 Methods
3.3.1 Reagents
Lipofectamine 2000, Lipofectamine 3000, Opti-MEM, Neurobasal Medium,
Dulbecco’s Modified Eagle Medium (DMEM), GlutaMAX, B-27, primary antibody to
COXIV, and Mitochondrial Transitional Pore Assay were purchased from Invitrogen
(Carlsbad, CA). Bax Inhibitor and Glutathione Monoethyl Ester were purchased from
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Calbiochem (San Diego, CA). Hank’s Balanced Salt Solution, Staurosporine , 2’,7’Dichlorofluorescin diacetate (DCF), Cyclosporin A (cyA), Q-VD-OPh-non-methylated
(QVD), Hoechst stain, and primary antibody to C-terminal of APP were purchased from
Sigma Aldrich (St. Louis, MO). CAS-BIND Pro Pan Caspase (Pro-VAD-FMK; Casp) was
purchased from Vergent Bioscience (Minneapolis, MN). DsRed-Express2 plasmids were
purchased from Clontech (Mountain View, CA). Primary antibody to Bax (6A7) was
purchased from Novus Biologicals (Centennial, CO). Primary antibody to active caspase3 was purchased from Promega (Madison, WI). Cy3-conjugated secondary antibodies were
purchased from Jackson Immunoresearch (Westgrove, PA). Antibody concentrations for
applications listed in Table 2.
3.3.2 Experimental Models
HT22 Cell Culture
Immortalized mouse hippocampal cells (HT22) were plated in 35mm diameter 6well culture plates in DMEM containing 1g/mL glucose and 2mM L-glutamine
supplemented with 10% fetal bovine serum (FBS), and 2mM penicillin/streptomycin (100
Units/mL/100μg/mL). Cells were incubated overnight at 37°C in 10% CO2 . The next day
the HT22 cells were transfected and treated appropriately at 80-90% confluence.
SH-SY5Y Cell Culture
SH-SY5Y ρ0 cells and SH-SY5Y ρ+ cells were plated in 35mm diameter 6 well
culture plates in 1mL DMEM supplemented with 10% FBS, 100 ug pyruvate, and 50 ug
uridine. Cells were incubated overnight at 37°C in 5% CO2. After 48-72 hours the ρ0 and
ρ+ cells were transfected and treated appropriately at 80 90% confluence.
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Primary Hippocampal Neuron Preparation
Primary hippocampal neurons were isolated from rat embryos at day 18 (E18) in
dissection medium consisting of 10X Hanks’ Balanced Salt Solution (HBSS), 1 M HEPES
buffer (pH 7.3) and 50 µg/mL gentamycin. Hippocampus were cut up then treated with
1000 U/mL papain added to the dissection medium and dissociated by trituration in 1
mg/mL DNase. Cells were plated in plating medium consisting of MEM supplemented
with glucose and 5% FBS on 1 mg/mL poly-L-lysine-coated 14 mm round glass coverslips
at a density of 40,000 cells/coverslip per dish. After checking that cells were adhered,
neuron plating medium was replaced with Neurobasal Medium supplemented with 0.3X
GlutaMAX and 1X B-27. Neurons were then incubated at 37 °C in 5% CO2. All animal
studies were conducted in accordance with a protocol approved by the University of
Denver Institutional Animal Care and Use Committee (Approval #1363214-1).
3.3.3 Plasmid Preparation
Empty pIRES2 DsRed-Express2 (DsRed2) bicistronic vectors or vectors containing
Aβ42, AICD59, or mitoAICD sequences were originally transformed using 50ng of plasmid
in JM109 Escherichia coli and grown on LB agar plates containing 35μg/mL kanamycin
sulfate at 37°C overnight. Primers were engineered with BamHI and SacI restriction sites
with the following primers:
Aβ42 Sac I Forward-GCG GAG CTC GTC ATG GAT GCA GAA TTC CGA C
Aβ42 BamHI Reverse-CGC GGA TCC TAC GCT ATG ACA ACA CC
AICD59 SacI Forward-GCG GAG CTC GTC ATG ATA GCG ACA GTG ATC
AICD59 BamHI Reverse- CGC GGA TCC TAG TTC TGC ATC TGC TC
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mAICD SacI Forward-GCG GAG CTC ATG TTG AGC CGG GCA GTG TGC
GGC ACC AGC AGG CAG CTG GCT CCG GCT TTG GGG TAT CTG GGC
TCC AGG CAG ATG ATA GCG ACA GTG ATC
mAICD BamHI Reverse-CGC GGA TCC TAG TTC TGC ATC TGC TCA AAG
AAC TTG TAG GTT GGA TTT TCG TAG CCG TTC TGC TGC
The mitochondrial targeting sequence used was as follows: ATG TTG AGC CGG
GCA GTG TGC GGC ACC AGC AGG CAG CTG GCT CCG GCT TTG GGG TAT CTG
GGC TCC AGG CAG (Fishel, Seo, Smith, & Kelley, 2003).
PCR products were purified from agarose gel (0.8%) and digested with restriction
enzymes one at a time, gel purified between each. The vector was linearized with restriction
enzymes separately one at a time, then gel purified, then dephosphorylated using calf
intestinal alkaline phosphatase and a phenol chloroform reaction was completed. Ligations
were set up and starter cultures were created using a colony containing transformed cells
and grown in LB broth with 35μg/mL kanamycin sulfate for 6 to 8 h at 37°C and diluted
to 1:250 into overnight cultures. Plasmids were isolated and purified using a Maxi prep Kit
according to the manufacturer’s instructions (Clontech, Mountain View, CA). Plasmid
concentrations were quantified using three averaged recordings by a Thermo Scientific
NanoDrop 2000. Bicistronic vectors that allow for co-expression of DsRed separate from
the protein of interest are used in this experiment in place of protein fusion construction to
prevent interference with the normal functioning and localization of the small proteins
being examined. Because DsRed is expressed in the cell separately from the APP cleavage
products, there is no interference with normal functioning of the cleavage products or
formation of unnatural APP cleavage product aggregates following overexpression.
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3.3.4 Transfection
5μg/mL DsRed2 plasmids containing Aβ42, AICD59, mitoAICD, or empty IRES
vector sequences were used to transfect either HT22 or SY5Y ρ0 and SY5Y ρ+ cells using
a standard Lipofectamine 2000 protocol as outlined by Bartley et al (Bartley et al., 2012).
Both cell types were incubated in Opti-MEM with the DsRed2 bicistronic
plasmid/Lipofectamine 2000 mixture for 4-6h at 37°C in 10% CO2 for HT22 and 5% CO2
for SY5Y ρ0 and ρ+. Transfection was terminated in both cell cultures after 4-6h through
replacement of the Opti-MEM with 1mL culture media with or without appropriate
treatments. Cells were incubated overnight at 37°C in 10% CO2 for HT22 and 5% CO2 for
SY5Y ρ0 and ρ+.
1.25μg/mL DsRed2 plasmids containing Aβ42, AICD59, mitoAICD, or empty IRES
vector sequences were used to transfect primary hippocampal neurons between 5-15 days
in vitro, using the manufacturer’s protocol for Lipofectamine 3000 (Invitrogen, Carlsbad,
CA) in 500 µL Opti-MEM. The reagent-DNA mixture was incubated for a minimum of 25
min at 25°C. Before adding reagent-DNA, 1 mL media was removed from each imaging
dish and syringe filtered with an equal volume of fresh neuron culture media (50:50 media),
which was then added to the neuron imaging dishes and incubated at 37 °C for 4 hours.
Neurons were then washed three times with 1 mL prewarmed neuron culture media. Then,
2 mL of the 50:50 media was added to the neurons and they were incubated at 37 °C in 5
CO2 for 48h until imaging.
3.3.5 Cell Treatments
Cell culture treatments were performed at the following concentrations in 1mL of
culture medium for both HT22 and SY5Y ρ0 and ρ+ cells immediately after the removal
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of the transfection medium: Glutathione Monoethyl Ester (GSH-MEE) was administered
at a 1mM concentration, Bax Inhibitor (BaxI) was administered at a 150μM concentration,
the pan-caspase inhibitor, QvD, was administered at a 20μM concentration, the pancaspase inhibitor Pro-VAD-FMK (Casp), was administered at 10μM, Staurosporine (staur)
was administered at 250 or 500nM and Cyclosporin A (CyA) was administered at a 10μM
concentration. All cells were left in treatment media overnight.
3.3.6 Reactive Oxygen Species Detection
Reactive oxygen species detection was performed on live HT22 cells using DCF
fluorescence 24h post transfection. Anhydrous DCF was reconstituted in DMSO to yield
2mM stocks that were used for up to 2mo. Positive control groups were treated with
hydrogen peroxide (H2O2; 125μM) for 45-60 min at 37°C protected from light prior to
loading with DCF. Then, all groups were loaded with 1mL of 10μM DCF dye in warmed
PBS (pH 7.4) for 30min at 37°C protected from light. Labeling solution was then aspirated
and cells were stained with Hoechst stain (1μM) in warmed PBS for 15min at 37°C
protected from light. The cells were then mounted in anti-quench solution consisting of
PBS with 5-10mg p-phenylenediamine for imaging.
3.3.7 Mitochondrial Transitional Pore Assay
Mitochondrial transitional pore assays were performed on live HT22 cells using the
Image-IT LIVE Mitochondrial Transitional Pore Assay Kit for microscopy (Invitrogen,
Carlsbad, CA). 24h post transfection, cells were loaded using 1 mL of warmed calcein
labeling solution consisting of 1μM calcein, 1μM Hoechst dye, 1mM CoCl2 in modified
HBSS (with HEPES; 10mM, L-glutamine; 2mM, succinate; 100μM) for 15min at 37°C
protected from light. Positive control groups were then loaded with 1mL of 1μM
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ionomycin in modified HBSS for 15min. Labeling solution was then aspirated, cells were
washed with warmed modified HBSS, then mounted in anti-quench solution consisting of
warmed HBSS with 5-10mg p-phenylenediamine for imaging.
3.3.8 Fluorescence Staining and Imaging
Transfected and treated HT22 and ρ 0 and ρ + cells were washed once with PBS
(pH 7.4) and fixed for 45 minutes in 4% paraformaldehyde at 25°C. Cells were then washed
twice with PBS then incubated in a 1:1000 dilution of Hoechst nuclear stain in PBS at 4°C
overnight. The following day, cells were washed twice with PBS and placed in an antiquench solution comprised of PBS with 5-10mg p-phenylenediamine for imaging.
Transfected primary hippocampal neurons were washed once with prewarmed PBS then
plated in a 1:1000 dilution of nuclear Hoechst stain in PBS for 15min at 37°C. Neurons
were then mounted in anti-quench solution for imaging.
For immunohistochemistry experiments, following paraformaldehyde fixation,
HT22 cells were washed twice with PBS then non-specific sites were blocked with 5%
BSA in PBS containing 0.2% TritonX-100 for 1h at 25°C. Blocking solution was then
aspirated and cells were incubated overnight at 4°C in a primary antibody solution
consisting of 2% BSA in PBS containing 0.2% TritonX-100 and primary antibody diluted
according to manufacturer’s recommendations. Cells were then washed five times with
PBS over the course of 1h and then incubated in 1:1000 dilution of Hoechst nuclear stain
and 1:250 dilution of secondary antibody in PBS at 25°C, protected from light for 1h. Cells
were then washed five times with PBS over the course of 1h before plating in an antiquench solution for imaging.
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Cells were imaged using a Zeiss Axiovert-200M epi-fluorescence microscope with
five representative images taken of each well for assessment of apoptosis. All experimental
conditions were performed in duplicate or triplicate wells in each experiment for HT22 and
ρ 0 and ρ + experiments and in singular or duplicate dishes for primary neuron
experiments. Only cells fluorescing red through the expression of the DsRed-Express2
vector were counted and assessed for apoptosis through the visual evaluation of condensed
or fragmented nuclei as indicated by Hoechst nuclear stain. Roughly 75-125 transfected
cells were quantified for each experimental condition in each HT22 and ρ 0 and ρ +
experiment and roughly 10-15 transfected cells were quantified for each primary neuron
experiment.
3.3.9 Statistical Analysis
All experimental conditions were performed in duplicate and statistical analysis
was only performed on experiments quantified a minimum of three times. Data represents
the means +/- SEM for the total number (n) of independent experiments carried out. Data
were analyzed using either an unpaired student’s T test or a one-way ANOVA with a post
hoc Tukey’s test. A p-value of <0.05 was considered statistically significant.

3.4 Results
3.4.1 Overexpression of Aβ42 or mitoAICD induced apoptosis in HT22 cells
APP can be processed via amyloidogenic or non-amyloidogenic pathways to
produce Aβ42 (amyloidogenic) and AICD59 (both pathways) (Muller et al., 2008). In order
to study the effects of APP cleavage products on cellular functioning, each peptide was
assessed for apoptotic effects in HT22 immortalized mouse hippocampal cells by transient
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transfection using pIRES2 DsRed-Express 2 bicistronic expression vectors. Because of the
presence of a mitochondrial γ-secretase and the known localization of APP to the
mitochondria, a mitochondrial-targeted APP intracellular domain (mitoAICD) construct
was also assessed for apoptotic effects to mimic AICD59 fragments which could be
generated locally at the mitochondria (Anandatheerthavarada et al., 2003; Pavlov et al.,
2011).
At 24 hours post-transfection, HT22 cells were stained with Hoechst dye and
DsRed-positive cells were examined for fragmented and/or condensed nuclei, which are
morphological hallmarks of apoptotic cell death. HT22 cells transfected with either the Ires
control vector or AICD59 displayed large, intact, and healthy nuclei (Figure 3.1A). In
contrast, many cells transfected with either Aβ42 or mitoAICD had nuclei that were
condensed and/or significantly fragmented, indicative of apoptotic cell death (Figure
3.1A). Utilizing a one-way Analysis of Variance (ANOVA), quantitative analysis of HT22
cell apoptosis, based on the percentage of cells with fragmented and/or condensed nuclei
as compared to the total number of transfected cells, was performed (Figure 3.1B).
Transient expression of Aβ42 significantly increased apoptosis as compared to the Ires
control [F(3,44)=50.22, p<0.001) and mitoAICD significantly increased apoptosis as
compared to AICD59 [F(3,44)=50.22, p<0.001], while AICD59 did not significantly increase
apoptosis as compared to Ires. These data show that, as expected, expression of Aβ42
induces significant apoptosis of HT22 cells. However, expression of AICD59 only causes
significant apoptosis of HT22 cells when this peptide is targeted to mitochondria.
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Figure 3.1 Aβ42 and mitoAICD each induced apoptosis in HT22 hippocampal cells. A)
Representative images of HT22 cells imaged 24 hours after transfection with empty pIRES
Ds-Red-Express2 (Ires) bicistronic vector or vector co-expressing either Aβ42 (Aβ),
AICD59, or mitoAICD (mAICD) as indicated. Nuclei are stained with Hoechst dye (blue).
Arrows indicate successfully transfected cells as indicated by DsRed2 protein expression
(red). Bottom panels are shown in black and white to emphasize nuclear morphology. Scale
bar = 10 μm. B) Quantitative apoptotic assessment of HT22 cells 24 hours after transfection
with Ires vector or vector co-expressing Aβ42, AICD59, or mitoAICD. Only DsRed2positive cells were counted and were scored as apoptotic based on the appearance of
condensed or fragmented nuclei, as demonstrated by Hoechst nuclear stain. Data are
expressed as the mean +/- SEM, n=12 independent experiments, performed in triplicate.
*** indicates p<0.001 for Aβ42 compared to Ires control; ### indicates p<0.001 for
mitoAICD compared to AICD59 control, as determined using one-way ANOVA with a post
hoc Tukey’s test.
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3.4.2 Functional mitochondria were required for Aβ42 or mitoAICD to induce
apoptosis in SH-SY5Y cytoplasmic hybrid cells
We have previously shown that apoptosis induced by the overexpression of wildtype APP requires functional mitochondria in SH-SY5Y cytoplasmic hybrid cells (Bartley
et al., 2012). As a means of further investigating the relationship between the APP cleavage
products and the mitochondria, Aβ42, AICD59, mitoAICD, and empty Ires vectors were
transfected into SH-SY5Y ρ0 and ρ+ cells. ρ0 cells are devoid of mitochondrial DNA,
resulting in a nonfunctional electron transport chain and sole dependence on glycolysis for
energy production. Imaging of nuclear morphology in ρ+ and ρ0 cells transfected with either
the Ires control or AICD59 expression plasmids showed relatively large, healthy, and intact
nuclei (Figure 3.2A). In contrast, a significant fraction of ρ+ cells transfected with either
Aβ42 or mitoAICD displayed very condensed nuclei characteristic of apoptosis (Figure
3.2A). However, neither Aβ42 nor mitoAICD caused significant nuclear condensation in ρ0
cells, which are devoid of functional mitochondria (Figure 3.2A). Quantitative analyses of
apoptosis in transfected SH-SY5Y cells, as indicated by fragmented or condensed nuclei
in DsRed-positive cells, demonstrated that Aβ42 and mitoAICD significantly increased
apoptosis as compared to the empty Ires control vector and AICD59, respectively, in the ρ+
cells; whereas AICD59 did not significantly increase apoptosis as compared to Ires (Figure
3.2B). However, expression of Aβ42 or mitoAICD failed to significantly increase apoptosis
in the ρ0 cells (Figure 3.2B). These data indicate that functional mitochondria are required
for either Aβ42 or mitoAICD to induce neuronal apoptosis.
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Figure 3.2 Aβ42 and mitoAICD each induced apoptosis in ρ+ cells, but not ρ0 cells. A)
Representative images of cytoplasmic hybrid SY-SY5Y ρ0 and ρ+ cells imaged 24 hours
after transfection with empty pIRES Ds-Red-Express2 (Ires) bicistronic vector or vector
co-expressing either Aβ42, AICD59, or mitoAICD (mAICD) as indicated. Arrows indicate
successfully transfected cells as indicated by DsRed2 protein expression. Only nuclei are
shown. Scale bar = 10 μm. B) Quantitative apoptotic assessment of SH-SY5Y ρ+ and ρ0
cytoplasmic hybrid cells 24 hours after transfection with Ires vector or vector co-expressing
Aβ42, AICD59, or mitoAICD. Only DsRed2-positive cells were counted and scored as
apoptotic based on the appearance of condensed or fragmented nuclei, as demonstrated by
Hoechst nuclear stain. Data are expressed as the mean +/- SEM, n=3 independent
experiments, performed in duplicate. ** indicates p<0.01 compared to Ires control and ##
indicates p<0.01 compared to AICD59 control (AICD59), as determined using one-way
ANOVA with a post hoc Tukey’s test. NS = no significant difference.
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3.4.3 Glutathione protected HT22 cells from apoptosis induced by Aβ42 and
mitoAICD
Next, we evaluated the role of ROS in HT22 cell apoptosis induced by the APPderived peptides. First, we stained cells with the peroxide-sensitive dye DCF to detect
hydrogen peroxide (H2O2). As expected, HT22 cells transfected with either the Ires control
vector or AICD59 did not display any significant DCF fluorescence; however, addition of
H2O2 to these cultures produced a marked increase in DCF fluorescence (Figure 3.3A).
HT22 cells transfected with either Aβ42 or mitoAICD showed marked increases in DCF
fluorescence, comparable to that observed in cells overexpressing Ires or AICD59 and
treated with H2O2, indicating significant oxidative stress in these cells (Figure 3.3A). In
order to investigate the potential role of MOS in neuronal apoptosis induced by Aβ42 and
mitoAICD, HT22 cells expressing these peptides were treated with 1mM glutathionemonoethyl-ester (GSH-MEE) as a free radical scavenger. GSH-MEE is actively
transported into many different cell types and preferentially increases the mitochondrial
GSH pool after it is converted intracellularly into free GSH (M. E. Anderson, Powrie, Puri,
& Meister, 1985; M. F. Anderson, Nilsson, Eriksson, & Sims, 2004). HT22 cells treated
with GSH-MEE and transfected with the Aβ42 and mitoAICD vectors showed essentially
no increase in apoptosis in comparison to the Ires and AICD59 control vectors, respectively
(Figure 3.3B). These results indicate that GSH completely protects HT22 cells from these
APP-derived peptides and furthermore, oxidative stress and most likely, MOS, plays a
significant role in the neuronal apoptosis induced by either Aβ42 or mitoAICD.
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Figure 3.3 Glutathione decreased HT22 cell apoptosis induced by either Aβ42 or
mitoAICD. A) Representative images of DCF assay to detect oxidative species in HT22
cells imaged 24 hours after transfection with empty pIRES Ds-Red-Express2 (Ires)
bicistronic vector or vector co-expressing either Aβ42, AICD59, or mitoAICD (mAICD) in
the presence or absence of hydrogen peroxide (H2O2; 125 μM). Top images display
Hoechst stained nuclei (blue) with successfully transfected cells indicated by DsRed2fluorescence (red). Below oxidative species are indicated by DCF staining (green) in the
transfected cells from top images. Scale bar = 10 μm. B) Quantitative assessment of HT22
cell apoptosis 24 hours after transfection with Ires vector or vector co-expressing Aβ42,
AICD59, or mitoAICD in absence or presence of GSH-MEE (GSH; 1 mM). Only DsRed2positive cells were counted and scored as apoptotic based on the appearance of condensed
or fragmented nuclei, as demonstrated by Hoechst nuclear stain. Data are expressed as the
mean +/- SEM performed in duplicate, n=4 independent experiments for Aβ42 and
mitoAICD, n=5 independent experiments for Ires, Aβ42 + GSH, AICD59, and mitoAICD +
GSH. *** indicates p<0.001 for Aβ42 compared to Ires control, ### indicates p<0.001 for
Aβ42 with GSH treatment compared to Aβ42 alone, *** indicates p<0.001 for mitoAICD
compared to AICD59 control, # indicates p<0.05 for mitoACID with GSH treatment
compared to mitoAICD alone, as determined using one-way ANOVA with a post hoc
Tukey’s test.
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3.4.4 Bax Inhibitor protected HT22 cells from apoptosis induced by Aβ42 and
mitoAICD
MOS is closely linked to Bax activation and subsequent mitochondrial outer
membrane permeabilization during neuronal apoptosis (Polster & Fiskum, 2004). In order
to investigate a potential role for Bax activation in HT22 cell apoptosis induced by Aβ42
and mitoAICD, we first stained cells with an antibody to the active conformation of Bax
(6A7). As anticipated, HT22 cells transfected with either the Ires control vector or AICD59
did not show any detectable active Bax staining; however, addition of the apoptosis
inducer, staurosporine, to these cultures caused a striking increase in active Bax (Figure
3.4A). HT22 cells transfected with either Aβ42 or mitoAICD displayed high levels of active
Bax, similar to those observed in cells overexpressing Ires or AICD59 and treated with
staurosporine (Figure 3.4A). To explore whether or not apoptosis induced by Aβ42 or
mitoAICD could be prevented by inhibition of Bax, transfected HT22 cells were treated
with 150μM Bax inhibitor (BaxI). The Bax inhibitor prevents the conformational change
and activation of Bax at the mitochondria. Incubation with the BaxI significantly decreased
HT22 cell apoptosis in cells transfected with either Aβ42 or mitoAICD (Figure 3.4B). These
data suggest that conformational activation of Bax is required for either Aβ42 or mitoAICD
to trigger neuronal apoptosis.
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Figure 3.4 Bax inhibitor decreased HT22 cell apoptosis induced by either Aβ42 or
mitoAICD. A) Representative images of active Bax staining in HT22 cells imaged 24
hours after transfection with empty pIRES DsRed-Express2 (Ires) bicistronic vector or
vector co-expressing Aβ42, AICD59, or mitoAICD (mAICD) in the presence or absence of
staurosporine (str; 500 nM) to activate Bax. Left images display Hoechst stained nuclei
(blue) with successfully transfected cells marked by DsRed2-fluorescence (red). Right
images display 6A7 staining cells for active Bax (green) of the cells from the images on
the left. Arrows indicate transfected cells. Scale bar = 10 μm. B) Quantitative assessment
of HT22 cells apoptosis 24 hours after transfection with Ires vector or vector co-expressing
Aβ42, AICD59, or mitoAICD in the absence or presence of Bax inhibitor (BaxI; 150 μM).
Only DsRed2-positive cells were counted and scored as apoptotic based on the appearance
of condensed or fragmented nuclei, as demonstrated by Hoechst nuclear stain. Data are
expressed as the mean +/- SEM performed in duplicate, n=3 independent experiments for
Aβ42 + BaxI and mitoAICD + BaxI, n=12 independent experiments for Ires, Aβ42, AICD59,
and mitoAICD. *** indicates p<0.001 for Aβ42 compared to Ires control, ## indicates
p<0.01 for Aβ42 with BaxI treatment compared to Aβ42 alone, *** indicates p<0.001 for
mitoAICD compared to AICD59 control, # indicates p<0.05 for mitoACID with BaxI
treatment compared to mitoAICD alone, as determined using one-way ANOVA with a post
hoc Tukey’s test.
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3.4.5 Mitochondrial permeability transition pore opening played a role in Aβ42
toxicity, but not toxicity induced by mitoAICD
Opening of the mPTP can be triggered by MOS and components of the mPTP (e.g.,
the adenine nucleotide translocase) have been shown to physically interact with active Bax
at the mitochondria (Polster & Fiskum, 2004). A calcein-cobalt assay was used to
determine whether the mPTP was opened following transfection of HT22 cells with Aβ42
or mitoAICD. In this assay, opening of the mPTP allows cobalt to permeate the inner
mitochondrial membrane and quench the fluorescence of the calcein dye within the
mitochondrial matrix (Petronilli et al., 1999). HT22 cells transfected with either the Ires
control vector or AICD59 displayed robust calcein staining of the mitochondrial matrix;
however, incubation with the Ca2+ ionophore, ionomycin, caused a rapid opening of the
mPTP and nearly complete quenching of the calcein fluorescence (Figure 3.5A). HT22
cells transfected with Aβ42 showed a similar quenching of the calcein fluorescence to that
observed in cells overexpressing Ires and treated with ionomycin, demonstrating opening
of the mPTP (Figure 3.5A). In contrast, significant calcein staining of the mitochondrial
matrix was maintained in cells transfected with mitoAICD, indicating that the mPTP
remained closed (Figure 3.5A). In agreement with these imaging data, incubation of
transfected HT22 cells with 10μM cyclosporin A, an inhibitor of cyclophilin D and a
blocker of the mPTP, significantly decreased apoptosis induced by Aβ42 [F(3,36)=37.28,
p<0.0001], but not mitoAICD (Figure 3.5B). Thus, opening of the mPTP appears to play a
significant role in neuronal apoptosis induced by Aβ42, but not that caused by mitoAICD.
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Figure 3.5 Cyclophilin D inhibitor, cyclosporin A decreased HT22 cell apoptosis
induced by Aβ42, but not mitoAICD. A) Representative images of mitochondrial
permeability transitional pore (mPTP) assay of HT22 cells imaged 24 hours after
transfection with empty pIRES DsRed-Express2 (Ires) bicistronic vector or vector coexpressing Aβ42, AICD59, or mitoAICD (mAICD) in the presence or absence of ionomycin
(ion; 0.5 μM) to open the mPTP. Successfully transfected cells are indicated by DsRed2fluorescence (red), closed mPTP indicated by calcein fluorescence (green) in mitochondria
(punctate staining), nuclei are stained with Hoechst dye (blue). Scale bar = 10 μm. B)
Quantitative assessment of HT22 cells apoptosis 24 hours after transfection with Ires vector
or vector co-expressing Aβ42, AICD59, or mitoAICD in the absence or presence of
cyclosporine A (CyA; 10 μM). Only DsRed2-positive cells were counted and scored as
apoptotic based on the appearance of condensed or fragmented nuclei, as demonstrated by
Hoechst nuclear stain. Data are expressed as the mean +/- SEM, n=7 independent
experiments, each performed in triplicate. *** indicates p<0.001 for Aβ42 compared to Ires
control, ### indicates p<0.001 for Aβ42 with CyA treatment compared to Aβ42 alone, ***
indicates p<0.001 for mitoAICD compared to AICD59 control, as determined using oneway ANOVA with a post hoc Tukey’s test. NS = no significant difference.
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3.4.6 Pan-caspase inhibitors protected HT22 cells from apoptosis induced by
mitoAICD, but they do not block Aβ42 toxicity
Next, we examined whether caspase activity was necessary for HT22 cell apoptosis
induced by either Aβ42 or mitoAICD. We first stained cells with an antibody to the active,
cleaved fragment of the executioner caspase-3. HT22 cells transfected with either the Ires
control vector or AICD59 showed little-to-no detectable active caspase-3 staining; however,
addition of the apoptosis inducer, staurosporine, to these cultures caused a dramatic
increase in active caspase-3 (Figure 3.6A). HT22 cells transfected with either Aβ42 or
mitoAICD displayed significant immunoreactivity for active caspase-3, similar to that
observed in cells overexpressing Ires or AICD59 and treated with staurosporine (Figure
3.6A). To determine if apoptosis induced by either Aβ42 or mitoAICD is caspasedependent, we used two pan-caspase inhibitors, Q-VD-OPh-non-methylated (QVD) and
CAS-BIND Pro Pan Caspase (Pro-VAD-FMK; Casp). In HT22 cells transfected with either
Aβ42 or mitoAICD in the absence of caspase inhibitors, we observed the expected
significant increase in apoptosis (Figures 3.6B, C). Incubation with either 20μM QVD or
10μM Casp had no significant effect on HT22 cell apoptosis induced by expression of Aβ42,
but both QVD [F(5,21)=30.36, p<0.0001] and Casp [F(5,21)=18.71, p<0.0001]
significantly protected cells from the toxic effects of mitoAICD. Collectively, the above
findings suggest that expression of either Aβ42 or mitoAICD triggers activation of caspase3 in HT22 cells. However, caspase activity appears to be dispensable for cell death induced
by Aβ42, whereas it is required for apoptosis caused by mitoAICD.
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Figure 3.6 Pan-caspase inhibitors decreased HT22 cell apoptosis induced by
mitoAICD, but not Aβ42. A) Representative images of HT22 cells imaged 24 hours after
transfection with empty pIRES DsRed-Express2 (Ires) bicistronic vector or vector coexpressing Aβ42, AICD59, or mitoAICD (mAICD) in the presence or absence of
staurosporine (str; 500 nM). Left images display Hoechst stained nuclei (blue) with
successfully transfected cells marked by DsRed2-fluorescence (red). Right images display
active caspase-3 staining (green) of the cells from the images on the left. Arrows indicate
transfected cells. Scale bar = 10 μm. B) Quantification of the effects of the pan-caspase
inhibitor, Q-VD-Oph (QvD; 20 μM) on apoptosis induced 24 hours post-transfection with
Aβ42 or mitoAICD. Only DsRed2-positive cells were counted and marked as apoptotic
based on the appearance of condensed or fragmented nuclei, as demonstrated by Hoechst
nuclear stain. Data are expressed as the mean +/- SEM, n=8 independent experiments, each
performed in triplicate. *** indicates p<0.001 for Aβ42 compared to Ires control, ***
indicates p<0.001 for mitoAICD compared to AICD59 control, ## indicates p<0.01 for
mitoAICD with QvD treatment compared to mitoAICD alone, as determined using one102

way ANOVA with a post hoc Tukey’s test. NS = no significant difference. C)
Quantification of the effects of the pan-caspase inhibitor Pro-VAD-FMK (Casp; 10 μM)
on apoptosis induced 24 hours post-transfection with Aβ42 or mitoAICD. Data are
expressed as the mean +/- SEM performed in triplicate, n=5 independent experiments for
Ires, Aβ42, Aβ42 with Casp, n=4 independent experiments for AICD59, mitoAICD, and
mitoAICD with Casp. *** indicates p<0.001 for Aβ42 compared to Ires control, ***
indicates p<0.001 for mitoAICD compared AICD59 control, # indicates p<0.05 for
mitoAICD with Casp treatment compared to mitoAICD alone, as determined using oneway ANOVA with a post hoc Tukey’s test. NS = no significant difference.
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3.4.7 Aβ42 and mitoAICD each induced cell death in primary hippocampal
neurons
Finally, we examined whether our initial finding that mitochondrial targeting is
required for AICD59 to induce apoptosis in the HT22 hippocampal cell line, could be
replicated in primary hippocampal neuron cultures. Primary hippocampal neurons
harvested from embryonic rats were transfected with empty Ires vector, Aβ42, AICD59, or
mitoAICD to examine the effects of these APP-derived peptides in a primary hippocampal
cell culture system. As shown in Figure 3.7A, hippocampal neurons transfected with either
the empty Ires control vector or AICD59 displayed large intact nuclei and a highly complex
arrangement of neuronal processes, indicative of healthy neurons. In marked contrast,
hippocampal neurons transfected with either Aβ42 or mitoAICD exhibited drastic changes
in the appearance of their neuronal processes, showing substantial reductions in both size
and complexity. Additionally, these cells often had fragmented and/or condensed nuclei
(Figure 3.7A). Upon quantification (Figure 3.7B), we found a significant increase in cell
death in hippocampal neurons expressing Aβ42 and mitoAICD in comparison to the Ires
control and AICD59, respectively [F(3,12)=29.18, p<0.0001]. Thus, as we observed in the
HT22 cell line, expression of Aβ42 induces significant apoptosis of primary hippocampal
neurons; however, expression of AICD59 only causes significant apoptosis of these cells
when this peptide is targeted to mitochondria.
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Figure 3.7 Aβ42 and mitoAICD induced cell death in primary hippocampal neurons.
A) Representative images of rat embryonic primary hippocampal neurons imaged live 48
hours after transfection with empty pIRES DsRed-Express2 (Ires) bicistronic vector or
vector co-expressing Aβ42, AICD59, or mitoAICD (mAICD) as indicated. Left images
display decolorized DsRed2-fluorescence, right panels display Hoechst nuclear staining.
Panels are shown in black and white to emphasize morphologies. Arrows indicate
successfully transfected cells fluorescing red through DsRed2-expression. Scale bar = 10
μm. B) Quantitative assessment of primary hippocampal neuron cell death 48 hours after
transfection with Ires vector or vector co-expressing Aβ42, AICD59, or mitoAICD. Only
DsRed2-positive cells were counted and assessed for cell death based on the appearance of
condensed or fragmented nuclei as demonstrated by Hoechst nuclear stain as well as overall
morphology and processes fragmentation. Data are expressed as the mean +/- SEM, n=4
independent experiments, each performed in triplicate.*** indicates p<0.001 for Aβ42
compared to Ires control, ### indicates p<0.001 for mitoAICD compared to AICD59
control, as determined using one-way ANOVA with a post hoc Tukey’s test.
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3.5 Discussion
Our data suggest that individual overexpression of two major cleavage products of
APP, Aβ42 and mitochondrial-targeted AICD59 (mitoAICD), each induce apoptosis via two
distinct mechanisms in HT22 immortalized hippocampal cells. We found that both
fragments require functional mitochondria through the investigation of apoptosis in cells
lacking mtDNA and further, that the proteins induce different apoptotic cascades at the
mitochondria. Apoptosis induced by either peptide could be reduced by blocking oxidative
stress and subsequent Bax activation at the mitochondria; however, following these events,
Aβ42 appears to be caspase-independent but requires opening of the mPTP, while
mitoAICD requires caspase activation. Finally, we investigated the ability of these
fragments to induce apoptosis in primary hippocampal cell cultures and found similar
results to HT22 cells in that AICD only elicits significant apoptosis if it is targeted to the
mitochondria. Collectively, these data not only indicate a novel neurotoxic role of AICD
at the mitochondria, but also suggest a potentially synergistic role of these proteins at the
mitochondria in inducing cell death during AD progression.
APP is processed by a series of cleavage events which can produce Aβ42 when
cleavage occurs via β- and γ-secretase. AICD59 is produced by the γ-secretase cleavage
event during both the amyloidogenic and non-amyloidogenic processing of APP (Muller
et al., 2008). Studies have suggested that APP associates with TOM40 and TIM23 and in
this manner, may block mitochondrial protein import (Anandatheerthavarada et al., 2003).
Coupled with the presence of a mitochondrial γ-secretase, we hypothesized that the
localization of APP to mitochondria may be the basis for the production of AICD within
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the mitochondria, which could lead to subsequent mitochondrial dysfunction and apoptosis
in cells (Devi et al., 2006; Pavlov et al., 2011). To mimic this endogenous production of
and localization of AICD to the mitochondria, we fused a mitochondrial targeting sequence
to the APP intracellular domain (mitoAICD) and evaluated its downstream effects. In
accordance with previous research, expression of Aβ42 was found to induce apoptosis in
HT22 cells (Bartley et al., 2012). Additionally, expression of mitoAICD was found to also
induce apoptosis in HT22 cells whereas AICD59 overexpression elicited no significant
apoptotic effect. When considered with previous studies which suggest that Aβ42
localization to the mitochondria via binding to amyloid beta peptide-binding alcohol
dehydrogenase (ABAD) is necessary for Aβ42 to induce apoptosis, these data suggest that
mitochondrial localization is also sufficient for AICD to cause apoptotic cell death
(Lustbader et al., 2004).
Evaluation of the toxicity induced by Aβ42 and mitoAICD in SH-SY5Y cytoplasmic
hybrid cells further supported the necessity of mitochondrial interaction in the apoptotic
mechanisms of both peptides. Similar to the results in HT22 cells, both Aβ42 and mitoAICD
were found to be toxic in SH-SY5Y ρ+ cells which harbor functional mitochondrial, while
neither AICD59 nor Ires exhibited toxicity. However, in SH-SY5Y ρ0 cells, which are
devoid of mitochondrial DNA (mtDNA) and in turn lack functional mitochondria, both
Aβ42 and mitoAICD were found to produce no significant apoptotic effect. These data
suggest that specific mtDNA products (e.g., mitochondrially-encoded respiratory chain
complexes) and a functional electron transport chain (ETC) are necessary for Aβ42 and
mitoAICD to induce apoptosis.
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Previous studies have indicated that oxidative damage is one of the first events in
the pathology of AD (Nunomura et al., 2001). Additionally, Aβ42 has been shown to induce
mitochondrial dysfunction partly through an increase in ROS (Casley, Canevari, Land,
Clark, & Sharpe, 2002; J. X. Chen & Yan, 2007; Nunomura et al., 2010). In the
mitochondria, ROS are mainly produced through the functioning of complexes I and III of
the ETC at the inner membrane and these free radicals participate in redox signaling
between the mitochondria and the rest of the cell (Droge, 2002; Murphy, 2009). Mutations
of mtDNA or nuclear-encoded respiratory chain complexes, impairment of oxidative
phosphorylation, and errant expression of antioxidant enzymes all lead to an increase in
ROS and eventually cell death through the intrinsic apoptotic pathway following oxidative
damage (C. H. Wang, Wu, Wu, & Wei, 2013). MOS, which results from an increase in
ROS at the mitochondria, can cause oxidation of cardiolipin and increase the amount of
soluble cytochrome c in the intermembrane space. This solubilized cytochrome c can then
be released through pro-apoptotic Bax/Bak-dependent pore formation of the outer
mitochondrial membrane or the opening of the mPTP, triggering formation of the
apoptosome, activation of effector caspases, and apoptosis (Orrenius, Gogvadze, &
Zhivotovsky, 2007). Both Aβ42 and mitoAICD resulted in an increase in ROS as indicated
by DCF staining, which suggests that an increase in mitochondrial ROS may play a role in
both Aβ42 and mitoAICD induction of HT22 cell apoptosis.
One potential cause of cellular oxidative damage are ROS that are not scavenged
by intracellular antioxidants (Halliwell, 1992). The reducing agent GSH is an essential
intracellular antioxidant that forms a discrete pool in the mitochondria, in addition to a
larger cytosolic pool, which are critical for maintaining cell survival in the presence of
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increased levels of ROS (Franco & Cidlowski, 2009; Wilkins, Kirchhof, Manning, Joseph,
& Linseman, 2013). Because GSH-MEE is known to be processed intracellularly into the
antioxidant GSH and preferentially increases the mitochondrial GSH pool, we utilized this
treatment to mitigate MOS generated as a result of overexpression of Aβ42 or mitoAICD
(M. E. Anderson et al., 1985; M. F. Anderson et al., 2004). In doing so, we found that
treatment with GSH-MEE was sufficient to significantly reduce apoptosis in HT22 cells
transfected with either Aβ42 or mitoAICD to levels not significantly different from their
respective controls. Based on these results, we next sought to determine if inhibiting the
cascade of apoptosis induced by MOS could distinguish different mechanisms by which
the overexpression of Aβ42 and mitoAICD each induce neuronal cell death.
We hypothesized that the pro-apoptotic member of the Bcl-2 family of proteins,
Bax, may be involved in the apoptotic mechanisms induced by both Aβ42 and mitoAICD.
Bax is activated in the intrinsic apoptotic pathway associated with MOS and previous
studies have shown that an increase in ROS can cause Bax to translocate to the
mitochondria and induce apoptosis through the formation of a pore in the outer
mitochondrial membrane. Immunohistochemistry revealed active Bax staining in HT22
cells overexpressing Aβ42 and mitoAICD like that of the controls treated with the Bax
activator, staurosporine. Further, apoptosis was significantly decreased upon inhibition of
Bax in cells transfected with either Aβ42 or mitoAICD, suggesting that Bax is involved in
the apoptotic cascades induced by both of these peptides.
Next, we investigated the role of the mPTP in HT22 cell apoptosis induced by Aβ42
and mitoAICD. Similar to Bax, activation of the mPTP has been shown to induce apoptosis
through the release of apoptotic factors from the mitochondria (Crompton, 1999). It has
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also been proposed that mPTP activation may play a role in the Aβ-mediated mitochondrial
dysfunction in AD through the dysregulation of cytosolic calcium concentrations (Du &
Yan, 2010). Using a calcein-cobalt fluorescence quenching assay, we found that only
overexpression of Aβ42 resulted in opening of the mPTP, while it remained closed
following incubation with mitoAICD. Next, we utilized CyA which has been shown to
inhibit opening of the mPTP through its binding to cyclophilin D on the matrix side of the
inner mitochondrial membrane (Halestrap, Connern, Griffiths, & Kerr, 1997). Expectedly,
inhibition of the mPTP using CyA protected against Aβ42 induced toxicity; however, it had
no effect on apoptosis induced by mitoAICD. These data suggest that mPTP opening is
necessary for Aβ42 overexpression to induce HT22 cell apoptosis but it is not required for
mitoAICD neurotoxicity.
Both translocation of Bax to the mitochondria and opening of the mPTP can induce
apoptosis through the release of cytochrome c from the intermembrane space following
MOS (Gomez-Lazaro et al., 2007; Orrenius et al., 2007; Weng, Li, Xu, Shi, & Tang, 2005).
Because cytochrome c is known to initiate an apoptotic caspase cascade through the
activation of caspase-9 and its subsequent activation of executioner caspases (Orrenius et
al., 2007), we evaluated activation of caspase-3 in HT22 cells following transfection with
Aβ42 and mitoAICD. This revealed active caspase-3 staining in cells transfected with either
peptide, like that of controls treated with staurosporine. However, when cells were treated
with pan-caspase inhibitors, QvD or Casp (Slee et al., 1999), there was only a significant
reduction in apoptosis in cells overexpressing mitoAICD, but not Aβ42. These data suggest
that mitoAICD elicits cell death in a caspase-dependent manner when it is targeted to the
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mitochondria. In contrast, although Aβ42 overexpression clearly induces caspase-3
activation, this action appears to be dispensable for neurotoxicity induced by this peptide.
We hypothesize that cell death induced by Aβ42 instead utilizes caspaseindependent apoptotic factors located within the mitochondria (e.g., apoptosis-inducing
factor or EndoG). MOS and mitochondrial damage that leads to mitochondrial membrane
permeation through either the recruitment of Bax or opening of the mPTP can cause the
release of AIF or EndoG, as well as calcium, into the cytosol. An increase in cytosolic
calcium concentration due to its release from intracellular stores, such as the mitochondria,
can initiate neurotoxic cascades involving calpains, nitric oxide synthase, and calcineurin
(Szydlowska & Tymianski, 2010). Additionally, Bax activation is necessary for the release
of AIF from the mitochondria and its subsequent translocation to the nucleus where it
induces apoptosis through chromatin condensation and DNA fragmentation (Moubarak et
al., 2007). Additional studies will need to be performed to determine which specific
caspase-independent apoptotic cascades are initiated by Aβ42.
Finally, using hippocampal neurons isolated from embryonic rats, we examined the
reproducibility of results we observed in HT22 cells in primary neurons. The health of the
primary cells were assessed following transfection with the peptides of interest. When
transfected with the Ires and AICD59 controls, the neurons displayed highly complex
processes and round intact nuclei, indicative of healthy cells. However, neurons transfected
with either Aβ42 or mitoAICD displayed fragmented, shortened and simpler processes, in
addition to fragmented and condensed nuclei, characteristic of cell death. Upon
quantification, there was a significant increase in cell death in these cells as compared to
the Ires and AICD59 controls, similar to the results obtained in the HT22 cell line.
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Taken together, our data suggest that two major cleavage products of APP, Aβ42
and mitochondrial-targeted AICD59, exhibit distinct apoptotic mechanisms through their
interaction with the mitochondria. While both peptides increase ROS and induce activation
of the pro-apoptotic protein Bax, it appears that Aβ42 proceeds primarily through a caspaseindependent mechanism of cell death that involves opening of the mPTP, whereas
mitoAICD stimulates a caspase-dependent mode of cell death. These data are novel in that
they elucidate a previously unrecognized neurotoxic role of AICD59 at the mitochondria,
where it can be formed endogenously through a resident γ-secretase. In addition, our
findings suggest a potentially synergistic role of Aβ42 and AICD59 acting at the
mitochondria, leading to the induction of neuronal apoptosis through distinct mechanisms.
The identification of distinct apoptotic mechanisms exhibited by these two cleavage
products of APP may provide valuable insight towards the discovery of new AD
therapeutics which could target both mechanisms of action as a means of mitigating disease
pathogenesis.

112

CHAPTER FOUR: PRESERVATION OF REELIN EXPRESSION WITH
IMMUNOCAL® SUPPLEMENT IN A MOUSE MODEL OF ALZHEIMER’S
DISEASE
4.1 Abstract
Deficits in Reelin expression play a pathogenic role in several nervous system
disorders including schizophrenia and Alzheimer’s Disease (AD). For example, Reelinexpressing neurons of the entorhinal cortex (EC) layer II are a highly vulnerable population
of cells that are lost very early in AD. Thus, strategies aimed at correcting deficits in Reelin
might provide a novel therapeutic approach for AD. Here, we examined the effects of the
cysteine-rich, whey protein supplement, Immunocal®, on Reelin expression in vitro in
hippocampal-entorhinal cortex rat brain slices and in vivo in the hAPPSweInd mutant (J20)
mouse model of AD. Incubation of brain slices with Immunocal® increased Reelin
expression at the mRNA and protein levels. Treatment of hemizygous J20 mice with
Immunocal®, given ad libitum in drinking water beginning at 3-months of age, corrected
a deficit in cortical glutathione (GSH) levels observed in the brains of untreated mice and
preserved Reelin and GAD67 expression in the hippocampal-entorhinal cortex sub-region
of 5-month-old J20 mice. We also assessed the long-term effects of Immunocal® by
treating J20 mice from 3-months-old to 12-months-old. Immunocal® treatment preserved
brain GSH in 12-month-old J20 mice and rescued Reelin mRNA and protein as measured
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by in situ mRNA hybridization, western blotting and immunofluorescence microscopy,
respectively. Furthermore, Immunocal ® treatment significantly suppressed amyloid
plaque formation in the EC and hippocampus. Collectively, these findings indicate that
Immunocal® induces Reelin expression in vitro in brain slices and rescues brain GSH and
Reelin expression while diminishing amyloid plaque burden in the EC and hippocampus
of J20 mice. We conclude that Immunocal® represents a novel therapeutic approach to
rescue Reelin expression and decrease amyloid deposition in AD.
4.2 Introduction
Alzheimer’s Disease is the leading cause of dementia and cognitive decline with
nearly 6 million patients currently diagnosed in the United States and over 500,000 new
cases each year (Alzheimer’s Association, 2021). Only 5% of AD cases are familial in
origin with aging being the most significant risk factor for developing sporadic AD. Given
the demographic shift to advancing age in our population, there is predicted to be a very
significant increase in the number of people diagnosed with AD in the next several decades.
Current FDA approved drugs for AD are limited to acetylcholinesterase inhibitors and the
NMDA antagonist memantine. These drugs are minimally effective and treat only the
symptoms of AD while having no effect on the underlying etiology of the disease. As such,
current therapies do not significantly delay or halt the progression of AD. Research focused
on identifying new molecular targets that underlie the pathogenesis of AD is critically
needed to develop novel therapeutic strategies for this devastating disorder.
Reelin is a large glycoprotein secreted by specific cells within the central nervous
system (CNS) that plays a key role in patterning and layering of the cerebral cortex and
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other regions of the brain during development. In adults, Reelin plays a central role in
processes that influence synapse formation and neuronal plasticity required for learning
and memory, such as the regulation of dendritic spine architecture and the maintenance of
long-term potentiation (Niu et al., 2004; Beffertt al., 2006; Kim et al., 2015; Bosch et al.,
2016). In particular, the Reelin-expressing neurons of the EC project to the hippocampus
and are involved in declarative memory formation and consolidation.
EC layer II neurons provide the principal excitatory glutamatergic input to the
dentate gyrus (DG) of the hippocampus and are also one of the first neuronal populations
to die in AD, resulting in a severe loss of these synaptic contacts. These Reelin-expressing
cells are significantly reduced in the brains of human APP transgenic mice expressing the
Swedish and Indiana mutant form of the hAPP gene (J20 strain). In accordance with the
loss of these Reelin-expressing EC layer II neurons, Reelin levels in the hippocampus of
J20 mice are also significantly reduced, compared to non-transgenic controls (Chin et al.,
2007). Similar loss of Reelin-expressing EC layer II neurons is also observed in the brains
of patients with AD (Chin et al., 2007; Herring et al., 2012). Finally, in a transgenic rat
model of AD (McGill-R-Thy1-APP strain), Reelin-expressing neurons of the EC layer II
were found to selectively express increased levels of soluble intracellular beta amyloid
peptides (Aβ) early in disease, prior to the deposition of amyloid plaques (Kobro-Flatmoen
et al., 2016). Collectively, these studies suggest that Reelin-expressing neurons of EC layer
II play a central role in the early pathogenic changes in AD and loss of these Reelinexpressing cells and their synaptic projections to the hippocampus are early markers of
disease (Krstic et al., 2013). Thus, deficits in Reelin signaling to the hippocampus likely
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underlie some of the cognitive deficits observed in patients with AD (Cuchillo-Ibañez et
al., 2016; Yu et al., 2016).
Several studies suggest that modulating Reelin expression has marked effects on
AD progression. For example, further reducing Reelin in J20 AD mice by crossing them
with heterozygous reeler mice accelerates amyloid plaque formation and tau pathology
(Kocherhans et al., 2010). On the other hand, Reelin overexpression in J20 AD model mice
significantly delays Aβ fibril formation and rescues cognitive deficits in these mice
(Pujadas et al., 2014). Thus, J20 mice are an established model of AD and the disease
course of these mice is significantly impacted by alterations in Reelin expression, making
this an excellent model system to investigate the effects of Immunocal® on these processes.
The whey protein supplement, Immunocal®, is a rich source of the GSH precursor,
cysteine, and is known to boost antioxidant levels in vivo. In addition, in a schizophrenia
mouse model characterized by low Reelin levels, Immunocal® was shown to elevate
Reelin in the brain (Song et al., 2017). Given that a similar loss of Reelin-expressing EC
layer II neurons has also been observed in the brains of patients with AD, determining if
Immunocal® elevates Reelin expression in the hippocampal-entorhinal cortex of J20 mice
and mitigates amyloid plaque deposition in these animals, will provide key preclinical data
to support future clinical trials of Immunocal® in patients with AD.

4.3 Methods
4.3.1 Reagents
Immunocal® was provided by Immunotec, Inc. (Vaudreuil-Dorion, QC, CA).
Gey’s balanced salt solution and ProLong Gold was purchased from Invitrogen (Carlsbad,
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CA, USA). Primary antibodies for Reelin (ab78540), NeuN (ab104225), DRAQ7™, and
β-actin (ab 115777) were purchased from Abcam (Cambridge, UK). Secondary antibodies
for immunofluorescence were purchased from Jackson Immunoresearch (Westgrove, PA,
USA). Horseradish peroxidase (HRP)-conjugated secondary antibodies for Western
blotting (catalogue no. 1706515) and all probes and reagents for qPCR were purchased
from Bio-Rad (Hercules, CA, USA). All probes (RNAscope® Probe Mm-Reln-C3;
catalogue no. 319361-C3) and reagents (RNAscope® fluorescent multiplex kit; catalogue
no. 320850) for in situ hybridization were purchased from Advanced Cell Diagnostics
(Newark, CA, USA). Amylo-Glo was purchased from Biosensis (Thebarton, SA, AU).
4.3.2

Experimental models

Rat brain slice cultures
To investigate the effects of Immunocal® on Reelin expression in vitro, we utilized
organotypic hippocampal-entorhinal cortex slices prepared from postnatal day 25 SpragueDawley male rats. Brain slices were sliced using a vibrating microtome essentially as
described by (Leutgeb, Frey, & Behnisch, 2003). Animal studies were conducted in
accordance with a protocol approved by the University of Denver Institutional Animal Care
and Use Committee (Approval #983340-4).
J20 AD mouse model studies
To investigate the effects of Immunocal® on Reelin expression in vivo, we utilized
the hAPPSwe-Ind mutant transgenic mouse model of AD (J20 strain). This mouse model was
obtained from Jackson Laboratories (Bar Harbor, ME, USA; strain B6.Cg-Tg(PDGFBAPPSwInd) 20Lms/2Mmjax) and displays significant brain pathology, amyloid plaques,
and cognitive deficits that recapitulates multiple aspects of AD in humans (Diaz-Hernandez
117

et al., 2012; Karl, Bhatia, Cheng, Kim, & Garner, 2012; Mucke et al., 2000). According to
previous reports, these transgenic mice typically show significant cognitive deficits,
diminished numbers of Reelin-positive EC layer II neurons, and decreased Reelin
expression in the hippocampus by approximately 4-5 months of age. As these mice age,
amyloid plaques (a hallmark of AD pathology) are visible in the brain, particularly the
hippocampus, by around 12-months of age. All animal studies were conducted in
accordance with a protocol approved by the University of Denver Institutional Animal Care
and Use Committee (Approval #927465-8).
4.3.3 Immunocal® treatment of brain slices
Approximately 400 micron hippocampal-entorhinal cortex slices were cultured in
a humidified incubator in tissue culture medium with 5% CO2 at 37 oC. After equilibration
overnight, slices were subsequently treated with either culture medium alone or containing
Immunocal® (3.3% w/v) for 24 h, followed by subsequent experimental analyses.
4.3.4 Immunoprecipitation
Following incubation in either culture medium alone or containing recombinant
Reelin, brain slices were lysed using a Dounce homogenizer in lysis buffer supplemented
with aprotinin and leupeptin (Linseman, Hampton, & Branstetter, 1995). Lysates were
cleared by centrifugation, protein measured using a BCA protein assay, and
immunoprecipitated with an antibody to Dab-1 followed by protein A/G-Sepharose beads.
Immune complexes were resolved by SDS-PAGE, transferred to PVDF membranes and
immunoblotted for phosphor-tyrosine. Membranes were then stripped and re-probed for
Dab-1.
4.3.5 Quantitative real-time polymerase chain reaction (qPCR)
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Following incubation in either culture medium alone or containing Immunocal®,
recombinant Reelin, or the combination, brain slices were lysed using a Dounce
homogenizer and RNA was isolated using a miRNeasy kit purchased from Qiagen
(Valencia, CA, USA). RNA was analyzed by real-time polymerase chain reaction (qPCR)
on an iQ5 Real Time PCR System (Bio-Rad, Hercules, CA, USA) using an iTAq Universal
SYBR Green One-step kit (BioRad, Hercules, CA, USA). Primers for rat Reelin
(PrimePCR SYBR Green Assay, Reln, rat, qRnoCED0008838) and rat GAPDH
(PrimePCR SYBR Green Assay, Gapdh, rat, qRnoCID0057018) were also purchased from
Biorad. PCR was performed using the following conditions: 95 °C for 5 min followed by
40 cycles of 95 °C for 15 s, 60 °C for 30 seconds, and 68 °C for 1 minute (Stankiewicz,
Schroeder, Kelsey, Bouchard, & Linseman, 2013). Threshold cycle (Ct) values for each
sample were selected by the iQ5 software. The analysis of differential fold change was
done using the Livak (ΔΔCt) method (Livak & Schmittgen, 2001).
4.3.6 Immunofluorescence
Approximately 200 micron thick brain slices were harvested in ice cold Gey’s
balanced salt solution such that the hippocampal-entorhinal cortex region was preserved,
then added to a 6-well plate (1 slice/well) containing ice cold 4% paraformaldehyde (PFA)
for 90 minutes. Fixative was removed from the wells and the slices were washed three
times for 5 minutes in PBS-T. After the final wash, PBS-T was removed and 1 mL of
Blocking Solution (5% BSA, 1× PBS, 0.05% Tween-20, pH 7.4) was added to the wells
and incubated at 25 °C for 90 minutes. Blocking solution was replaced with primary
antibody in blocking solution at the specified dilutions (Supplementary Table 3) and
incubated overnight at 4 0C. The following day, primary antibody was removed, and the
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tissue was washed 3 times for 5 minutes in PBS-T. Slices were then incubated with the
secondary antibody diluted in blocking solution at the indicated concentrations for 90
minutes at 25 °C. Then, secondary antibody solution was removed and immediately
replaced with 1ml of DRAQ7™ diluted in PBS-T and incubated for 20 minute at 25 °C.
The tissue was carefully transferred to a SuperFrost Plus Slide and excess PBS-T was
removed using a Kimwipe. Prolong Gold was added onto the tissue and a coverslip was
placed over it.
4.3.7 Immunocal® treatment of mice
For the in vivo study, we used three groups of mice: hAPP(Swe/Ind) mutant
hemizygous mice (J20 strain) treated with Immunocal® (3.3% w/v in drinking water ad
libitum, as previously described by Ross et al., 2014), untreated hemizygous J20 mice, and
untreated non-transgenic (non-carrier) control mice. For 5-month studies, Immunocal®
treatment was initiated at 3 months-old and continued until the mice were 5 months old.
For 12-month studies, Immunocal® treatment was initiated at 3 months old and continued
until the mice were 12 months old.
4.3.8 Tissue processing
Mice were euthanized and biochemical and immunohistochemical analysis was
conducted on brain tissue to evaluate Reelin-expressing neurons in the EC and Reelin
staining in the DG, CA1, and CA3 of the hippocampus. For western blotting, brains were
micro-dissected to obtain tissue samples enriched for the hippocampal-entorhinal cortex
architecture. For immunofluorescence staining of brain tissue, slices were prepared using
a vibrating microtome essentially as described by Leutgeb et al. (Leutgeb, et al., 2003)
before fixing with PFA for staining.
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Cortical tissue was obtained from mice and immediately frozen in liquid nitrogen.
For HPLC-ECD analysis, 2.5M perchloric acid was added and the brains were roughly
chopped using pointed surgical scissors. Samples were then sonicated 3 times for 15sec
intervals. Samples were then centrifuged for 5 minutes at 13,000 rpm and the supernatant
was removed. A 20µL aliquot of the supernatant was used for a BCA protein assay. The
remainder of each solution was neutralized with 500µL of 4M KOH and vortexed
thoroughly. Samples were then centrifuged for 15 minutes at 13,000rpm, and stored at -80
°C until separation and analysis by HPLC-ECD.
4.3.9 Analysis of brain GSH and GSSG by HPLC with electrochemical
detection
GSH in samples and known standards were separated by reversed phase HPLC on
a C18 bonded silica column at 35 °C (5µm, 4.6mmID x 25cm) from Tosoh Bioscience.
(Grove City, OH, USA). Analytes were detected using a CoulArray® detector (model
5600, ESA) on three coulometric array cells in series; electrochemical detectors were set
between 0 and 900mV at increments of 75mV. Concentrations were determined with a
standard curve of each identified analyte. Mobile phase consisted of 50mM lithium acetate
and 1% acetonitrile in water, pH 3.8. The flow rate was set to 0.4mL/min for all samples.
CoulArray® software was used for baseline correction and peak analysis.
4.3.10 Western Blotting
Mouse brains were rapidly dissected and one hemisphere was placed into ice cold
Gey’s balanced salt solution for slicing while the other half was flash frozen in liquid
nitrogen and stored at -800C. Briefly, the flash frozen halves were thawed, then brain slices
were lysed using a Dounce homogenizer and lysis buffer supplemented with aprotinin and
121

leupeptin. The samples were diluted 1:100 for a BCA protein assay. Western blotting was
done to immunochemically detect proteins immobilized on polyvinylidene difluoride
(PVDF) membranes. Protein samples (50 µg/lane) were resolved by SDS-PAGE and
proteins were then transferred to PVDF membranes. Non-specific binding sites were
blocked using 1% BSA in PBS (pH 7.4) containing 0.1% Tween-20 (PBS-T) for 1 h at
25°C. The blocking buffer was drained, and the membrane was allowed to incubate in
primary antibody diluted in blocking buffer per manufacturer’s recommendations
(Supplementary Table 3) overnight at 4 °C. The membrane was washed 3 times for 15
minutes in PBS-T and was then incubated with the secondary antibody (1:5000) for 1.5 h
at 25 °C. The secondary was then removed, and the membrane was washed again in PBST, 3 times for 15 minutes. Immunoreactive proteins were detected using enhanced
chemiluminescence (GE Healthcare; Pittsburgh, PA, USA) and films were developed using
a ChemiDoc developer (BioRad, Hercules, CA, USA). Re-probing of blots was performed
by stripping in 0.1 M Tris-HCl (pH 8.0), 2% SDS, and 100 mM β-mercaptoethanol for 30
minutes at 52 °C. The blots were rinsed twice in PBS-T and processed as above with a
different primary antibody. Relative intensities of the protein bands were quantified by
scanning densitometry using ImageJ.
4.3.11 In-situ mRNA hybridization
Samples were processed according to ACD RNAscope® Fluorescent Multiplex
Assay manual (Newark, CA, US). Using a vibratome (Leica), brain tissue was freshly
sliced in ice cold Gey’s balanced salt solution at approximately 500 microns thickness such
that the hippocampal-entorhinal cortex region was preserved, then the slices were
embedded in OCT and frozen in liquid nitrogen. Brains were then sliced at 30 microns
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thickness with a cryostat (Leica CM 1950) and adhered onto SuperFrost Plus Slides and
stored at -80 0C until use. Sections were fixed and permeabilized using 4% PFA and
incubated for 15 minutes. Slides were rinsed twice with PBS (pH 7.4) buffer. Tissues were
dehydrated consecutively in 50%, 70% and 100% ethanol for 2 minutes each. A barrier
was created around the tissue using a hydrophobic pen. Tissues were then incubated with
protease inhibitor for 30 minutes at 25°C in HybEZ™ Humidity Control Tray. About 4-6
drops of Reelin or NeuN (positive control) probe was added to tissues. The slides were
inserted in a slide holder and placed in HybEZ™ Humidity Control Tray and incubated for
2 h at 400C in HybEZ™ Oven. After washing in PBS, samples were hybridized by adding
4-6 drops with Amp1, Amp2 and Amp3 for 30, 15, 30 minutes respectively at 400C.
Samples were incubated with FITC dye for 15 minutes at 25°C and counter stain DRAQ7
was added for 15 minutes.
4.3.12 Quantification of reelin staining and amyloid plaques
Images were collected using an Olympus FLUOVIEW FV3000 confocal laser
scanning microscope using an Olympus 20X PLN objective. Confocal z-series were
captured at equal exposure times across all samples (n=4 to 5 in each group for protein
staining and n=3 in each group for in situ hybridization). Each region (EC, DG, CA3/CA1)
was captured in triplicate. Total fluorescent intensity was analyzed in Adobe Photoshop
for protein staining and in situ hybridization. Any adjustments made in the analysis step
were equally applied to all groups.
For amyloid plaque quantification by image J software, the color images were
converted into HSV format and 8-bit channels. Plaques were quantified in an unbiased
manner by an investigator blind to the treatment group assignments of the samples. Plaque
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number was calculated from each area of hippocampus, whereas plaque load was
calculated as the area occupied by the plaques divided by the area of the total brain region
analyzed.
4.3.13 Statistical analysis
All data collected were analyzed with GraphPad Prism 5 software using one-way
analysis of variance (ANOVA) followed by a post-hoc Tukey’s test. Descriptive statistics
were displayed as an expressed mean ± S.E.M. Quantitative differences were deemed
significant when p < 0.05.

4.4 Results
4.4.1 Immunocal® treatment increased expression of Reelin in vitro
To demonstrate the overall health of our brain slice preparation, we first examined
Reelin signaling in vitro by incubating rat hippocampal-entorhinal cortex slices with
recombinant Reelin which resulted in a marked increase in the tyrosine phosphorylation of
the adapter protein DAB1 (Figure 4.1A). Next, we incubated slices in either tissue culture
medium alone or containing Immunocal®. Immunocal® treatment induced an increase in
the full length Reelin protein and in the most prominent Reelin cleavage product (180kDa)
(Figure 4.1B). We also measured the Reelin transcript by qPCR after incubation of brain
slices in control medium, medium containing Immunocal®, recombinant Reelin, or a
combination of the two. As seen in Figure 4.1C, incubation with Immunocal® induced a
statistically significant increase in Reelin mRNA transcript levels in either the absence or
presence of recombinant Reelin protein as revealed via one way Analysis of Variance
(ANOVA) [F(3,16)=9.622, p=0.0007]. Incubation with recombinant Reelin protein alone
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had no significant effect on the amount of Reelin transcript detected in the slices, although
a slight trend towards decreased Reelin mRNA levels was observed under these conditions.
Next, we assessed the effects of Immunocal® treatment on Reelin expression in
hippocampal-entorhinal cortex slices by co-staining for Reelin and NeuN using specific
antibodies and immunofluorescence microscopy. Incubation of brain slices with
Immunocal® induced a striking increase in Reelin immunoreactivity in the EC, DG, and
CA1 region of the hippocampus (Figure 4.2).
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Figure 4.1 Immunocal® treatment increased Reelin expression in vitro in
hippocampal-entorhinal cortex slices. A) Brain slices were incubated for 24h in either
control medium alone (Con) or containing recombinant Reelin (recRln). Following
incubation, slices were lysed and DAB1 was immunoprecipitated (IP). The immune
complexes were resolved by SDS-PAGE and immunoblotted (IB) for phosphor-tyrosine
(PY) followed by stripping and re-probing for DAB1. B) Brain slices were incubated for
24h in either Con medium or containing Immunocal® (ICAL). Protein lysates were IB
for Reelin. C) Brain slices were incubated for 24h in either control medium (Con),
medium containing Immunocal® (ICAL), recombinant Reelin protein (Rln), or a
combination of the two (Rln + ICAL). Total RNA was extracted from the slices, cDNA
was prepared and subjected to qPCR using primers and probes for rat Reelin and
GAPDH. Data are expressed as the mean +/- SEM ΔΔCt levels of the Reelin transcript
normalized to GAPDH, n=5 independent preparations. ** indicates p<0.01 compared to
Con; # indicates p<0.05 versus Rln alone, as determined using a one-way ANOVA with a
post hoc Tukey’s test.
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Figure 4.2 Immunocal® treatment increased Reelin staining in vitro in
hippocampal-entorhinal cortex slices. A) Cortex brain slices were incubated for 24h in
either control medium alone (Con) or Immunocal® (ICAL) then fixed in formalin and
stained with antibodies for Reelin (green) and NeuN (red) then imaged in specific regions
including the EC (A), DG (B) and CA1 of the hippocampus (C).
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4.4.2 Immunocal® treatment preserved the GSH:GSSG ratio in 5-month-old
AD model mice
Next, we analyzed the effects of Immunocal® treatment in vivo utilizing J20 AD
model mice which were given Immunocal® supplementation ad libitum from 3 to 5 months
old. We measured the brain levels of reduced glutathione (GSH) and oxidized glutathione
disulfide (GSSG) in cortical tissue from the mice using HPLC-ECD. Untreated
hemizygous J20 mice displayed a statistically significant decrease in cortical GSH
[F(2,12)=10.07, p=0.0027] and coinciding increase in GSSG [F(2,12)=5.202, p=0.0236] at
5 months-old when compared to non-carrier control mice (Figure 4.3A, B). However,
hemizygous J20 mice treated with Immunocal® showed a complete preservation of cortical
GSH and a reduction in GSSG, which was statistically significantly different than the levels
observed in untreated hemizygous mice (Figure 4.3A, B). Furthermore, the GSH/GSSG
ratio, a measure of oxidative stress, showed a statistically significant reduction in the
untreated hemizygous mice when compared to the non-carrier control mice, and this effect
was completely prevented by treatment with Immunocal® [F(2,12)=5.379, p=0.0215]
(Figure 4.3C).
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Figure 4.3 Immunocal® treatment preserved brain GSH in 5-month-old J20 AD
model mice. Cortical brain tissue was harvested from 5-month-old non-carrier control
mice (Non-carrier) and hemizygous J20 AD mice (Hemi) either untreated (unt) or treated
with 3.3% w/v Immunocal® in drinking water ad libitum for 2 months (ICAL). Tissue
was extracted then GSH (A) and GSSG (B) and GSH:GSSG ratio (C) were measured by
HPLC with electrochemical detection. Values are normalized to protein content
represented as mean +/- SEM, n=5 mice per group. * indicates p<0.05, ** indicates
p<0.01 as determined using a one-way ANOVA with a post hoc Tukey’s test.
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4.4.3 Immunocal® treatment rescued Reelin expression in 5-month-old AD
model mice
Brain lysates enriched for the hippocampal-entorhinal cortex sub-region from the
5-month-old mice were immunoblotted for Reelin. Reelin expression was significantly
reduced in untreated hemizygous J20 AD mice compared to non-carrier controls and
Immunocal® treatment largely corrected this deficiency. The 180 kDa cleavage fragment
of Reelin was the major Reelin form detected in mouse brain lysates (Figure 4.4A).
Quantitative densitometric analysis of the 180 kDa Reelin band revealed an approximate
25% reduction in Reelin protein expression in hemizygous untreated AD mice compared
to non-carrier controls, and a complete preservation of Reelin expression in Immunocal®treated mice [F(2,6)=128.7, p<0.0001] (Figure 4.4B).
Next, we used immunofluorescence microscopy to evaluate Reelin expression in
the EC, DG, and CA1/CA3 regions of the hippocampus in J20 AD model mice (Figure
4.5). The EC of non-carrier control mice showed significant Reelin immunoreactivity,
particularly in layer II, the area demarcated in the Figure (Figure 4.5A, see lower panels).
In comparison to the non-carrier control, untreated hemizygous J20 mice displayed a
marked reduction in Reelin immunoreactivity in layer II of EC, which was increased upon
Immunocal® treatment (Figure 4.5A).
Next, we assessed Reelin staining in the DG and CA1/CA3 regions of the
hippocampus in J20 mice. In the DG, Reelin expression was diffuse and moderate in
intensity in non-carrier control mice (Figure 4.5B). Untreated hemizygous J20 mice
showed a slight overall reduction in Reelin staining in the DG, whereas Immunocal®130

treated hemizygous J20 mice displayed a striking increase in the intensity of Reelin staining
in this brain region (Figure 4.5B). In the CA1 region of the hippocampus, Reelin expression
was very high in non-carrier control mice and was markedly reduced in untreated
hemizygous J20 AD mice (Figure 4.5C). Notably, this deficit in Reelin staining was
essentially prevented by treatment of hemizygous J20 mice with Immunocal® for 2 months
(Figure 4.5C). A very similar effect on Reelin expression was observed in the CA3 region
of the hippocampus. In particular, Reelin-expressing neurons in the middle section of this
sub-region were particularly evident in non-carrier control mice, essentially absent in
untreated hemizygous J20 mice, and largely preserved in Immunocal®-treated J20 mice
(Figure 4.5D).
Finally, we evaluated GAD67 staining in the CA3 region of the hippocampus.
GAD67 staining in the CA3 of non-carrier control mice was relatively diffuse with several
distinct complex neurite patterns (Figure 4.5E). The overall intensity was diminished in
untreated hemizygous J20 mice and this complex neurite staining was essentially absent
(Figure 4.5E). In contrast, GAD67 staining and the complex neurite patterning were
markedly increased in the CA3 of hemizygous J20 mice which had been treated with
Immunocal® for 2 months (Figure 4.5E).
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Figure 4.4 Immunocal® treatment rescued Reelin expression in 5-month-old J20 AD
model mice. A) Western blot analysis using an antibodies specific for Reelin (top) and
beta actin (bottom) in tissue was harvested from 5-month-old non-carrier control mice
(Non-carrier) and hemizygous J20 AD mice (Hemi) either untreated (Unt) or treated with
3.3% w/v Immunocal® in water ad libitum for 2 months (ICAL). Tissue was microdissected to enrich for hippocampal-entorhinal sub-region. A) Densitometry
quantification of (A) represented as the mean +/- SEM, n=3 mice per group. ****
indicates p<0.0001 as compared to non-carrier, **** indicates p<0.0001 as compared to
Hemi (unt) as determined using a one-way ANOVA with a post hoc Tukey’s test.
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Figure 4.5 Immunocal® treatment rescued Reelin expression in hippocampalentorhinal regions of 5 month old J20 AD model mice. Brain slices from the
hippocampal-entorhinal region were harvested from 5 month old non-carrier control mice
(Non-carrier) and hemizygous J20 AD mice (Hemi) either untreated (unt) or treated with
3.3% w/v Immunocal® in drinking water ad libitum for 2 months (ICAL). A-D) Sliced
sections were fixed in formalin and stained with antibodies for Reelin (Rln; green), NeuN
(red), and Draq nuclear stain (blue). Specific regions were images in the hippocampalentorhinal region including the EC (A), DG (B). CA1 of the hippocampus (C) and CA3
of the hippocampus (D). E) Sliced sections were fixed in formalin and stained with
antibodies for GAD67 (green), NeuN (red), and Draq nuclear stain (blue) then imaged in
the CA3 region.
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4.4.4 Immunocal® treatment increased GSH:GSSG ratio in 12-month-old
AD model mice
Next, we measured the effects of Immunocal® treatment in vivo utilizing J20 AD
model mice which were given Immunocal® supplementation ad libitum from 3 to 12
months of age. First, we measured brain levels of GSH and GSSG in cortical tissue from
the mice using HPLC-ECD as in the 5 month-old mice. Untreated hemizygous J20 mice
displayed a reduction in cortical GSH [F(2,12)=6.447, p=0.0125] and a marked increase
in GSSG [F(2,12)=20.08, p=0.0001] at 12 months-old when compared to non-carrier
control mice (Figure 4.6A, B). Hemizygous J20 mice treated with Immunocal® from 3
months-old to 12 months-old showed a complete preservation of cortical GSH and a
reduction in GSSG, both of which were statistically significantly different from the levels
observed in untreated hemizygous mice (Figure 4.6A, B). Finally, the GSH/GSSG ratio
showed a statistically significant reduction in the untreated hemizygous mice when
compared to the non-carrier control mice; an effect that was completely blunted by
treatment with Immunocal® [F(2,10)=5.106, p=0.0296](Figure 4.6C).
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Figure 4.6 Immunocal® treatment preserved brain GSH in 12-month-old J20 AD
model mice. Cortical brain tissue was harvested from 12-month-old non-carrier control
mice (Non-carrier) and hemizygous J20 AD mice (Hemi) either untreated (unt) or treated
with 3.3% w/v Immunocal® in drinking water ad libitum for 9 months (ICAL). Tissue
was extracted then GSH (A) and GSSG (B) and GSH:GSSG ratio (C) were measured by
HPLC with electrochemical detection. Values are normalized to protein content
represented as mean +/- SEM, n=3 mice per group. * indicates p<0.05, ** indicates
p<0.01, *** indicates p<0.001, NS indicates no significant difference as determined
using a one-way ANOVA with a post hoc Tukey’s test.
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4.4.5 Immunocal® treatment increased mRNA Reelin expression in 12month-old AD model mice
To analyze mRNA expression of Reelin in response to Immunocal® treatment, we
used in situ hybridization to analyze regions of hippocampus and EC that express Reelin
transcripts. In particular, we measured these levels in cells which produce Reelin including
the EC layer 2 and interneurons of the CA3 region. We found mRNA expression for Reelin
mostly concentrated in the regions of hilus layer in DG, CA3 of hippocampus and
entorhinal cortex (Figure 4.7A). We then quantified regions of EC and CA3 using one-way
ANOVA of the treatment groups, which revealed a significant decrease in Reelin transcript
levels detected in CA3 [F(2,23)=4.030, p=0.0316] and EC [F(2,21)=6.862), p=0.0051]
regions of hemizygous untreated mice when compared to non-carrier controls (Figure 4.7B,
C). Further, Immunocal® treatment significantly sustained Reelin transcript expression,
but only in the entorhinal cortex (Figure 4.7C).
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Figure 4.7 Immunocal® treatment increased Reelin mRNA expression in
hippocampal-entorhinal cortex slices of 12-month-old J20 AD model mice. A) Brain
slices from the hippocampal-entorhinal region were harvested from 12-month-old noncarrier control mice (Non-carrier) and hemizygous J20 AD mice (Hemi) either untreated
(unt) or treated with 3.3% w/v Immunocal® in drinking water ad libitum for 9 months
(ICAL). Sliced sections were fixed in formalin and hybridized with antisense Reelin
transcript (Rln; green) along with Drag nuclear stain (blue). B) Total fluorescent
intensities in the CA3 region of the hippocampus from (A) represented as the mean +/SEM, n=3 mice per group. * indicates p<0.05 for Hemi (unt) as compared to Non-carrier.
C) Total fluorescent intensities in the EC from (A) represented as mean +/- SEM, n=3
mice per group. ** indicates p<0.01 as compared to Non-carrier, # indicates p<0.05 as
compared to Hemi (unt) as determined using a one-way ANOVA with a post hoc Tukey’s
test.
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4.4.6 Immunocal® treatment rescued Reelin expression in 12-month-old AD
model mice
We next evaluated the expression of Reelin protein in the 12-month-old J20 AD
mice by western blotting brain tissues enriched for the hippocampal-entorhinal cortex
region. Reelin expression was significantly reduced in untreated hemizygous J20 mice
compared to non-carrier controls and Immunocal® treatment largely corrected this
deficiency (Figure 4.8A). Using quantitative densitometric analysis of the 180 kDa Reelin
band revealed a significant reduction in Reelin protein expression in hemizygous untreated
AD mice compared to non-carrier controls, and a complete rescue of Reelin expression in
Immunocal®-treated mice [F(2,6)=12.62, p=0.0071] (Figure 4.8B).
We then performed immunofluorescence microscopy to evaluate Reelin expression
in the EC, DG, and CA1/CA3 regions of the hippocampus in 12-month-old J20 mice. The
EC of non-carrier control mice showed significant Reelin immunoreactivity (Figure 4.9A),
particularly in layer II, reminiscent of the pattern observed in J20 mice analyzed at 5months-old. In comparison to the non-carrier control, untreated hemizygous J20 mice
displayed a marked reduction in Reelin immunoreactivity in layer II of EC. Intriguingly,
treatment with Immunocal® from 3 months-old to 12 months-old essentially rescued this
deficit in Reelin expression within layer II of the EC of J20 mice F(2,11)=18.70, p=0.0003]
(Figure 4.9A). Next, we assessed Reelin staining in the DG and CA1/CA3 regions of the
hippocampus in J20 mice. In the DG, Reelin expression was diffuse and moderate in
intensity in non-carrier control mice (Figure 4.9B). Untreated hemizygous J20 AD mice
showed a significant reduction in Reelin staining, whereas Immunocal®-treated
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hemizygous J20 mice displayed a significant increase in the intensity of Reelin staining in
this brain region F(2,9)=12.42, p=0.0026] (Figure 4.9B). In the CA1 region of the
hippocampus, Reelin expression was very high in non-carrier control mice and was
significantly reduced in untreated hemizygous J20 AD mice [F(2,11)=7.385, p=0.0093]
(Figure 4.9C). A very similar effect on Reelin expression was observed in the CA3 region
of the hippocampus [F(2,9)=12.01, p=0.0029]. In particular, Reelin-expressing neurons in
the middle section of this sub-region were particularly evident in non-carrier control mice,
but essentially absent in untreated hemizygous J20 AD mice (Fig. 9D). Although
Immunocal® treatment appeared to have some effect at sustaining Reelin staining in CA1
and CA3, quantitative analysis of multiple sets of mice did not show a statistically
significant effect in these subregions (Figure 4.9C, D).
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Figure 4.8 Immunocal® treatment rescued Reelin expression in 12-month-old J20
AD model mice. A) Western blot analysis using an antibodies specific for Reelin (top)
and beta actin (bottom) in tissue was harvested from 12-month-old non-carrier control
mice (Non-carrier) and hemizygous J20 AD mice (Hemi) either untreated (Unt) or treated
with 3.3% w/v Immunocal® in water ad libitum for 9 months (ICAL). Tissue was microdissected to enrich for hippocampal-entorhinal sub-region. A) Densitometry
quantification of (A) represented as the mean +/- SEM, n=3 mice per group. * indicates
p<0.05 as compared to non-carrier, ** indicates p<0.01 as compared to Hemi (unt) as
determined using a one-way ANOVA with a post hoc Tukey’s test.
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Figure 4.9 Immunocal® treatment rescued Reelin expression in hippocampalentorhinal regions of 12-month-old J20 AD model mice. Brain slices from the
hippocampal-entorhinal region were harvested from 12-month-old non-carrier control
mice (Non-carrier) and hemizygous J20 AD mice (Hemi) either untreated (unt) or treated
with 3.3% w/v Immunocal® in drinking water ad libitum for 9 months (ICAL). Sliced
sections were fixed in formalin and stained with antibodies for Reelin (Rln; green), NeuN
(red), and Draq nuclear stain (blue). A) Images taken in the EC and quantification of total
fluorescent intensities represented as the mean +/- SEM, n=4 for Non-carrier, n=5 for
Hemi (unt) and Hemi (ICAL) mice per group. *** indicates p<0.001 as compared to
Non-carrier, # indicates p<0.05 as compared to Hemi (unt). B) Images taken in the DG
and quantification of total fluorescent intensities represented as the mean +/- SEM, n=4
mice per group. ** indicates p<0.01 as compared to Non-carrier, ## indicates p<0.01 as
compared to Hemi (unt). C) Images taken in the CA1 region of the hippocampus and
quantification of total fluorescent intensities represented as the mean +/- SEM, n=5 for
Non-carrier and Hemi (ICAL), n=4 for Hemi (unt) mice per group. ** indicates p<0.01 as
compared to Non-carrier. D) Images taken in the CA3 region of the hippocampus and
quantification of total fluorescent intensities represented as the mean +/- SEM, n=4 mice
per group. ** indicates p<0.01 as compared to Non-carrier. All statistical analyses were
determined using a one-way ANOVA with a post hoc Tukey’s test.
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4.4.7 Immunocal® treatment reduced amyloid plaques in 12-month-old AD
model mice
The J20 mice have been shown to display extensive Aβ plaque pathology in the
hippocampal-entorhinal cortex formation by 12-months of age. To evaluate the effects of
Immunocal® treatment on the deposition of amyloid plaques, we used Amylo-glo, an Aβ
aggregate-specific stain used to mark amyloid plaques. After treating the mice from 3
months-old to 12 months-old with Immunocal® there was a dramatic reduction in both
the plaque number [t(11)=3.418, p=0.0057] and plaque load [t(11)=2.253, p=0.0456] in
the entorhinal cortex (Figure 4.10A). Further, upon examination in the remainder of the
hippocampal regions of untreated J20 mice there was a significant plaque load throughout
with distinct dense formations (Figure 4.10B-D). However, treatment with Immunocal®
for 9-months dramatically diminished the plaque number in the DG [t(11)=4.920,
p=0.0005], CA1 [t(11)=2.664, p=0.0220], and CA3 [t(11)=3.551, p=0.0045] regions.
This reduction in plaque number coincided with significant plaque load reduction in DG
[t(11)=4.672, p=0.0007], CA1 [t(11)=2.505, p=0.0292], and CA3 [t(11)=3.006,
p=0.0119] in comparison to the untreated J20 mice (Figure 4.10B-D).
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Figure 4.10 Immunocal® treatment reduced amyloid plaque load and number in the
hippocampal-entorhinal region of 12-month-old J20 AD model mice. Brain slices from
the hippocampal-entorhinal region were harvested from 12-month-old hemizygous J20 AD
mice (Hemi) either untreated (unt) or treated with 3.3% w/v Immunocal® in drinking water
ad libitum for 9 months (ICAL). Sections were fixed in formalin and stained with Amyloglo (green) and Draq nuclear stain (grayscale) then imaged in the EC (A), DG (B), CA1 of
the hippocampus (C), and CA3 region of the hippocampus (D). The number of the plaques
and plaque load (number of plaques/area) were quantified and shown as the mean +/- SEM,
n=7 for Hemi (unt), n=6 for Hemi (ICAL) mice per group. * indicates p<0.05, ** indicates
p<0.01, *** indicates p<0.001 as compared to Hemi (unt) as determined using an unpaired
t-test.
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4.5 Discussion
The amyloid cascade hypothesis has dominated the field of AD research for the
past two decades and is founded on the premise that deposition of amyloid-beta (Aβ)
peptide is the initiating event in disease pathogenesis, ultimately leading to neurofibrillary
tangle formation, synaptic loss, and neuronal cell demise (Hardy and Higgins, 1992).
Throughout the years, the molecular form of Aβ thought to initiate the toxic cascade
responsible for AD pathology has shifted from insoluble plaques to protofibrils to soluble
oligomers (Klein et al., 2001; Naylor et al., 2008; Ferreira and Klein, 2011; Larson and
Lesné, 2012). Regardless of which particular form(s) of Aβ leads to disease pathology, for
more than a decade, the amyloidogenic processing of amyloid precursor protein (APP) to
form Aβ through the sequential cleavage of APP by β-secretase (BACE) and γ-secretase
has been recognized as a viable molecular target for AD therapeutic development (Vassar,
2001; Evin et al., 2006).
Due to this, selective inhibitors of BACE and γ-secretase have been developed as
drugs to decrease the tissue load of Aβ in AD brain (Vassar et al., 2009; D’Onofrio et al.,
2012). The development of selective BACE inhibitors that are orally bioavailable and
penetrate the blood brain barrier has been slow; however, this class of compounds has been
clinically tested in AD patients (Ghosh et al., 2012). These compounds have been met by
failure including the Merck compound, MK-8931 (Menting and Claassen, 2014; Kennedy
et al., 2016), which was terminated in Phase II/III clinical trials (EPOCH) after an interim
analysis suggested little chance of discerning any positive therapeutic benefit.
Additionally, Merck attempted another trial in patients with prodromal AD (APECS),
resulting in terminated upon findings of adverse effects and worsened cognition in patients
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(Doggrell, 2019). Likewise, γ-secretase inhibitors have also been largely disappointing in
the clinic like two large Phase III clinical trials of the Eli Lilly compound, semagacestat,
in mild-to-moderate AD patients, which were terminated early due to a statistically
significant worsening of clinical measures of cognition and ability to perform activities
associated with daily living (D’Onofrio et al., 2012). This may have been due to γsecretase-mediated cleavage of Notch-signaling, which has resulted in investigation of
Notch-sparing γ-secretase inhibitors (Augelli-Szafran et al., 2010; Wolfe, 2012). More
recently, the FDA conditionally approved Biogen’s anti- antibody, aducanumab, for
treatment of familial AD (FAD; making up less than 5% of cases), still requiring additional
data collection in lieu of full approval despite an expert panel’s warning against doing so
(Alexander et al., 2021) Regardless, due to these recent clinical disappointments, and the
observation that brain amyloid load does not necessarily correlate with the severity of
cognitive deficits in AD, some have begun to question whether the amyloid cascade
hypothesis is sufficient to explain the underlying pathogenesis of late onset, sporadic AD
(Giannakopoulos et al., 2003; Pimplikar et al., 2010; Castellani and Smith, 2011; Karran
et al., 2011; Mullane and Williams, 2013; Karran and De Strooper, 2016; Swerdlow et al.,
2017; Tse and Herrup, 2017).
Reelin is a secreted glycoprotein that is essential for proper layering in areas of the
brain during development and this protein continues to play a role in synaptic plasticity
and regulation of longterm potentiation, notably in the entorhinal cortex-hippocampal
region, in adulthood. Previous work has shown that deficits in Reelin expression and Reelin
signaling play a pathogenic role in several nervous system disorders including
schizophrenia and AD (Guidotti et al., 2000; Herring et al., 2012; Kocherhans et al., 2010).
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Thus, strategies aimed at correcting these deficits might provide a novel therapeutic
approach to these devastating diseases. The cysteine-rich whey protein and GSH precursor,
Immunocal®, has previously been shown to preserve Reelin expression in a mouse model
of schizophrenia (Song et al., 2017). The purpose of the present study was to determine if
supplementation with Immunocal® increases Reelin expression in vitro in a hippocampalentorhinal cortex slice model and in vivo within the brain of an AD mouse model (J20
strain). In addition, we assessed whether Immunocal® administration to J20 AD model
mice resulted in diminished brain amyloid load when compared to untreated mice.
Upon incubation of rat hippocampal-entorhinal cortex slices with Immunocal®
acutely increased Reelin expression at the mRNA and protein levels. We assessed
transcript expression of Reelin by qPCR using Reelin specific probes and show the ability
of Immunocal® incubation to increase the Reelin transcript expression. When we
evaluated the protein level expression of Reelin using western blotting and
immunohistochemistry, we show that in addition to the increase in transcript expression,
there are elevated levels of protein expression in the hippocampal-entorhinal cortex regions
following Immunocal® treatment in vitro. These data indicate that Immunocal® is capable
of elevating Reelin expression in vitro.
Summary of 5-month-old J20 mouse in vivo studies
Next, we evaluated the effects of Immunocal® treatment in vivo by treating
hemizygous J20 AD mice from 3 months-old to 5 months-old. Immunocal® treatment
corrected a deficit in cortical GSH levels observed in the brains of untreated hemizygous
J20 mice. Western blotting of brain sections micro-dissected and enriched for the
hippocampal-entorhinal cortex subregion revealed a decrease in Reelin expression in
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untreated hemizygous J20 mice compared to non-carrier control mice, which was
prevented by treatment with Immunocal®. Immunofluorescence microscopy revealed
Reelin expression was diminished in the studied subregions of the hippocampus in
untreated hemizygous J20 AD mice compared to non-carrier control mice, which again
was recused by Immunocal® treatment, noticeably in layer II of the EC. In some cases,
treatment markedly increased the expression of Reelin even above what was observed in
the non-carrier control mice. In parallel with the observed rescue of Reelin expression in
the hippocampus-entorhinal cortex of J20 mice, Immunocal® also preserved GAD67
expression in the CA3 region of the hippocampus, often expressed and secreted in patterns
similar to Reelin in this region, but in GABAergic neurons. Collectively, these findings
indicate that treatment with Immunocal® induces Reelin expression in vitro in
hippocampal-entorhinal cortex brain slices and rescues Reelin expression in vivo within
the EC and hippocampus of the J20 mouse model of AD when assessed at 5 months-old.
Summary of 12-month-old J20 mouse in vivo studies
We next evaluated the chronic effects of Immunocal® treatment in vivo by treating
hemizygous J20 AD mice from 3 months-old to 12 months-old. As in the 5-month-old
mice, Immunocal® treatment corrected a deficit in cortical GSH levels observed in the
brains of untreated hemizygous J20 mice. We assessed Reelin expression at the transcript
level by in situ mRNA hybridization and observed rescue of Reelin protein expression in
the hippocampus-entorhinal cortex of J20 mice, Immunocal® also preserved Reelin
transcript expression, particularly in regions which secrete Reelin, including EC and CA3.
Protein expression reflected this observation in that western blotting micro-dissected to
enrich for the hippocampal-entorhinal cortex sub-region revealed a decrease in Reelin
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expression in untreated hemizygous J20 AD mice compared to non-carrier control mice,
corrected by treatment with Immunocal®. Using immunofluorescence microscopy, Reelin
expression was significantly diminished in the EC, DG and CA1/CA3 regions of the
hippocampus in untreated hemizygous J20 mice compared to non-carrier control mice. In
contrast, Immunocal® treatment significantly rescued these deficits in the EC and DG
regions. Perhaps most importantly in the context of AD, we evaluated the deposition of
amyloid plaques in the J20 mice. These mice have been shown to have significant plaque
load at 12 months-old. We show that untreated J20 mice do indeed accumulate a significant
plaque load in the hippocampus and entorhinal cortex. After treatment with Immunocal®
the plaque load was diminished significantly, both in size and number. Collectively, these
findings indicate that chronic treatment with Immunocal® rescues Reelin expression and
reduces amyloid load in vivo within hippocampal-entorhinal cortex regions of the J20
mouse model of AD when assessed at 12 months-old.
Conclusion
Immunocal® has previously been shown to be neuroprotective in vitro in diverse
models of oxidative stress and neurotoxicity (Winter et al., 2017). This supplement has
also been demonstrated to elevate GSH in the brain and spinal cord and is therapeutically
efficacious in mouse models of schizophrenia, amyotrophic lateral sclerosis, and traumatic
brain injury (Ross et al., 2014; Song et al., 2017; Ignowski et al., 2018). In addition,
Immunocal® treatment has been shown to rescue Reelin expression at the mRNA and
protein level in the prefrontal cortex of a mouse model of schizophrenia (Song et al., 2017).
In the current study, we initially found that incubation with Immunocal® significantly
increased Reelin expression in vitro. We show that Immunocal ® treatment of J20 AD
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model mice was effective at sustaining brain GSH levels, rescuing Reelin expression and
diminishing amyloid pathology in vivo. Together, these findings demonstrate that
Immunocal® treatment produces marked beneficial effects on antioxidant status, Reelin
expression and amyloid pathology in this model of AD. This is significant since, the
neuronal population of Reelin-secreting cells in the EC, and the hippocampal neurons to
which they project, are some of the earliest populations most vulnerable to
neurodegeneration. Furthermore, our data are consistent with previous studies showing that
genetic manipulation of Reelin expression in J20 mice has profound effects on AD
pathology (Kocherhans et al., 2010; Pujadas et al., 2014). We conclude that Immunocal®
represents a novel therapeutic approach to rescue Reelin expression and decrease amyloid
deposition in AD. This supplement should be evaluated in additional preclinical models of
AD to determine if the therapeutic effects extend to mitigating Tau pathology and
ameliorating the cognitive deficits associated with disease progression.
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CHAPTER FIVE: CONCLUSIONS AND FUTURE DIRECTIONS
5.1 Revisiting the current approaches to treating and preventing AD
Alzheimer’s disease and related dementias (ADRD) significantly affect the lives of
millions in the United States. Currently, there are only a limited number of approved drugs
that merely treat symptoms of AD, are only moderately effective in the early stages of the
disease, and do not slow the ongoing process of neuronal cell death (D'Onofrio et al., 2012;
Menting & Claassen, 2014; Vassar et al., 2009). Traditionally the focus of therapeutic
development has been in targeting amyloid production under the assumption that the
amyloid cascade hypothesis was the explanation for development of AD. Proposed targets
included β-secretase (BACE), γ-secretase, and beta amyloid (Aβ) peptides, resulting in
some drugs that proceeded to clinical trials based on promising preclinical studies.
Unfortunately, clinical trials have repeatedly been halted due to worsening cognitive
measures or no benefit realized in patients. The only significant, albeit slight, success in
targeting this pathway has been in the conditional FDA approval of amyloid antibody
therapy, aducanumab, which still requires additional data collection and is only applicable
to familial cases, which makes up a minimal fraction of those with AD (Alexander et al.,
2021).Beyond amyloid, there are a collection of alternative hypotheses which theorize what
the initiating factor(s) and perhaps proper target(s) are for therapeutic development. Some
aforementioned examples include the tau hypothesis, mitochondrial cascade hypothesis,
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cholinergic hypothesis, gut and inflammatory axis hypothesis, and insulin resistance to
name a few. It stands without question that aspects of each of these hypotheses are involved
in the deleterious neuronal loss which occurs during disease onset. Uncovering alternative
and perhaps combination strategies for addressing AD, specifically sporadic AD, has never
been more necessary. Approaches for developing new therapeutic regimens include
uncovering cellular and molecular mechanisms to design pharmaceuticals, diet and
supplement interventions, and lifestyle interventions – all aimed at reducing pathologies
and downstream effects exhibited in AD progression. Here, we present a collection of
interventional proposals to combat AD including two pharmacological, one nutritional, and
one lifestyle intervention. Since AD is a complicated, multifarious disease, successful
treatment will likely require a dynamic and multifaceted intervention addressing multiple
pieces of the “puzzle” rather than a “silver bullet” approach. Identifying multiple successful
interventions, likely in combination, is apt to be the most promising way to improve the
lives of those who are diagnosed as well as to hopefully prevent or delay the onset in others
who are at high risk of developing AD.
5.2 The relationship between PA and Aβ aggregation and toxicity: a pharmacological
intervention
In Chapter Two, we investigated the relationship between the ubiquitous class of
molecules, polyamines (PA) and Aβ-induced neurotoxicity. There is a collection of
research which has been conducted to understand PA association with AD. There has
largely been alternative ideas of how PA might be affecting disease pathogenesis,
especially due to the delicate balance in PA concentration which exists as well as the state
of acetylation of PA which seems to result in different outcomes. For example, the PA
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stress response has been found to be chronically elevated in AD patients, resulting in the
hypothesis that AD might be a result of sustained PA production (Polis, Karasik, &
Samson, 2021). Interestingly, studies have found that tau may be contributing to the
increase in chronic PA stress response through increasing PA acetylation via SSAT.
Additionally, PA seems to be protective against tau hyperphosphorylation, but only when
un-acetylated (Sandusky-Beltran et al., 2021). In fact, by blocking acetylation, researchers
have found that there are significant decreases in NFT and associated behavioral deficits
in mice (Sandusky-Beltran et al., 2019). Given previous research reporting shifts in PA
levels and synthesis in AD patients, but limited understanding of the interaction between
PA and Aβ, we sought to reveal a relationship between the two. In doing so, we propose a
feedforward mechanism in which higher PA leads to increased Aβ aggregation which
induces an increase in PA; a rampant cycle that accelerates the neurotoxic effects. It
appears that PA alone are sufficient to induce aggregation of Aβ peptides, evidenced by
results from cell free Tht assays and further, that increasing concentration of Aβ in vitro
via transfection, results in increased levels of PA produced in hippocampal cells. The
increased levels of Aβ are associated with aggregation, ROS production, and neuronal
apoptosis. Interestingly, by blocking PA synthesis, through the irreversible inhibitor of the
rate limiting enzyme ODC, we see a rescue in the downstream effects of Aβ.
The inhibitor used, DFMO, is already FDA approved, noted as one of the safest
medications in medical practice by the World Health Organization (World Health
Organization, 2019), and is currently utilized in treating African sleeping sickness and
chemotherapy (Priotto et al., 2006; Raul, 2007). This poses a unique opportunity to design
a therapeutic regimen to combat AD pathology utilizing a drug already approved for use.
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The data collected in these studies support the investigation of DFMO in preclinical mouse
models of AD in order to evaluate not only the effectiveness in reducing Aβ and subsequent
plaques, but also in cognitive changes that occur in animal models. In particular, the use of
the J20 model, which has high levels of amyloidogenic processing and thus develop
amyloid plaques and displays decreased cognitive functioning, would be a worthwhile
model to test the effectiveness of DFMO on Aβ pathogenesis in vivo. Further, were that to
show promising results, testing the effectiveness of DFMO in a mouse model of LOAD,
such as mice with APOE4 knockin, could support testing DFMO for use in sporadic AD
prevention. The fact that DFMO is FDA approved and AD could be extended as an
additional indication of the drug also eliminates a significant proportion of the clinical trials
needed for approval to use in AD. If DFMO does indeed reduce Aβ aggregation, diminish
ROS and decrease neuronal apoptosis in vivo, then it could very well be a good candidate
for pairing with additional therapies in order to slow or prevent amyloid pathogenesis in
human AD patients.
5.3 The novel neurotoxic role of AICD at the mitochondria: a pharmacological
intervention
In Chapter Three, we analyzed the implications of production of the APP
intracellular domain (AICD) at the mitochondria given the resident γ-secretase that is
stationed within the membrane and can produce protein there locally. AICD has
traditionally been studied as a transcription factor, and has downstream targets which are
implicated in the dysregulation seen in AD. For example, AICD has been found to increase
GSK3β, one of the kinases responsible for the hyperphosphorylation of tau (K. A. Ryan &
Pimplikar, 2005). In fact, transgenic mice overexpressing AICD showed increased tau
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phosphorylation, increased NFTs and behavioral deficits, which were improved upon
blocking GSK3β through treatment with lithium (Ghosal et al., 2009). This is notable in
that AICD is generally unstable in the cytoplasm but can be stabilized by phosphorylation
of 8 possible sites. Previous research has uncovered that in the disease state, 7 of the 8
possible sites are phosphorylated, resulting in sustained AICD presence and perhaps
increased GSK3β activity and increased tau phosphorylation (Pastorino and Lu, 2006).
However, AICD has been mostly unexplored outside its role as a nuclear transcription
factor; specifically there has been little research looking at how it may affect the
mitochondria when located there, which is particularly worthwhile since studies have
found that it can be produced there when APP gets stuck within the mitochondrial
membrane (Pavlov et al., 2011). This is particularly important since AICD can be produced
through both amyloidogenic and non-amyloidogenic pathways and traditional amyloid
therapies only target amyloidogenic processing. Here, we propose a novel neurotoxic role
of AICD at the mitochondria; one that appears to be different than Aβ. Notably Aβ seems
to require the opening of the mitochondrial permeability transition pore (mPTP) while
mitochondrially targeted AICD (mitoAICD) does not, but rather requires caspase
activation. Due to their difference in initiating downstream apoptotic cascades at the
mitochondria, we propose a potentially synergistic role of both Aβ and AICD at the
mitochondria in AD development. This is of particular interest due to the notable role that
mitochondrial dysfunction plays in AD pathogenesis, highlighted by the mitochondrial
cascade hypothesis. Given the increase in MOS and the role of other apoptotic factors in
increasing both Aβ aggregation and tau hyperphosphorylation, improving or protecting the
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health of mitochondria in the disease state could be a vital piece of therapeutic design
(Eckert, Schmitt, & Gots, 2011).
Based on these findings, inhibiting the activity of the mitochondrial γ-secretase
might be a worthwhile target in addition to blocking Aβ production or aggregation in
preventing pathogenesis of AD. This differs from the past drug development projects like
Eli Lilly’s semagacestat which have focused on ubiquitous γ-secretase inhibition. This
broad inhibition failed in clinical trials repeatedly (Doody et al., 2013). It has been
proposed that this is likely due to the involvement of γ-secretase in Notch signaling, which
is required for a number of signaling cascades in cells (Bray, 2016; Olsauskas-Kuprys,
Zlobin, & Osipo, 2013). By designing a pharmaceutical that only targets the mitochondrial
γ-secretase, this would eliminate the interference with Notch signaling at the cellular
membrane.
Utilizing this target in combination with targeting Aβ could prove useful in
preventing the multitude of apoptotic inducing cascades seen in AD. Testing a
mitochondrial γ-secretase inhibitor alone or in combination with an amyloid preventive
therapy in preclinical mouse models of AD, perhaps in the 3xTg-AD model which exhibits
both plaques and tangles, would provide useful insight into the effectiveness of this
strategy. If successful in reducing amyloid pathologies and neuronal loss, such a regimen
could be an effective pharmacological intervention for preventing AD pathology in
patients.
5.4 The neuroprotective effects of Immunocal ® in the J20 mouse model of AD: a
nutritional intervention
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In Chapter Four, we assessed the effectiveness of the cysteine-rich whey protein
supplement Immunocal® in preserving glutathione (GSH), rescuing Reelin expression, and
reducing amyloid plaques in a mouse model of AD. We utilized the J20 AD mouse model
which has the human Swedish and Indiana APP mutations (hAPPswe-ind), which drive
amyloidogenic processing of APP, exhibiting hallmark plaque pathology and cognitive
deficits as the animals age (Karl et al., 2012). We predicted that Immunocal® would be
protective against disease pathology for several reasons in this model. First, Immunocal®
has been found to preserve Reelin and GSH in mouse models of other diseases like
schizophrenia and ALS (Ross et al., 2014; Song et al., 2017) and second, Reelin-expressing
cells of the EC are some of the first populations to be lost in AD pathogenesis. Therefore,
in protecting this vulnerable population of neurons, we hoped to see improvements in the
hemizygous J20 AD mice treated with Immunocal® over time in comparison to untreated
hemizygous controls.
Indeed, we saw improvements in a number of measures in two cohorts (treated 3to 5-months old and 3- to 12-months-old) of hemizygous J20 mice in comparison to those
untreated. Specifically, we saw increases in the GSH/GSSG ratios in the hippocampus of
both groups, indicating reduced oxidative stress through maintenance of the essential
antioxidant GSH. Further, we saw substantial preservation of Reelin expression in the
hippocampal-entorhinal cortex regions of the brain of both groups. We saw a significant
reduction in both amyloid plaque number and load in the 12-month-old group in
comparison to untreated mice, indicating protection due to chronic Immunocal®
supplementation over time.
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We also investigated the expression of brain derived neurotrophic factor (BDNF)
in 5-mo-old mice and found an increase in BNDF expression (data not shown). This is of
interest since neurotrophins (NT), BDNF and nerve growth factor (NGF), are associated
with the interfacing of the basal cholinergic neurons and EC/hippocampus and have been
found be decreased in the disease state (Beeri & Sonen, 2016; Laske et al., 2007). Previous
research has found that BDNF can be protective against dysfunction caused by amyloid
and tau pathologies (Jiao et al., 2016; Nagahara et al., 2013), further connecting them to
protection from hallmark pathologies and subsequent downstream effects. Our data show
that Immunocal® may also be protecting against BDNF loss. This could be through the
scavenging of ROS by GSH since ROS leads to inhibition of CREB, which is responsible
for BDNF production and other pro-survival pathways. Also, the preservation of Reelin
via Immunocal might be affecting BDNF production in that Reelin is able to induce the
phosphorylation of NMDA receptors which activate CREB downstream, supporting
synaptic plasticity and learning (Lee & D'Arcangelo, 2016). In fact, modulation of the
CREB-BDNF pathway has been postulated as a promising target for preventing AD
(Amidfar, de Oliveira, Kucharska, Budni, & Kim, 2020).
Together, these findings suggest that Immunocal® is a candidate nutritional
intervention to prevent changes that occur in the development of AD including increased
ROS, loss of Reelin expression, and amyloid plaque deposition. As a result, utilizing this
supplement, which poses minimal to no risk with consumption, could be considered as a
preventive strategy against neurodegenerative diseases including ADRD. These data
support investigating the effectiveness of prevention in a longitudinal study of older adults
to assess its effectiveness at preventing dementia diagnoses. Indeed, Immunotec, Inc.
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(Quebec, CA), in collaboration with McGill University, is currently performing a small
open-label pilot study with Immunocal® in patients with mild cognitive impairment
(MCI).
5.5 Pilot study of the Kynemics program at the Alumia Institute: a multi-modal
lifestyle intervention
Altogether, the potential benefits of any single non-pharmacological intervention
on the progressive course of dementia is likely small. This realization has led to several
large multimodal studies as well as smaller pilot trials in older adults at risk of dementia or
those diagnosed with ADRD as a non-pharmacological intervention (Ngandu et al., 2015;
Richard et al., 2009; Rosenberg et al., 2018; Vellas et al., 2014). One of the largest studies
in recent history, the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment
and Disability (FINGER), studied individuals considered at risk of developing dementia
with a multimodal intervention including exercise, cognitive training, nutrition, social
activity, and maintenance of other metabolic risk factors, and then followed for two years
(Kivipelto et al., 2013). Researchers found a significant difference in measures of cognitive
performance in the control group compared to the intervention group, regardless of
socioeconomic or demographic measures (Rosenberg et al., 2018). However, other studies
have found mixed results in the benefits of combination therapy, such as the Multi-domain
Approach for Preventing AD (MAPT) study, which utilized a multidomain approach or
isolated interventions alone and found little difference amongst outcomes in the different
patient groups (Vellas et al., 2014). Collectively, these trials suggest that there is potential
for certain multimodal approaches to slow cognitive decline, enhance mood, and improve
quality of life in patients suffering from dementia; however, not all lifestyle interventions
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are equally successful in combating development of dementia. We hypothesized that the
multimodal approach and lifestyle intervention therapy used by the Alumia Institute would
significantly slow the rate of cognitive decline while improving mood and quality of life
in patients with mild-to-moderate dementia. Here, we report the results of a pilot study
implementing a multimodal lifestyle intervention therapy developed by the Alumia
Institute in a small population.
The Kynemics Program at the Alumia Institute consists of activities designed to
reduce symptoms of dementia, enhance mood, and promote quality of life. Within this
program, patients attended the Institute 2-5 days a week, where they participated in a
number of activities including cognitive training sessions, art sessions, music sessions, and
physical activity. Additionally, the patients were fed meals adhering to the MediterraneanDASH Intervention for Neurodegenerative Delay (MIND) diet and also participated in all
activities with the other patients in attendance, fostering socialization and community
within the cohort.
Previous research has noted the benefit of using these therapies including art
therapy (Chancellor, Duncan, & Chatterjee, 2014), music therapy (Gomez Gallego &
Gomez Garcia, 2017; Pongan et al., 2017), physical activity (J. K. Morris et al., 2017;
Paillard, Rolland, & de Souto Barreto, 2015; Spielman, Little, & Klegeris, 2016), cognitive
engagement (Rojas et al., 2013), socialization (Penninkilampi, Casey, Singh, & Brodaty,
2018), and the MIND diet (M. C. Morris, Tangney, Wang, Sacks, Barnes, et al., 2015; M.
C. Morris, Tangney, Wang, Sacks, Bennett, et al., 2015). Additionally, studies suggest that
combinations of these therapies yield beneficial effects more so than when used alone (Han
et al., 2017; Satoh et al., 2014).
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Upon enrollment, each patient’s baseline time “0” was established for the following
assessments: St. Louis University Mental Status (SLUMS), Barthel Index of Activities of
Daily Living (ADLs), Lawton Brody Index of ADLs, Time Up & Go (TUG), Mini
Nutritional Assessment, Geriatric Depression Scale (GDS), and caregivers were given a
stress assessment to complete. All participants had a clinical diagnosis of mild-to-moderate
dementia. Following baseline, data for each assessment was repeated quarterly with the
exception of GDS which was collected monthly.
5.5.1 Patients showed increased cognitive function after Alumia intervention
Though at time of data collection, there were approximately 30 patients enrolled,
there was only a limited subset of patients who completed sufficient data points to be
included in the measures reported here. First, and perhaps the most notable finding from
this pilot study, was that of the change in SLUMS scores (Figure 5.1). SLUMS is one of
the gold standards in measuring cognitive capability in adults (Kaya et al., 2016;
Szczesniak & Rymaszewska, 2016). The scores are interpreted as follows: scores of 27 to
30 are considered normal in a person with a high school education. Scores between 21 and
26 suggest a mild neurocognitive disorder. Scores between 0 and 20 indicate dementia. At
the completion of this pilot study, for a subset of six patients who had at least three
assessments having been enrolled for 6 months, there was a significant increase over time,
indicating cognitive improvement (Figure 5.1B). It was not expected that the SLUMS
scores would exceed that of a dementia diagnosis (greater than 20) in these patients;
however, the significant increase indicated an improvement in cognitive function amongst
these patients after Alumia intervention over time.
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Figure 5.1 St. Louis University Mental State (SLUMS) evaluation in a subset of
participants in the Alumia multi-modal lifestyle intervention program. Baseline values
at time “0” were assessed prior to beginning the program. SLUMS assessments were then
performed once per quarter. SLUMS evaluation criteria: Scores of 27 to 30 are considered
normal in a person with a high school education. Scores between 21 and 26 suggest a mild
neurocognitive disorder. Scores between 0 and 20 indicate dementia. A) Plotted change
over time in SLUMS scores for patients with at least 2 assessments. Each line represents
an individual patient change in score from baseline time “0” and subsequent quarterly
assessments. B) Quantification of SLUMS scores of patients with at least 2 quarterly
assessments and a baseline SLUMS of <25. Data are expressed as mean+/-SEM, n=6. *
indicates p<0.05 SLUMS scores at baseline vs 6 months as determined using a paired ttest.
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5.5.2 Patients displayed no change in independence after Alumia intervention
Progressive loss in independence through decrease in ADL is a defining
characteristic of the progression of dementia (Desai, Grossberg, & Sheth, 2004; Roehr et
al., 2019). In order to measure this change amongst patients enrolled, Barthel Index and
Lawton-Brody Instrumental ADL assessments were collected. These are indicative of
patient independence as these measures assess the ability of patients to effectively complete
tasks on their own. Such tasks for the Barthel Index are more generalized and include
examples such as eating, bathing, dressing, bowel control, and mobility, with a higher score
correlates to higher levels of ability. The Lawton-Brody Instrumental ADL are considered
more complex and include tasks such as the ability to manage finances, mode of
transportation, responsibility for medication, food preparation, and housekeeping with
higher scores correlating to higher levels of independence (Lawton & Brody, 1969). Both
assessments were collected quarterly to track changes in abilities of patients. We found no
significant change in the assessments after 2-3 quarters, indicating that participants
maintained their performance and did not have significant decreases in independence while
enrolled at Alumia (Figure 5.2).
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Figure 5.2 Activities of daily living change over time in a subset of participants in the
Alumia multi-modal lifestyle intervention program. Baseline values at time “0” were
assessed prior to beginning the program. A) Change in Barthel’s Index of Activities of
Daily Living over time for patients over one year in the Alumia program. Data is
represented as the mean +/- SEM, n=13 for time 0 to 6 months, n=5 for 9 months. *
indicates p<0.05 as compared to baseline t=0 as determined using a paired t-test. B) Change
in Lawton-Brody Index of Activities of Daily Living over time for patients with at least 2
quarterly assessments. Data are expressed as mean+/-SEM, n=13.
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5.5.3 Patients improved in mobility and maintained nutritional measures after
Alumia intervention
Additionally, patients’ mobility and fall risk were analyzed through the use of the
TUG test. This assessment is performed by measuring the time it takes for a patient to rise
from a chair, walk 10 feet and return to the chair. It is scored such that a time higher than
12 seconds indicates a high fall risk (Podsiadlo & Richardson, 1991). Of the patients who
were in this risk group at baseline assessment, after two quarters, there was a significant
decrease in their TUG times (Figure 5.3). In fact, this reduction in TUG times fell outside
the high fall risk category, indicating an improvement in patients’ mobility after Alumia
intervention over time.
Patients’ nutritional status was also measured over time through the use of the
MNA. The MNA takes into account a number of factors that are involved in nutritional
status including food intake, weight changes, mobility, and stress, which is totaled to
indicate whether the patient is of normal status, at risk of malnourishment, or malnourished
(Kaiser et al., 2009). A score of 12 or higher indicates a normal status, which patients
maintained over time at Alumia (Figure 5.4). In having the majority of their meals prepared
and consumed at Alumia when attending, patients received well balanced and nutrientpacked MIND diet meals that helped maintain consistent nutritional health.
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Figure 5.3 Timed Up and Go (TUG) evaluation in a subset of participants in the
Alumia multi-modal lifestyle intervention program. Baseline values at time “0” were
assessed prior to beginning the program. TUG assessments were performed quarterly. TUG
evaluation criteria: score of >/= to 12s indicates a high risk of falls. Data is represented as
the mean +/- SEM, n=6. * indicates p<0.05 in comparison to baseline as determine by a
paired t-test.
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Figure 5.4 Mini Nutritional Assessment (MNA) in a subset of participants in the
Alumia multi-modal lifestyle intervention program. Baseline values at time “0” were
assessed prior to beginning the program. Mini nutritional assessments were performed
quarterly. Data is represented as the mean +/- SEM, n=12 for time 0 to 6 months, n=5 for
9 months.
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5.5.4 Patients and caregivers emotional state improved after Alumia
intervention
Changes in mood and mental health are closely associated with the onset of
dementia in patients and caring for the distress experienced by patients through these
changes is vital to improving patient well-being (Sorensen, Duberstein, Gill, & Pinquart,
2006). In order to follow changes in patients’ mental health, they were scored using the
GDS, a self-reported assessment which has been tested extensively to measure depression
in the older population (Greenberg, 2007). A subset of patients had baseline testing,
followed by at least three months of testing using this method. Of this subset of ten patients,
only three had baseline GDS scores > 4, which is indicative of mild depression. Of these
three patients, two showed marked decreases in their GDS scores, which indicates
improvement while one displayed an increase (Figure 5.5).
Additionally, it is well documented that the caregivers of patients with ADRD
undergo increasing amounts of stress with more severe impairment of the patients they care
for. This is due to a number of reasons including the time, resource, and emotional burdens
felt by those who are caretakers (Pinquart & Sorensen, 2006). To follow the stress and in
turn quality of life of this group, we collected self-reported Caregiver Self-Assessment
from caretakers quarterly. Only six caregivers had baseline testing followed by completion
of at least one quarterly assessment. Of these six caregivers, only three started out with
baseline scores of > 5. Two of three caregivers showed decreases in their scores, showing
reduced stress after enrollment at Alumia (Figure 5.6).
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Figure 5.5 Geriatric depression scale (GDS) in a subset of participants in the Alumia
multi-modal lifestyle intervention program. Baseline values at time “0” were assessed
prior to beginning the program. GDS assessments were performed monthly. Evaluation
criteria is such that scores of 0-4 are considered normal; 5-8 indicate mild depression; 911 indicate moderate depression; 12-15 indicate severe depression. Plotted change over
time in GDS scores for patients with an initial baseline score of 4 or higher. Each line
represents an individual patient change in score from baseline ”0”.
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Figure 5.6 Caregiver Stress evaluation in a subset of caregivers for patients enrolled
in the Alumia multi-modal lifestyle intervention program. Baseline values at time “0”
were assessed prior to beginning the program. Caregiver self-assessments were performed
quarterly. Evaluation criteria is such that chances of the caregiver is experiencing a high
degree of distress is a score of 10 or more. Each line represents an individual caregiver
change in score from baseline ”0”.
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5.5.5 Benefits and limitations of Alumia intervention
Though these results are noteworthy, there are a number of caveats in this study
that are important to consider. First, the sample size is small and skewed socioeconomically
considering there is a fee to attend Alumia, which increases with the number of days spent
there per week. Due to this, there is not a large enough sample size for statistical
significance in many measures; however, we would predict to see similar trends as the n
value increases. Additionally, and perhaps the biggest issue with this study, is the lack of
a control group for comparison. A true control group with no intervention would be needed
in order to relate the natural progression of these measures in similar patient populations.
The large takeaways from this study are the positive trends, which support the value in
designing a study which brings these interventions to a larger population to evaluate the
benefit over time.
Expanding this study to a large cohort of patients would be beneficial to strengthen
the findings significantly as well as pose an opportunity to further investigate the
biochemical changes occurring due to the intervention. For example, measuring
biomarkers present in cerebrospinal fluid (CSF) and brain derived exosomes might reveal
changes that are contributing to the positive trends we report here. In particular, physical
activity is known to increase BDNF levels (Ledreux et al., 2019), which has a positive
impact on amyloid and tau pathologies as mentioned previously. Correlating these changes
would be useful information to collect for the design of future studies and understanding
the measures we reported here.
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Additionally, a larger cohort would allow for us to investigate the results based on
gender. This is particularly worthwhile since there are differences in prevalence and
development of AD depending on gender through expression of hormones like estrogen
and progesterone. Previous research has found that estrogen appears to regulate the
appearance of AD pathologies in the 3xTg-AD mouse model of AD (Carroll et al., 2007).
Additionally, estrogen replacement therapy has been found to correlate with a decreased
risk of developing AD in women (Song et al., 2020). Therefore, increasing the sample size
would allow us to further elucidate differences in outcome based on hormonal differences
in the patients.
Regardless, the findings suggest that patients diagnosed with mild-to-moderate
dementia may benefit from enrollment in the Alumia Institute. The Kynemics Program has
a significant positive impact on the well-being of patients with mild to moderate ADRD by
increasing cognitive function and mobility, maintaining independence, and decreasing
caregiver stress. This was anticipated both given the breadth of research that has shown
benefits of these interventions individually as well as the adherence to this program, which
is often an issue in lifestyle interventions of older adults. The therapeutic benefits of the
Alumia multimodal approach to lifestyle intervention therapy for patients with dementia
may help in the planning of future care and studies using this treatment paradigm.
5.6 Discussion and future directions
As mentioned, the likelihood of successfully preventing or resolving AD with one
single intervention is small considering the complicated nature of the disease, notably in
sporadic cases. As a result, investigating alternative approaches beyond the traditional
amyloid hypothesis is key. Here, we have identified a number of approaches including
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pharmacological, nutritional, and lifestyle interventions. These have the potential to benefit
patients, possibly in combination with other treatments, by preventing and mitigating
disease onset and progression at the molecular level up to the wellbeing of the patients and
the caregivers they depend on.
These data pose a number of opportunities to further investigate their potential
benefit in additional preclinical models as well as in the clinic. First, the effectiveness of
DFMO in reducing amyloid-mediated toxicity could be easily studied in preclinical mouse
models of AD or in healthy volunteers to track progression of amyloid load and subsequent
toxicity over time. Given that this drug is already approved by the FDA, there has already
been research conducted to establish safe usage, reducing the amount of time and resources
that would be required to translate its use to alternative purposes, like preventing ADRD.
In regard to reducing AICD locally at the mitochondria, further investigation into
how it disrupts bioenergetics in the cell would be worthwhile and provide a foundation for
proceeding with mitochondrial-specific γ-secretase inhibitors as potential therapeutics.
Given the requirement of a functional mitochondria for AICD-mediated neurotoxicity, this
suggests that AICD must somehow be affecting the ETC and mitochondrial bioenergetics.
Since a limitation of this study is the transient transfection system used, future directions
would include utilizing a hippocampal model which has widespread expression of the
proteins of interest, like that induced by a lentiviral infection or stable, inducible cell line.
This would allow for a more in-depth investigation of the mechanisms, notably the
alteration of mitochondrial and ETC function that is occurring due to AICD locally.
Elucidating such mechanisms would be required to move forward in developing this as a
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therapy to target AICD in combination alongside amyloid-targeted approaches like BACE
inhibitors or amyloid antibodies.
Other events occurring in the development of AD beyond that of the peptides
aforementioned, like the rampant ROS, which is well-characterized in AD, is another
avenue to explore in prevention of disease onset and progression. The use of the
supplement, Immunocal® as a nutritional intervention poses a safe option to maintain
levels of antioxidants in the brain and in turn protect important Reelin-expressing neuronal
populations which are first lost in AD development. It would be worthwhile to study this
supplement in healthy volunteers as well as those at risk of developing dementia to track
changes like Aβ, tau, and phospho-tau in their CSF as early markers of changes associated
with AD. Using Immunocal® as prevention, rather than treatment, might help to delay or
prevent neuronal loss and amyloid load experienced by those developing AD.
Lastly, though limited in a number of ways due to small sample size and lack of
control subject, the Alumia pilot study presented here shows promising results to support
the use of multi-modal care for older adults at risk of diagnosis or already diagnosed with
dementia. The well-rounded curriculum which is supported by previous studies of
individual interventions for these patient populations appears to be effective in improving
patients’ cognition, mobility, maintaining independence, and finally increasing the quality
of life for not only the patients, but caregivers as well. Additionally, the structure of the
program ensures regular participation of patients, eliminating the general issue of lack of
adherence to regimens prescribed by providers. Granted, the resources necessary to
participate, notably financial, is a large limitation of such a model, but understanding the
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utility in these results should help guide the development of multi-modal lifestyle
approaches to benefit patients with ADRD.
In conclusion, the studies presented here pose opportunities to develop approaches
to hopefully delay or prevent AD pathologies and improve the quality of life of those who
are diagnosed. The likelihood of a “silver bullet” pharmacological treatment does not seem
feasible to address this diverse disease. Together, these proposed interventions involve
multiple aspects of the mechanisms which are involved in AD pathogenesis and pose
opportunities to design regimens to prevent onset and improve outcomes (Figure 5.7).
Elucidating mechanisms beyond amyloid, or in addition to amyloid, could be successful in
mitigating the disruptive molecular changes seen within neuronal populations. In addition,
utilizing preventive treatments like antioxidant-packed nutritional interventions, which do
not require the time-consuming and resource-consuming approval process like
pharmaceuticals, might help to reduce some of the downstream cascades experienced by
neurons as a result of pathogenesis. Lastly, lifestyle approaches to take care of the
population affected is vital to improving descriptive measures and importantly, quality of
life, which might foster hope and relief in the millions of people both diagnosed with and
affected by ADRD.
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Figure 5.7 Summary of major findings in relation to AD pathogenesis and
downstream effects.
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APPENDIX A: ABBREVIATIONS
3xTg-AD: triple transgenic mouse model of AD
Aβ: beta amyloid
Aβ42: beta amyloid 42
ABAD: Aβ- binding alcohol dehydrogenase
AD: Alzheimer’s disease
ADLs: activities of daily living
ADRD: Alzheimer’s disease and age-related dementias
AICD: APP intracellular domain
AIF: apoptosis inducing factor
ALS: amyotrophic lateral sclerosis
ANOVA: analysis of variance
APC: antigen presenting cells
apoE: apolipoprotein E
APOER2: ApoE receptor-2
APP: amyloid precursor protein
BACE: β- secretase
BaxI: Bax inhibitor
BDNF: brain derived neurotrophic factor
CA: Cornus Ammonius
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Casp: pan caspase inhibitor Pro-VAD-FMK
CAT: catalase
CTF 89/99: C terminal fragment 89/99
Con: incubated in control medium
CNS: central nervous sustem
CSF: cerebrospinal fluid
COXI: subunit 1 of Complex IV
COXIV: cytochrome c oxidase
CyA: cyclosporine A
DCF: 2’,7’-Dichlorofluorescin diacetate
DFMO: d, l-α-difluoromethylornithine
DG: dentate gyrus
DMEM: Dulbecco’s modified eagle’s medium
DS: Down Syndrome
DsRed: pIRES DsRed-Express2 vector
EC: entorhinal cortex
ECL: enhanced chemiluminescence
EGFR: epidermal growth factor receptor
ELISA: enzyme-linked immunosorbent assay
ER: endoplasmic reticulum
ETC: electron transport chain
FBS: fetal bovine serum
γ-GCL: γ-glutamylcysteine
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GAPDH: glyceraldehyde 3-phosphate dehydrogenase
GDS: Geriatric Depression Scale
GPx, GP: GSH peroxidase
GR: GSH reductase
GS: GSH synthase
GSH: glutathione
GSH:GSSG: ratio of reduced to oxidized GSH
GSH-MEE: GSH monoethyl ether
GSK3β: glycogen synthase kinase 3 β
H2O2: hydrogen peroxide
Hemi (unt): untreated J20 mice
Hemi (ICAL): J20 mice treated with ICAL
HPLC-ECD: with electrochemical detection
IRES: empty pIRES DsRed-Express2 vector
FAD: familial AD
hAPPwt: transgenic mouse harboring human APP gene
hAPPswe-ind: transgenic mouse harboring human Swedish and Indiana APP mutant genes
HBSS: Hank’s balanced salt solution
HIV: human immunodeficiency virus
HT22: immortalized mouse hippocampal cell line
IB: immunoblotted
ICAL: Immunocal®
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IP: immunoprecipitated
J20: hAPPswe-ind transgenic AD model mice
LOAD: late onset AD
McGill-R-Thyl-APP strain: rat model of AD
MCI: mild cognitive impairment
MEKC-LIF: micellar electrokinetic chromatography with laser induced fluorescence
MIND: Mediterranean-DASH intervention for neurodegenerative delay diet
MOS: mitochondrial oxidative stress
mPTP: mitochondrial permeability transition pore
NGF: nerve growth factor
NOS: nitric oxide synthase
LDL: low density lipoprotein
mitoAICD, mAICD: AICD with mitochondrial targeting domain
NADPH: nicotinamide adenine dinucleotide phosphate
NT: neurotrophins
NFTs: neurofibrillary tangles
NMDA: N-methyl-D-aspartic acid
ODC: ornithine decarboxylase
OTC: ornithine transcarbamlayse
P13K: phosphatidylinositol 3-kinase
PA: polyamines
PBS: phosphate buffered saline solution
PS1: presenilin-1
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PS2: presenilin-2
PVDF: polyvinylidene difluoride
qPCR: quantitative real-time polymerase chain reaction
QVD: Q-VD-Oph-non-methylated
Rln: Reelin
ROS: reactive oxygen species
sAPPα: soluble amyloid-beta precursor protein - α
sAPPβ: soluble amyloid-beta precursor protein- β
SFK: Src family kinase
SLUMS: St. Louis University Medical Status
SOD: superoxide dismutase
SpdS: spermidine synthase
SpmS: spermine synthase
Str: staurosporine
Sxc-: system xc- antiporter
T3D: Type 3 Diabetes
t50: time to reach 50% fluoresence
ThT: thioflavin T
TIM, TIM23: translocase of the inner mitochondrial membrane
TOM, TOM40: translocase of the outer mitochondrial membrane
TNF-APLPHA: tumor necrosis factor- ALPHA
TGF- β1: transforming growth factor- β1
TUG: time up and go
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VLDR: very low-density lipoprotein receptor
WB: Western blot
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APPENDIX B: SUPPLEMENTARY TABLES
Supplementary Table 1. Antibodies and stains utilized in chapter one: antibodies
utilized in immunohistochemistry (IHC) and Western blot (WB) experiments at indicated
concentrations according to manufacturer’s recommedations for specific applications.
Antibody

Manufacturer

Application

Concentration

Hoechst stain

Sigma (14530)

IHC

1 ug/mL in PBS

MOAB-2

Abcam (ab126649)

IHC

5 ug/mL in primary

ODC

Abcam (ab97395)

WB

1:1000 in blocking

Beta actin

Abcam (ab8227)

WB

1:1000 in blocking

Anti-mouse HRP

BioRad (1706516)

WB

1:500 in PBS0T

Anti-rabbit HRP

BioRad (1706515)

WB

1:500 in PBS-T

Supplementary Table 2. Antibodies and stains utilized in chapter two: antibodies and
stains utilized immunohistochemistry (IHC) and Western blotting (WB) experiments at
indicated concentrations according to manufacturer’s recommendations for specific
applications.
Antibody/Stain
6A7
Active caspase-3
Fluorescein
isotiocyanate
(FITC) conjugated
Hoechst stain

Manufacturer

Jackson
Immunoresearch
(715-095-150, 711095-152)
Sigma (14530)

Application
IHC; primary
IHC; primary
IHC; secondary

Concentration

IHC; nuclear stain

1 ug/mL in PBS
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1:5000 in secondary

Supplementary Table 3. Antibodies utilized in immunohistochemistry (IHC) and
Western blotting (WB) experiments at indicated concentrations according to
manufacturers’ recommendations for specific applications.
Antibody/stain
Manufacturer
Application
Concentration
Reelin (RLN)
Abcam (ab78540)
IHC; primary
1:1000 in primary
WB; primary
1:1000 in blocking
GAD67
Abcam (ab26116)
IHC; primary
1:1000 in primary
NeuN
Abcam (ab104225)
IHC; primary
1:1000 in primary
Fluorescein
Jackson
IHC; secondary
1:5000 in secondary
isothiocyanate
Immunoresearch (715(FITC)
095-150, 711-095-152)
conjugated
Cyanine-3 (Cy3) Jackson
IHC; secondary
1:5000 in secondary
conjugated
Immunoresearch (715165-150, 711-165-152)
Anti-mouse HRP BioRad (1706516)
WB; secondary
1:500 in PBS-T
Anti-rabbit HRP BioRad (1706515)
WB; secondary
1:500 in PBS-T
Beta actin
Abcam (ab8227)
WB; primary
1:1000 in blocking
DRAQ7™
Abcam (ab109202)
IHC; nuclear stain 1:1000 in PBS-T
Amylo-Glo ®
Biosensis (TR-300)
IHC; plaque stain 1:100 in PBS
Dab1
Cell
Signaling IP, IB
1:500 in blocking
Technologies (3328)
PhosphoMillipore Sigma (clone IB
1:1000 in blocking
tyrosine
4G10)
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APPENDIX C: LIST OF PUBLISHED ABSTACTS AND MANUSCRIPTS
Manuscripts

Chapter Two, titled “Modulating Polyamines as a Method of Reducing Amyloidogenic
Toxicity and Aggregation” has been submitted to Journal of Alzheimer’s Disease.
Sandberg A., Johnson A., Fudge D., Melgar S., Hicks C., Patterson D., Vacano G.,
Margittai M., Weismiller H., Harvey S., Hernandez L., Caviedes P., Ledreux A.,
Qin Y., Granholm A., Linseman D., and Paredes D. Inhibition of polyaminesynthesis decreases AB42-mediated apoptosis.

Chapter Three, titled “The Novel Neurotoxic Role of the APP Intracellular Domain at the
Mitochondria” is published in the Journal of Alzheimer’s Disease.
Sandberg A., Manning E., Wilkins H., Mazzarino R., Minckley T., Patterson D.,
Qin Y., and Linseman D. Mitochondrial targeting of the APP intracellular domain
(AICD) induces hippocampal cell death via a mechanism distinct from that of
amyloid beta 1-42 (AB1-42). doi:10.3233/JAD-215108
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Chapter Four, titled “Preservation of Reelin Expression with Immunocal® Supplement in
a Mouse Model of Alzheimer’s Disease” is in preparation for submission to
Neurotherapeutics.
Puttagunta S.*, Sandberg A.*, Duval N., Fleming H., and Linseman D.
Amelioration of Alzheimer’s disease pathology in 12-month-old hAPP(SweInd)
transgenic mice after treatment with cysteine rich whey supplement, Immunocal ®.
Abstracts
Sandberg A., Lind C., Meyer L., Gorgens K., Wolff A., and Linseman D. The ALLOTTED
study: Alumia Lifestyle Options To Treat Dementia. Alzheimer’s Association
International Conference, Denver, CO, 2021.
Sandberg A., Johnson A., Fudge D., Melgar S., Hicks C., Patterson D., Vacano G.,
Margittai M., Weismiller H., Harvey S., Hernandez L., Caviedes P., Ledreux A.,
Qin Y., Granholm A., Linseman D., and Paredes D. AB42 and polyamines:
elucidating a potential mechanism is amyloid-mediated apoptosis and aggregation.
Alzheimer’s Association International Conference, Virtual Conference, 2020.
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